

Approved



Zambia

Country Operational Plan

FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Total
	GAP	GHP-State	GHP-USAID	
DOD		1,600,000		1,600,000
HHS/CDC	2,412,531	88,054,043		90,466,574
HHS/HRSA		700,000		700,000
HHS/NIH		700,000		700,000
HHS/OS		200,000		200,000
PC		4,452,053		4,452,053
State		553,936		553,936
State/AF		150,000		150,000
State/PRM		150,000		150,000
USAID		160,916,103	0	160,916,103
Total	2,412,531	257,476,135	0	259,888,666

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency								On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	HHS/NIH	PC	USAID	AllOther		
CIRC	2,333	16,740	6,133,468				6,537,418	0	0	12,689,959
HBHC		12,555	5,801,356			213,478	9,953,014		0	15,980,403
HKID	11,667	1,000,000	250,000				20,457,232	150,000	0	21,868,899
HLAB		71,145	2,597,836		350,000		8,809,637		0	11,828,618
HMBL			1,235,767						0	1,235,767
HMIN			0						0	0
HTXD			0				49,892,60		0	49,892,60

Approved



							5			5
HTXS		16,740	30,866,784	350,000	25,000		19,010,113	150,000	0	50,418,637
HVAB	10,500	4,185	460,671			12,505	2,813,689	20,000	0	3,321,550
HVCT	1,167	12,555	4,057,628				9,656,688	20,000	0	13,748,038
HVMS	412,769	252,645	6,815,228			4,202,316	3,883,581	110,000	0	15,676,539
HVOP	11,667	16,740	892,761			23,754	6,524,389	10,000	0	7,479,311
HVSI	32,667	16,740	6,538,007				1,007,114		0	7,594,528
HVTB		16,740	6,115,671				3,199,832		0	9,332,243
IDUP			0						0	0
MTCT		33,480	6,233,184				5,925,660		0	12,192,324
OHSS	71,166	108,810	3,081,960	350,000	75,000		6,956,579	40,000	0	10,683,515
PDCS		4,185	4,300,774		250,000		2,024,217		0	6,579,176
PDTX		16,740	5,085,479				4,264,335		0	9,366,554
	553,936	1,600,000	90,466,574	700,000	700,000	4,452,053	160,916,103	500,000	0	259,888,666



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	15,834,641	0
HKID	21,700,257	0
HVTB	9,158,599	0
PDCS	6,446,295	0
Total Technical Area Planned Funding:	53,139,792	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	11,294,068	0
HVSI	4,685,051	0
OHSS	9,366,001	0
Total Technical Area Planned Funding:	25,345,120	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	12,533,131	0
HMBL	1,221,350	0
HMIN	0	0
HVAB	3,137,483	0

Approved



HVCT	13,438,633	0
HVOP	7,213,047	0
IDUP	0	0
MTCT	11,772,110	0
Total Technical Area Planned Funding:	49,315,754	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	49,844,554	0
HTXS	50,145,790	0
PDTX	9,256,810	0
Total Technical Area Planned Funding:	109,247,154	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	5,439	4,439
	By program area/support type: HTC Direct Service Delivery (DSD)	1,656	1,656
	By program area/support type: HTC Technical Assistance-only (TA)	856	120
	By program area/support type: Treatment Direct Service Delivery (DSD)	424	424
	By program area/support type: Treatment Technical Assistance-only (TA)	127	50
	By program area/support type: Care and Support Direct Service Delivery (DSD)	1,364	1,364
	By program area/support type: Care and Support Technical Assistance-only (TA)	189	189
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	827	827
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	18	18



	By program area/support type: PMTCT Direct Service Delivery (DSD)	628	628
	By program area/support type: PMTCT Technical Assistance-only (TA)	577	577
	By program area/support type: TB/HIV Direct Service Delivery (DSD)	610	610
	By program area/support type: TB/HIV Technical Assistance-only (TA)	123	123
	By program area/support type: VMMC Direct Service Delivery (DSD)	153	153
	By program area/support type: VMMC Technical Assistance-only (TA)	13	13
	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	1,306	1,306
	By program area/support type: General Population Prevention Technical Assistance-only (TA)	370	370
	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	68	68
	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	36	36
	By program area/support	3,188	3,188



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	52	52
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	118	118
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	359	359
	By program area/support type: Lab Direct Service Delivery (DSD)	177	177
	By program area/support type: Lab Technical Assistance-only (TA)	541	541
PMTCT_SITE	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	79 %	
	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	950	950
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1,205	1,205
	By site support type: Direct Service Delivery (DSD):	325	325



	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	625	625
	Sum of Numerator Support Type disaggregates	950	950
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	409	409
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	796	796
	Sum of Denominator Support Type disaggregates	1,205	1,205
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	88 %	
	Number of pregnant women	356,191	374,001



	with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients	406,727	427,063
	By: Known positives at entry	22,929	24,075
	By: Number of new positives identified	26,262	27,575
	Sum of Positives Status disaggregates	49,191	51,650
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		
	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_NA	PMTCT_STAT_NA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (Neither)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
	Number of new ANC and L&D clients	0	0
	By: Known positives at entry	0	0
	By: Number of new positives identified	0	0
	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received	90 %	



	their results) (NGI)		
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	609,298	639,763
	Number of new ANC and L&D clients	676,480	710,304
	By: Known positives at entry	32,864	34,507
	By: Number of new positives identified	43,577	45,756
	Sum of Positives Status disaggregates	76,441	80,263
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	94 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	253,107	265,762
	Number of new ANC and L&D clients	269,753	283,241
	By: Known positives at entry	9,935	10,432
	By: Number of new positives identified	17,315	18,181
	Sum of Positives Status disaggregates	27,250	28,613
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS		



	countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator: 15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	96 %	



	mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)		
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	36,400	45,500
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	37,793	47,241
	Life-long ART (including Option B+)	36,400	45,500
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	15,494	19,367
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	20,906	26,133
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0



	Sum of Regimen Type disaggregates	36,400	45,500
	Sum of New and Current disaggregates	36,400	45,500
PMTCT_ARV_NA	PMTCT_ARV_NA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (Neither)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	210	263
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	218	272
	Life-long ART (including Option B+)	210	263
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	34	43
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	176	220
	Maternal triple ARV prophylaxis (provided with	0	0



	the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen disaggregates	210	263
	Sum of New and Current disaggregates	210	263
PMTCT_ARV_NGI	PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI)	94 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	64,936	81,171
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	69,161	86,451
	Life-long ART (including Option B+)	64,936	81,171



	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	25,662	32,078
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	39,274	49,093
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen disaggregates	64,936	81,171
	Sum of New and Current disaggregates	64,936	81,171
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	91 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission	28,326	35,408



	(MTCT) during pregnancy and delivery		
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	31,150	38,938
	Life-long ART (including Option B+)	28,326	35,408
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	10,134	12,668
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	18,192	22,740
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	28,326	35,408
	Sum of New and Current disaggregates	28,326	35,408
BS_COLL	Number of whole blood collections each year by the NBTs network	111,904	120,000
	By: Number of whole blood	111,904	120,000



	donations screened for HIV in an NBTS network laboratory		
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	3,735	16,800
ZM.346	ZM.346 Percentage of donated blood units screened for HIV in a quality assured manner	100 %	
	Number of donated blood units screened for HIV in a quality assured manner	148,000	150,000
	Total number of blood units donated	148,000	150,000
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	413	392
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	10	10
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	4	4



	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6	6
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	361	343
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	319	303
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	42	40
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	42	40
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	32	30



	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	10	10
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	115,125	247,636
	By Age: <1	10,182	21,901
	By Age: 1-9	0	0
	By Age: 10-14	32,196	69,254
	By Age: 15-19	32,196	69,254
	By Age: 20-24	19,819	42,631
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	798	1,717
	Sum of age disaggregates	115,125	247,636
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	13,815	29,716
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	100,215	216,825
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,095	1,095
	By circumcision technique:	115,125	247,636



	Surgical VMMC		
	By circumcision technique: Device-based VMMC	0	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	97,856	210,491
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	17,269	37,145
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	0	0
	By Age: 15-19	0	0
	By Age: 20-24	0	0
	By Age: 25-49	0	0
	By Age: 50+	0	0
	Sum of Age disaggregates	0	0
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC)	0	0



	program		
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
	By circumcision technique: Surgical VMMC	0	0
	By circumcision technique: Device-based VMMC	0	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	122,268	263,000
	By Age: <1	10,187	21,913
	By Age: 1-9	0	0
	By Age: 10-14	34,061	73,265
	By Age: 15-19	34,122	73,396
	By Age: 20-24	21,331	45,884
	By Age: 25-49	21,142	45,477
	By Age: 50+	1,425	3,065



	Sum of Age disaggregates	122,268	263,000
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	13,858	29,808
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	107,315	232,097
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,095	1,095
	By circumcision technique: Surgical VMMC	116,076	262,295
	By circumcision technique: Device-based VMMC	328	705
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	98,606	222,951
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	17,470	39,344
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,143	15,364
	By Age: <1	5	12



	By Age: 1-9	0	0
	By Age: 10-14	1,865	4,011
	By Age: 15-19	1,926	4,142
	By Age: 20-24	1,512	3,253
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	627	1,348
	Sum of Age disaggregations	7,143	15,364
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	43	92
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	7,100	15,272
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
	By circumcision technique: Surgical VMMC	951	14,659
	By circumcision technique: Device-based VMMC	328	705
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	750	12,460
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14	201	2,199



	days of circumcision surgery		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	13 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	759,024	796,977
	Total number of people in the target population	6,023,386	6,324,555
	Age/sex: 10-14 Male	68,514	71,940
	Age/sex: 15-19 Male	74,776	78,515
	Age/sex: 20-24 Male	116,559	122,387
	Age/sex: 25-49 Male	81,350	85,418
	Age/sex: 50+ Male	16,616	17,447
	Age/sex: 10-14 Female	65,931	69,228
	Age/sex: 15-19 Female	78,078	81,982
	Age/sex: 20-24 Female	127,677	134,061
	Age/sex: 25-49 Female	109,237	114,699
	Age/sex: 50+ Female	20,286	21,300
	Sum of Age/Sex disaggregates	759,024	796,977
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the	38 %	



	reporting period (TA-only)		
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	92,417	97,039
	Total number of people in the target population	246,168	258,476
	Age/sex: 10-14 Male	4,878	5,122
	Age/sex: 15-19 Male	15,468	16,241
	Age/sex: 20-24 Male	7,470	7,844
	Age/sex: 25-49 Male	17,918	18,814
	Age/sex: 50+ Male	816	857
	Age/sex: 10-14 Female	5,471	5,745
	Age/sex: 15-19 Female	16,123	16,929
	Age/sex: 20-24 Female	7,792	8,182
	Age/sex: 25-49 Female	16,026	16,827
	Age/sex: 50+ Female	455	478
	Sum of Age/Sex disaggregates	92,417	97,039
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence	15,331	16,098



	and/or meet the minimum standards required		
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,024	15,775
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12	13
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12	13
	By key population type: Men who have sex with	271	285



	<p>men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		
	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	12	13
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		



	area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,374	16,530
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key	2,100	2,415



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,274	14,115



	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	0	0
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)</p>		



	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,171,397	1,194,825
	By Test Result: Negative	1,026,120	1,046,642
	By Test Result: Positive	145,277	148,183
	Sum of Test Result disaggregates	1,171,397	1,194,825
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		



	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		



	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	80,572	82,183
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	408,238	416,403
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	79,501	81,091
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	603,086	615,148
	Sum of Aggregated Age/Sex <15	160,073	163,274
	Sum of Aggregated Age/Sex 15+	1,011,324	1,031,551
	Sum of Aggregated Age/Sex disaggregates	1,171,397	1,194,825
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by		



	Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		



	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by		



	Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		



	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	114,906	117,204
	By Test Result: Negative	99,923	101,921
	By Test Result: Positive	14,983	15,283
	Sum of Test Result disaggregates	114,906	117,204



	Age/sex: <1 Male	846	864
	Age/sex: 1-4 Male	1,601	1,633
	Age/sex: 5-9 Male	1,374	1,401
	Age/sex: 10-14 Male	3,673	3,746
	Age/sex: 15-19 Male	7,654	7,807
	Age/sex: 20-24 Male	13,090	13,352
	Age/sex: 25-49 Male	21,319	21,745
	Age/sex: 50+ Male	1,273	1,298
	Age/sex: <1 Female	879	898
	Age/sex: 1-4 Female	924	942
	Age/sex: 5-9 Female	1,120	1,142
	Age/sex: 10-14 Female	3,172	3,235
	Age/sex: 15-19 Female	8,878	9,056
	Age/sex: 20-24 Female	20,691	21,105
	Age/sex: 25-49 Female	23,806	24,282
	Age/sex: 50+ Female	4,606	4,698
	Sum of Age/Sex disaggregates	114,906	117,204
	Aggregated Age/sex: <15 Male	7,494	7,644
	Aggregated Age/sex: 15+ Male	43,336	44,202
	Aggregated Age/sex: <15 Female	6,095	6,217
	Aggregated Age/sex: 15+ Female	57,981	59,141
	Sum of Aggregated Age/Sex <15	13,589	13,861
	Sum of Aggregated Age/Sex 15+	101,317	103,343
	Sum of Aggregated Age/Sex disaggregates	114,906	117,204
HTC_TST_NGI	Number of individuals who	2,044,090	2,084,972



	received T&C services for HIV and received their test results during the past 12 months		
	By Test Result: Negative	1,776,558	1,812,089
	By Test Result: Positive	267,532	272,883
	Sum of Test Result disaggregates	2,044,090	2,084,972
	Age/sex: <1 Male	20,944	21,363
	Age/sex: 1-4 Male	23,656	24,129
	Age/sex: 5-9 Male	20,303	20,709
	Age/sex: 10-14 Male	56,297	57,423
	Age/sex: 15-19 Male	162,701	165,955
	Age/sex: 20-24 Male	162,647	165,900
	Age/sex: 25-49 Male	329,736	336,331
	Age/sex: 50+ Male	92,498	94,348
	Age/sex: <1 Female	20,753	21,167
	Age/sex: 1-4 Female	22,767	23,222
	Age/sex: 5-9 Female	19,827	20,224
	Age/sex: 10-14 Female	37,575	38,327
	Age/sex: 15-19 Female	218,562	222,933
	Age/sex: 20-24 Female	261,832	267,069
	Age/sex: 25-49 Female	422,830	431,287
	Age/sex: 50+ Female	171,162	174,585
	Sum of Age/Sex disaggregates	2,044,090	2,084,972
	Aggregated Age/sex: <15 Male	121,200	123,624
	Aggregated Age/sex: 15+ Male	747,582	762,534
	Aggregated Age/sex: <15 Female	100,922	102,940
	Aggregated Age/sex: 15+	1,074,386	1,095,874



	Female		
	Sum of Aggregated Age/Sex <15	222,122	226,564
	Sum of Aggregated Age/Sex 15+	1,821,968	1,858,408
	Sum of Aggregated Age/Sex disaggregates	2,044,090	2,084,972
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	757,787	772,943
	By Test Result: Negative	650,515	663,526
	By Test Result: Positive	107,272	109,417
	Sum of Test Result disaggregates	757,787	772,943
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		



	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		



	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	33,134	33,797
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	296,008	301,928
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,326	15,633
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	413,319	421,585
	Sum of Aggregated Age/Sex <15	48,460	49,430
	Sum of Aggregated Age/Sex 15+	709,327	723,513
	Sum of Aggregated Age/Sex disaggregates	757,787	772,943
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by		



	Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		



	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by		



	Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		
	Service Delivery Point by		



	Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
GEND_GBV_DSD	Number of people receiving post-GBV care	13,601	15,642
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		



	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex Disaggregates		
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	11,644	13,391
	By type of service: Sexual Violence (Post-Rape Care)	2,047	2,354
	By PEP service provision (related to sexual violence services provided)	465	535
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	64,316	73,963
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9	4,360	5,014
	By Age: 10-14	10,682	12,284
	By Age: 15-19	13,575	15,611
	By Age: 20-24	15,400	17,710
	By Age: 25+	20,299	23,344
	Sum of Age disaggregates	64,316	73,963
OVC_ACC_DSD	Number of active	3,060	3,213



	beneficiaries receiving support from PEPFAR OVC programs to access HIV services		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex disaggregates		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	733,404	770,074
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		



	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS		



	countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age		



	and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS		



	countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,567	10,045
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By age/sex: 18-24 Male		



	By age/sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By age/sex: 18-24 Female		
	By age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex:		



	Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program		



	Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social		



	Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	602,803	632,943



	By Age/Sex: <15 Female	23,450	24,622
	By Age/Sex: <15 Male	24,798	26,038
	By Age/Sex: 15+ Female	345,533	362,810
	By Age/Sex: 15+ Male	209,022	219,473
	Sum of Age/Sex disaggregates	602,803	632,943
	By Age: <15	48,248	50,660
	By Age: 15+	554,555	582,283
	Sum of Age disaggregates	602,803	632,943
	By Sex: Female	368,983	387,432
	By Sex: Male	233,820	245,511
	Sum of Sex disaggregates	602,803	632,943
	Number of HIV-positive individuals receiving a minimum of one clinical service	31,049	32,602
C2.1.D_NA	By Age/Sex: <15 Female	1,170	1,229
	By Age/Sex: <15 Male	1,207	1,267
	By Age/Sex: 15+ Female	17,001	17,851
	By Age/Sex: 15+ Male	11,671	12,255
	Sum of Age/Sex disaggregates	31,049	32,602
	By Age: <15	2,377	2,496
	By Age: 15+	28,672	30,106
	Sum of Age disaggregates	31,049	32,602
	By Sex: Female	18,171	19,080
	By Sex: Male	12,878	13,522
	Sum of Sex disaggregates	31,049	32,602
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	911,889	957,484
	By Age/Sex: <15 Female	37,897	39,792



	By Age/Sex: <15 Male	39,861	41,854
	By Age/Sex: 15+ Female	515,575	541,354
	By Age/Sex: 15+ Male	318,556	334,484
	Sum of Age/Sex disaggregates	911,889	957,484
	By Age: <15	77,758	81,646
	By Age: 15+	834,131	875,838
	Sum of Age disaggregates	911,889	957,484
	By Sex: Female	553,472	581,146
	By Sex: Male	358,417	376,338
	Sum of Sex disaggregates	911,889	957,484
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	278,037	291,939
	By Age/Sex: <15 Female	13,277	13,941
	By Age/Sex: <15 Male	13,856	14,549
	By Age/Sex: 15+ Female	153,041	160,693
	By Age/Sex: 15+ Male	97,863	102,756
	Sum of Age/Sex disaggregates	278,037	291,939
	By Age: <15	27,133	28,490
	By Age: 15+	250,904	263,449
	Sum of Age disaggregates	278,037	291,939
	By Sex: Female	166,318	174,634
	By Sex: Male	111,719	117,305
	Sum of Sex disaggregates	278,037	291,939
C2.4.D_DSD	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	20 %	
	Number of HIV-positive	120,479	126,503



	patients who were screened for TB in HIV care or treatment setting		
	Number of HIV-positive individuals receiving a minimum of one clinical service	602,803	632,943
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	215,389	226,158
	Age/sex: <1 Male	988	1,037
	Age/sex: 1-4 Male	1,987	2,086
	Age/sex: 5-9 Male	3,785	3,974
	Age/sex: 10-14 Male	2,792	2,932
	Age/sex: 15-19 Male	2,786	2,925
	Age/sex: 20-24 Male	6,648	6,980
	Age/sex: 25-49 Male	48,776	51,215
	Age/sex: 50+ Male	13,841	14,533
	Age/sex: <1 Female	1,053	1,106
	Age/sex: 1-4 Female	2,596	2,726
	Age/sex: 5-9 Female	4,785	5,024
	Age/sex: 10-14 Female	4,251	4,464
	Age/sex: 15-19 Female	5,198	5,458
	Age/sex: 20-24 Female	12,339	12,956
	Age/sex: 25-49 Female	82,155	86,263
	Age/sex: 50+ Female	21,409	22,479
	Sun of Age/Sex disaggregates	215,389	226,158
	Aggregated Age/sex - USE WITH HQ PERMISSION	9,552	10,029



	ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	72,051	75,654
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,685	13,319
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	121,101	127,156
	Sum of Aggregated Age/Sex disaggregates	215,389	226,158
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	204,259	214,473
	Age/sex: <1 Male	226	237
	Age/sex: 1-4 Male	754	792
	Age/sex: 5-9 Male	2,347	2,464
	Age/sex: 10-14 Male	2,038	2,140
	Age/sex: 15-19 Male	1,576	1,655
	Age/sex: 20-24 Male	1,355	1,423
	Age/sex: 25-49 Male	49,662	52,145
	Age/sex: 50+ Male	16,841	17,683
	Age/sex: <1 Female	196	206
	Age/sex: 1-4 Female	1,032	1,084
	Age/sex: 5-9 Female	2,821	2,962
	Age/sex: 10-14 Female	2,460	2,583
	Age/sex: 15-19 Female	2,524	2,650
	Age/sex: 20-24 Female	4,593	4,823
Age/sex: 25-49 Female	92,824	97,465	



	Age/sex: 50+ Female	23,010	24,161
	Sum of Age/Sex disaggregates	204,259	214,473
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,365	5,633
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	69,434	72,906
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,509	6,835
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	122,951	129,099
	Sum of Aggregated Age/Sex disaggregates	204,259	214,473
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	43,555	45,734
	Age/sex: <1 Male	325	341
	Age/sex: 1-4 Male	953	1,001
	Age/sex: 5-9 Male	560	588
	Age/sex: 10-14 Male	776	815
	Age/sex: 15-19 Male	1,030	1,082
	Age/sex: 20-24 Male	1,616	1,697
	Age/sex: 25-49 Male	11,523	12,099
	Age/sex: 50+ Male	1,416	1,487



	Age/sex: <1 Female	346	363
	Age/sex: 1-4 Female	771	810
	Age/sex: 5-9 Female	588	617
	Age/sex: 10-14 Female	892	937
	Age/sex: 15-19 Female	1,361	1,429
	Age/sex: 20-24 Female	4,073	4,277
	Age/sex: 25-49 Female	15,718	16,504
	Age/sex: 50+ Female	1,607	1,687
	Sum of Age/sex disaggregates	43,555	45,734
	Aggregated Age/sex: <15 Male	2,614	2,745
	Aggregated Age/sex: 15+ Male	15,585	16,365
	Aggregated Age/sex: <15 Female	2,597	2,727
	Aggregated Age/sex: 15+ Female	22,759	23,897
	Sum of Aggregated Age/sex disaggregates	43,555	45,734
CARE_SITE	CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	93 %	
	Number of PEPFAR-supported HIV clinical care sites at which at	522	522



	<p>least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole</p>		
	<p>Total number of PEPFAR supported sites providing clinical care services</p>	564	564
	<p>By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole</p>	431	431
	<p>By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND</p>	91	91



	3) if eligible, cotrimoxazole		
	Sum of Numerator Site Support Type disaggregates	522	522
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	411	411
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	153	153
	Sum of Denominator Site Support Type disaggregates	564	564
FN_SITE	FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition assessments that result in an accurate categorization of malnutrition	90 %	
	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	62	62
	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	69	69
	By site support type: Direct Service Delivery (DSD):	43	43



	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	19	19
	Sum of Numerator Support Type disaggregates	62	62
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	50	50
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	19	19
	Sum of Denominator Support Type disaggregates	69	69
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary	100 %	



	food		
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	19,846	22,822
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	19,846	22,822
	Age: <1	580	667
	Age: 1-4	2,294	2,638
	Age: 5-14	4,795	5,514
	Age: 15-17	2,683	3,085
	Age: 18+	9,494	10,918
	Sum of Age disaggregates	19,846	22,822
	Aggregated Age: <18	10,352	11,904
	Aggregated Age: 18+	9,494	10,918
	Sum of Aggregated Age disaggregates	19,846	22,822
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	36 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,852	6,730



	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	16,297	18,742
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male	1,910	2,197
	Female	3,942	4,533
	Sum of Sex disaggregates	5,852	6,730
	Newly tested	922	1,060
	Known HIV-positive	4,930	5,670
	Sum of Test Status disaggregates	5,852	6,730
	Aggregated Age: <15	1,856	2,135
	Aggregated Age: 15+	3,996	4,595
	Sum of Aggregated Age disaggregates	5,852	6,730
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ARTSITE	TB_ARTSITE Proportion of PEPFAR-supported TB basic management units at which 80% of registered TB cases	100 %	



	who are HIV-positive are on ART		
	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	442	442
	The number of PEPFAR-supported TB basic management units	442	442
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	403	403
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	39	39
	Sum of Numerator Site Support Type disaggregates	442	442
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic	398	398



	management units		
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	44	44
	Sum of Denominator Site Support Type disaggregates	442	442
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	97 %	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	208,027	222,589
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	215,389	226,158
	Age: <1	235	252
	Age: 1-4	1,262	1,350
	Age: 5-9	2,807	3,003
	Age: 10-14	5,106	5,463
	Age: 15-19	17,879	19,131
	Age: 20+		
	Sum of Age disaggregates	27,289	29,199
Aggregated Age - USE WITH HQ PERMISSION ONLY:	9,410	10,068	



	<15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	198,617	212,521
	Sum of Aggregated Age disaggregates	208,027	222,589
	Sex: Male	89,009	95,240
	Sex: Female	119,018	127,349
	Sum of Sex disaggregates	208,027	222,589
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	87 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	55,066	65,326
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	63,013	72,465
	By infants who received a virologic test within 2 months of birth	27,605	33,746
	By infants who received their first virologic HIV test between 2 and 12 months of age	27,461	31,580
	Sum of Infant Age disaggregates	55,066	65,326
	By infants with a positive virologic test result within 12	7,463	7,836



	months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	530,886	654,591
	Age/Sex: <1 Male	1,966	2,449
	Age/Sex: 1-4 Male	3,995	4,977
	Age/Sex: 5-14 Male	13,009	16,208
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	2,044	2,547
	Age/Sex: 1-4 Female	4,047	5,042
	Age/Sex: 5-14 Female	13,055	16,265
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	1,966	2,449
	Aggregated Age/Sex: <1 Female	2,044	2,547
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	186,216	225,162
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	306,554	381,941
	Sum of Aggregated Age/Sex <15	38,116	47,488



	Sum of Aggregated Age/Sex 15+	492,770	607,103
	Sum of Aggregated Age/Sex disaggregates	530,886	654,591
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	27,119	30,303
	Age/Sex: <1 Male	842	950
	Age/Sex: 1-4 Male	122	152
	Age/Sex: 5-14 Male	235	293
	Age/Sex: 15+ Male	8,723	9,630
	Age/Sex: <1 Female	842	901
	Age/Sex: 1-4 Female	127	158
	Age/Sex: 5-14 Female	233	291
	Age/Sex: 15+ Female	15,995	17,928
	Sum of Age/Sex disaggregates	27,119	30,303
	Aggregated Age/Sex: <1 Male	842	950
	Aggregated Age/Sex: <1 Female	842	901
	Aggregated Age/Sex: <15 Male	1,199	1,395
	Aggregated Age/Sex: 15+ Male	8,723	9,630
	Aggregated Age/Sex: <15 Female	1,202	1,350
	Aggregated Age/Sex: 15+ Female	15,995	17,928
	Sum of Aggregated Age/Sex <15	2,401	2,745
	Sum of Aggregated Age/Sex 15+	24,718	27,558
	Sum of Aggregated Age/Sex	27,119	30,303



	disaggregations		
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	578,083	720,243
	Age/Sex: <1 Male	2,912	3,529
	Age/Sex: 1-4 Male	4,267	5,316
	Age/Sex: 5-14 Male	13,722	17,097
	Age/Sex: 15+ Male	206,545	246,652
	Age/Sex: <1 Female	22,964	24,864
	Age/Sex: 1-4 Female	4,275	5,326
	Age/Sex: 5-14 Female	13,392	16,686
	Age/Sex: 15+ Female	323,275	400,773
	Sum of Age/Sex disaggregates	591,352	720,243
	Aggregated Age/Sex: <1 Male	2,912	3,529
	Aggregated Age/Sex: <1 Female	22,964	24,864
	Aggregated Age/Sex: <15 Male	20,901	25,942
	Aggregated Age/Sex: 15+ Male	206,545	246,652
	Aggregated Age/Sex: <15 Female	40,631	46,876
	Aggregated Age/Sex: 15+ Female	323,275	400,773
	Sum of Aggregated Age/Sex disaggregates	591,352	720,243
	Sum of Aggregated Age/Sex <15	61,532	72,818
	Sum of Aggregated Age/Sex 15+	529,820	647,425
	TX_CURR_TA	Number of adults and children receiving	20,078



	antiretroviral therapy (ART)		
	Age/Sex: <1 Male	101	126
	Age/Sex: 1-4 Male	148	184
	Age/Sex: 5-14 Male	477	594
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	104	130
	Age/Sex: 1-4 Female	150	187
	Age/Sex: 5-14 Female	478	596
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations	1,458	1,817
	Aggregated Age/Sex: <1 Male	101	126
	Aggregated Age/Sex: <1 Female	104	130
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	7,014	7,739
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	11,606	11,860
	Sum of Aggregated Age/Sex <15	1,458	1,817
	Sum of Aggregated Age/Sex 15+	18,620	19,599
	Sum of Aggregated Age/Sex disaggregates	20,078	21,416
TX_DIST	TX_DIST Percentage of Districts that are PEPFAR	100 %	



	supported with documented routine supportive supervision visits to 75% of ART sites in District		
	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	31	31
	Total number of PEPFAR supported District Health Offices	31	31
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	77,135	120,980
	By Age/Sex: <1 Male	422	662
	By Age/Sex: 1-4 Male	1,210	1,897
	By Age/Sex: 5-9 Male	984	1,544
	By Age/Sex: 10-14 Male	1,232	1,932
	By Age/Sex: 15-19 Male	1,429	2,242
	By Age/Sex: 20-24 Male	2,499	3,920
	By Age/Sex: 25-49 Male	18,557	29,105
	By Age/Sex: 50+ Male	3,809	5,975
	By Age/Sex: <1 Female	582	912
	By Age/Sex: 1-4 Female	1,063	1,667
	By Age/Sex: 5-9 Female	1,132	1,776
	By Age/Sex: 10-14 Female	1,997	3,132
	By Age/Sex: 15-19 Female	2,405	3,772
	By Age/Sex: 20-24 Female	6,165	9,669
	By Age/Sex: 25-49 Female	28,666	44,960
	By Age/Sex: 50+ Female	4,983	7,815
	Sum of Age/Sex disaggregates	77,135	120,980



	Aggregated Grouping by Age: <1 Male	422	662
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	26,294	41,242
	Aggregated Grouping by Age/Sex: <1 Female	582	912
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	42,219	66,216
	Sum of Aggregated Age/Sex disaggregates	77,135	120,980
	Pregnancy status	7,735	12,132
	Breastfeeding status	361	556
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	77 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	54,178	89,775
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	70,412	105,618
	Age/Sex: <5 Male (Numerator: Number of		



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of		



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,		



	including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number		



	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_SITE	TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	58 %	
	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	246	297



	Total number of PEPFAR-supported ART sites	424	424
	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	193	233
	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	53	64
	Sum of Numerator Site Support Type disaggregates	246	297
	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	311	304
	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	113	120
	Sum of Denominator Site Support Type disaggregates	424	424
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that	181	181



	are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	292	292
	By clinical laboratories	256	256
	By Point-of-care testing sites	36	36
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	78	78
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	472	472
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	481	481
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	440	440



	CD4: Number of laboratories that perform this testing	177	177
	CD4: Number of laboratories that participate in this PT program	161	161
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	161	161
	Early infant diagnostics: Number of laboratories that perform this testing	4	4
	Early infant diagnostics: Number of laboratories that participate in this PT program	3	3
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3	3
	HIV viral load: Number of laboratories that perform this testing	3	3
	HIV viral load: Number of laboratories that participate in this PT program	2	2
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	2
	TB diagnostics (AFB microscopy): Number of laboratories that perform this		



	testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of		



	laboratories that achieve acceptable successful passing criteria in this PT program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	3,557	3,735
	By Graduates: Doctors	128	134
	By Graduates: Nurses	238	250
	By Graduates: Midwives	146	153
	By Graduates: Social service workers	253	266
	By Graduates: Laboratory professionals	1	1
	By Graduates: Other	2,791	2,931
	Sum of Graduates disaggreagtes	3,557	3,735
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	100 %	
	Number of individuals who received competency-based, certificate or higher-level training to conduct or support	4	4



	supply chain, inventory management, supportive supervision or distribution activities		
	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	4	4
	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	0	0
	By: Individuals who passed a competency-based training to conduct supply chain activities	4	4
	By: Individuals who passed a competency-based training to perform inventory management	2	2
	By: Individuals who passed a competency-based training to develop distribution plans	0	0
	By: Individuals who passed a competency-based training to perform supportive supervision	4	4
	By: Individuals who passed a competency-based training to perform quantification	4	4
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of	83 %	



	HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services		
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	33	36
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	40	40
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
QI_SITE	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address clinical HIV program processes or outcomes and have documented process results in the last 6 months	98 %	
	Number of PEPFAR-supported clinical	239	243



	service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		
	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	243	243
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	70	74
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	169	169
	Sum of Numerator Site Support Type disaggregates	239	243
	By site support type: Direct Service Delivery (DSD):	201	201



	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC		
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	42	42
	Sum of Denominator Site Support Type disaggregates	243	243
SC_STOCK	SC_STOCK Storage sites which stock commodities according to plan	96 %	
	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	3,386	3,386
	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	3,527	3,527
	System Level: Central Medical Stores	0	0



	System Level: Regional Medical Stores	0	0
	System Level: District	0	0
	System Level: Health facility	15	15
	Commodity: Condoms	668	668
	Commodity: ARV drugs	281	281
	Commodity: Rapid test kits	1,644	1,644
	Commodity: OI drugs	653	653
	Commodity: Other	140	140
SI_HIS	Existence of a national registry of health facilities that is updated annually	0	1
	No common facility list	0	1
	USG only or Government only facility list	1	0
	Full national facility list coordinated with PEPFAR	0	1
	Full coordinated list made available as a common and managed Registry	0	0
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7422	Central Contraceptive Procurement	Private Contractor	U.S. Agency for International Development	GHP-State	2,000,000
7423	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	66,899,554
7427	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
7428	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,945,024
10203	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
10207	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	500,000
10212	Central Statistics Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	50,000



			Prevention		
10219	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,341,223
10220	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,370,000
10224	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
10225	Provincial Health Office - Eastern Province	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,198,292
10227	Provincial Health Office - Western Province	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,995,872



10235	University of Zambia School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
10236	University Teaching Hospital	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,280,000
10238	Zambia National Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,521,350
10241	Catholic Relief Services	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,600,671
10260	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	8,715,000
10274	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	900,000



			Control and Prevention		
10296	TBD	TBD	Redacted	Redacted	Redacted
10299	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
10314	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	0
10332	University of Nebraska	University	U.S. Department of Health and Human Services/National Institutes of Health	GHP-State	600,000
10354	Save the Children US	NGO	U.S. Agency for International Development	GHP-State	600,000
10364	Creative Associates International Inc	NGO	U.S. Agency for International Development	GHP-State	1,364,978
10725	Catholic Relief Services	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10726	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	1,400,000
10816	Boston University	University	U.S. Department of Health and Human	GHP-State	0



			Services/Centers for Disease Control and Prevention		
10817	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10875	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	150,000
10984	Project Concern International	NGO	U.S. Department of Defense	GHP-State	1,000,000
11027	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of State/Bureau of African Affairs	GHP-State	0
11626	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
11627	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
11694	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
12267	Catholic Relief	FBO	U.S. Agency for	GHP-State	1,500,000



	Services		International Development		
12271	Population Council	NGO	U.S. Agency for International Development	GHP-State	500,000
12272	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
12276	Macha Research Trust, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12283	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	40,000
12821	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	0
12942	Project Concern International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	725,000
12988	Care International	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	604,460



			for Disease Control and Prevention		
13006	CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	615,000
13016	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	575,000
13033	Population Council	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	663,427
13071	TBD	TBD	Redacted	Redacted	Redacted
13076	John Snow, Inc.	Private Contractor	U.S. Department of Defense	GHP-State	0
13096	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
13258	TBD	TBD	Redacted	Redacted	Redacted
13409	University of North Carolina at Chapel Hill, Carolina	University	U.S. Department of Health and Human Services/Centers	GHP-State	0



	Population Center		for Disease Control and Prevention		
13562	Chreso Ministries	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,644,125
13580	Centre for Infectious Diseases Research in Zambia (CIDRZ)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,334,723
13653	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	30,000
13684	University of Zambia School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	875,000
13731	Development Aid from People to People Humana Zambia	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	1,057,143



			Control and Prevention		
13787	Churches Health Association of Zambia	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,201,714
13792	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	2,608,500
14276	New York AIDS Institute	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	150,000
14338	World Vision International	FBO	U.S. Agency for International Development	GHP-State	0
14339	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
14392	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	495,000
14420	Lusaka Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	1,245,590



			for Disease Control and Prevention		
14421	Southern Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,978,564
14452	Population Services International	NGO	U.S. Department of Defense	GHP-State	0
14507	FHI 360	NGO	U.S. Department of Defense	GHP-State	0
16634	TBD	TBD	Redacted	Redacted	Redacted
16656	TBD	TBD	Redacted	Redacted	Redacted
16690	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	934,917
16833	Emory University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
16903	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers	GHP-State	200,000



			for Disease Control and Prevention		
17100	Zambia Center for Communication Programs	NGO	U.S. Agency for International Development	GHP-State	700,000
17168	Expanded Church Response Trust	NGO	U.S. Agency for International Development	GHP-State	1,000,000
17354	FHI 360	NGO	U.S. Agency for International Development	GHP-State	300,000
17355	(ASSIST) - Applying Science to Strengthen and Improve Systems Project	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
17356	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,292,384
17360	Education Development Center	NGO	U.S. Agency for International Development	GHP-State	4,250,000
17395	Luapula Foundation	NGO	U.S. Agency for International Development	GHP-State	1,000,000
17396	TBD	TBD	Redacted	Redacted	Redacted
17399	TBD	TBD	Redacted	Redacted	Redacted
17400	TBD	TBD	Redacted	Redacted	Redacted
17403	World Vision International	FBO	U.S. Agency for International Development	GHP-State	1,659,017
17410	TBD	TBD	Redacted	Redacted	Redacted
17411	TBD	TBD	Redacted	Redacted	Redacted



17413	TBD	TBD	Redacted	Redacted	Redacted
17414	TBD	TBD	Redacted	Redacted	Redacted
17421	TBD	TBD	Redacted	Redacted	Redacted
17422	TBD	TBD	Redacted	Redacted	Redacted
17424	ECSA-HC/Health Resouces for Alliance for Health (HRAA)	NGO	U.S. Agency for International Development	GHP-State	0
17425	TBD	TBD	Redacted	Redacted	Redacted
17439	TBD	TBD	Redacted	Redacted	Redacted
17440	TBD	TBD	Redacted	Redacted	Redacted
17441	TBD	TBD	Redacted	Redacted	Redacted
17448	Women and Law in Southern Africa	NGO	U.S. Agency for International Development	GHP-State	500,000
17449	TBD	TBD	Redacted	Redacted	Redacted
17477	TBD	TBD	Redacted	Redacted	Redacted
17478	TBD	TBD	Redacted	Redacted	Redacted
17479	TBD	TBD	Redacted	Redacted	Redacted
17483	TBD	TBD	Redacted	Redacted	Redacted
17497	TBD	TBD	Redacted	Redacted	Redacted
17499	Tropical Diseases Research Centre	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	362,271
17500	University of Zambia	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	525,000



			Prevention		
17501	University Teaching Hospital	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,568,400
17502	University of North Carolina	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	484,000
17513	TBD	TBD	Redacted	Redacted	Redacted
17514	TBD	TBD	Redacted	Redacted	Redacted
17517	TBD	TBD	Redacted	Redacted	Redacted
17519	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	25,000
17523	TBD	TBD	Redacted	Redacted	Redacted
17573	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	50,000
17587	TBD	TBD	Redacted	Redacted	Redacted

Approved



17761	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	249,737
-------	------------------	------------------	------------------	-----------	---------



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 17761	Mechanism Name: U.S. Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 249,737	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	249,737

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	135,181
Food and Nutrition: Policy, Tools, and Service Delivery	25,107
Economic Strengthening	17,843
Education	78,393
Gender: Gender Equality	21,088
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	7,282

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- Family Planning

Budget Code Information

Mechanism ID: 17761			
Mechanism Name: U.S. Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	213,478	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	12,505	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	23,754	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	182	182
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	84	84
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	98	98
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,527	15,254
PP_PREV_DSD	Total number of people in the target population	29,054	30,508
PP_PREV_DSD	Age/sex: 10-14 Male	1,741	1,829
PP_PREV_DSD	Age/sex: 15-19 Male	2,180	2,289
PP_PREV_DSD	Age/sex: 20-24 Male	1,670	1,754
PP_PREV_DSD	Age/sex: 25-49 Male	1,670	1,754
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	1,744	1,831
PP_PREV_DSD	Age/sex: 15-19 Female	2,182	2,289
PP_PREV_DSD	Age/sex: 20-24 Female	1,670	1,754
PP_PREV_DSD	Age/sex: 25-49 Female	1,670	1,754
PP_PREV_DSD	Age/sex: 50+ Female	0	



PP_PREV_DSD	Sum of Age/Sex disaggregates	14,527	15,254
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,949	17,796
PP_PREV_TA	Total number of people in the target population	33,898	35,592
PP_PREV_TA	Age/sex: 10-14 Male	2,032	2,133
PP_PREV_TA	Age/sex: 15-19 Male	2,543	2,671
PP_PREV_TA	Age/sex: 20-24 Male	1,949	2,046
PP_PREV_TA	Age/sex: 25-49 Male	1,949	2,046
PP_PREV_TA	Age/sex: 50+ Male	0	0
PP_PREV_TA	Age/sex: 10-14 Female	2,035	2,137
PP_PREV_TA	Age/sex: 15-19 Female	2,543	2,671
PP_PREV_TA	Age/sex: 20-24 Female	1,949	2,046
PP_PREV_TA	Age/sex: 25-49 Female	1,949	2,046
PP_PREV_TA	Age/sex: 50+ Female	0	0
PP_PREV_TA	Sum of Age/Sex disaggregates	16,949	17,796

Implementing Mechanism Details

Mechanism ID: 17587	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17573	Mechanism Name: ICAP/NEPI
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 50,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	50,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17573		
Mechanism Name:	ICAP/NEPI		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
------------------	-------	------	------	-------------------------



SITE_SUPP	Number of unique sites supported by PEPFAR	1		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	170	170	Redacted
HRH_PRE	By Graduates: Doctors	0	0	Redacted
HRH_PRE	By Graduates: Nurses	124	124	Redacted
HRH_PRE	By Graduates: Midwives	46	46	Redacted
HRH_PRE	By Graduates: Social service workers	0	0	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	0	0	Redacted
HRH_PRE	Sum of Graduates disaggregated	170	170	Redacted

Implementing Mechanism Details

Mechanism ID: 17523	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17519	Mechanism Name: CDC Technical Assistance - DRH
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 25,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 25,000	

Approved



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	25,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17519		
Mechanism Name:	CDC Technical Assistance - DRH		
Prime Partner Name:	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	25,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17517	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17514	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17513	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17502	Mechanism Name: UNC Eastern
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 484,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	484,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Family Planning

Budget Code Information

Mechanism ID: 17502			
Mechanism Name: UNC Eastern			
Prime Partner Name: University of North Carolina			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	244,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	126	126	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	28	28	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	98	98	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	19	19	Redacted

SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	54	54	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	482	437	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	538	484	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	482	437	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	209	175	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	273	262	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	482	437	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	482	437	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	54	54	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	54	54	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of	0	0	Redacted



	PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women			
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	54	54	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	54	54	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	54	54	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	54	54	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	23,778	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	0	24,206	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	0	228	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	0	294	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	0	522	Redacted
PMTCT_STAT_TA	Number of pregnant women with known	22,578	23,778	Redacted



	HIV status (includes women who were tested for HIV and received their results)			
PMTCT_STAT_TA	Number of new ANC and L&D clients	23,732	24,206	Redacted
PMTCT_STAT_TA	By: Known positives at entry	244	228	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	294	294	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	538	522	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,142	43,142	Redacted
HTC_TST_NGI	By Test Result: Negative	38,998	38,998	Redacted
HTC_TST_NGI	By Test Result: Positive	4,144	4,144	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	43,142	43,142	Redacted
HTC_TST_NGI	Age/sex: <1 Male	88	88	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2	2	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	134	134	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	4,780	4,780	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	13,852	13,852	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_NGI	Age/sex: <1 Female	112	112	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	16	16	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	3,196	3,196	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	8,428	8,428	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	12,534	12,534	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	43,142	43,142	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	90	90	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	18,766	18,766	Redacted



HTC_TST_NGI	Aggregated Age/sex: <15 Female	128	128	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	24,158	24,158	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	218	218	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	42,924	42,924	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	43,142	43,142	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,142	43,142	Redacted
HTC_TST_TA	By Test Result: Negative	38,998	38,998	Redacted
HTC_TST_TA	By Test Result: Positive	4,144	4,144	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	43,142	43,142	Redacted
HTC_TST_TA	Age/sex: <1 Male	88	88	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	2	2	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	134	134	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	4,780	4,780	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	13,852	13,852	Redacted
HTC_TST_TA	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_TA	Age/sex: <1 Female	112	112	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	16	16	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	3,196	3,196	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	8,428	8,428	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	12,534	12,534	Redacted
HTC_TST_TA	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	43,142	43,142	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	90	90	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	18,766	18,766	Redacted



	PERMISSION ONLY: 15+ Male			
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	128	128	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,158	24,158	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	218	218	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	42,924	42,924	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	43,142	43,142	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	9,178	0	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	287	0	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	262	0	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	2,776	0	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	5,853	0	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	9,178	0	Redacted
C2.1.D_TA	By Age: <15	549	0	Redacted
C2.1.D_TA	By Age: 15+	8,629	0	Redacted
C2.1.D_TA	Sum of Age disaggregates	9,178	0	Redacted
C2.1.D_TA	By Sex: Female	5,725	0	Redacted
C2.1.D_TA	By Sex: Male	3,453	0	Redacted
C2.1.D_TA	Sum of Sex disaggregates	9,178	0	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	432	387	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	538	484	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	389	348	Redacted
PMTCT_EID_DSD	By infants who received their first	43	39	Redacted

	virologic HIV test between 2 and 12 months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	432	387	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	17	15	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	5	25	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	54	54	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	5	25	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	5	25	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV	0	0	Redacted



	Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	54	54	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	54	54	Redacted

Implementing Mechanism Details

Mechanism ID: 17501	Mechanism Name: University Teaching Hospital
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Teaching Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,568,400	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 216,600	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,568,400

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 17501			
Mechanism Name: University Teaching Hospital			
Prime Partner Name: University Teaching Hospital			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,568,400	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1	1	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	9,386	4,693	Redacted

	mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,850	4,925	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	9,386	4,693	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	350	175	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	9,036	4,518	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	9,386	4,693	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	9,386	4,693	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,386	4,693	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,850	4,925	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	9,386	4,693	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	350	175	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	9,036	4,518	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted



PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	9,386	4,693	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	9,386	4,693	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	1	1	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	1	1	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,000	9,500	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	19,000	9,500	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	9,500	4,750	Redacted

PMTCT_STAT_DS D	By: Number of new positives identified	350	175	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	9,850	4,925	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,000	9,500	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	19,000	9,500	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	9,500	4,750	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	350	175	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	9,850	4,925	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,000	5,500	Redacted
PP_PREV_DSD	Total number of people in the target population	11,000	5,500	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	200	100	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,325	663	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	200	96	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,000	5,500	Redacted

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,000	38,000	Redacted
HTC_TST_DSD	By Test Result: Negative	66,655	33,327	Redacted
HTC_TST_DSD	By Test Result: Positive	9,345	4,673	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	76,000	38,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	3,000	1,500	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,375	688	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	750	375	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	300	150	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,235	2,118	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	8,470	4,235	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	17,264	8,631	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,606	803	Redacted
HTC_TST_DSD	Age/sex: <1 Female	3,000	1,500	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,375	688	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	750	375	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	300	150	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,235	2,118	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	8,469	4,235	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	17,265	8,631	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,606	1,803	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	76,000	38,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,425	2,713	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,575	15,787	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,425	2,713	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	33,575	16,787	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,850	5,426	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	65,150	32,574	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	76,000	38,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,000	38,000	Redacted
HTC_TST_NGI	By Test Result: Negative	66,655	33,327	Redacted
HTC_TST_NGI	By Test Result: Positive	9,345	4,673	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	76,000	38,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	3,000	1,500	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,375	688	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	750	375	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	300	150	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,235	2,118	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	8,470	4,235	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	17,264	8,631	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,606	803	Redacted
HTC_TST_NGI	Age/sex: <1 Female	3,000	1,500	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,375	688	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	750	375	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	300	150	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	4,235	2,118	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	8,469	4,235	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	17,265	8,631	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	3,606	1,803	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	76,000	38,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,425	2,713	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	31,575	15,787	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	5,425	2,713	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	33,575	16,787	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	10,850	5,426	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	65,150	32,574	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex	76,000	38,000	Redacted



	disaggregates			
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,324	662	Redacted
OVC_ACC_DSD	Sex: Male	464	232	Redacted
OVC_ACC_DSD	Sex: Female	860	430	Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,324	662	Redacted
OVC_ACC_DSD	Age: 5-9	142	71	Redacted
OVC_ACC_DSD	Age: 10-14	328	164	Redacted
OVC_ACC_DSD	Age: 15-17	266	133	Redacted
OVC_ACC_DSD	Age: 18+	588	294	Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,324	662	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,324	662	Redacted
OVC_SERV_DSD	Sex: Male	464	232	Redacted
OVC_SERV_DSD	Sex: Female	860	430	Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	1,324	662	Redacted
OVC_SERV_DSD	Age: 5-9	142	71	Redacted
OVC_SERV_DSD	Age: 10-14	328	164	Redacted
OVC_SERV_DSD	Age: 15-17	266	133	Redacted
OVC_SERV_DSD	Age: 18+	588	294	Redacted
OVC_SERV_DSD	Sum of Age disaggregates	1,324	662	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,000	6,000	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,000	1,000	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	2,000	1,000	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	7,600	3,800	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	400	200	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	12,000	6,000	Redacted
C2.1.D_DSD	By Age: <15	4,000	2,000	Redacted
C2.1.D_DSD	By Age: 15+	8,000	4,000	Redacted

C2.1.D_DSD	Sum of Age disaggregates	12,000	6,000	Redacted
C2.1.D_DSD	By Sex: Female	9,600	4,800	Redacted
C2.1.D_DSD	By Sex: Male	2,400	1,200	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	12,000	6,000	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	12,000	6,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	2,000	1,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	2,000	1,000	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	7,600	3,800	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	400	200	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	12,000	6,000	Redacted
C2.1.D_NGI	By Age: <15	4,000	2,000	Redacted
C2.1.D_NGI	By Age: 15+	8,000	4,000	Redacted
C2.1.D_NGI	Sum of Age disaggregates	12,000	6,000	Redacted
C2.1.D_NGI	By Sex: Female	9,600	4,800	Redacted
C2.1.D_NGI	By Sex: Male	2,400	1,200	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	12,000	6,000	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	12,000	6,000	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,000	6,000	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,500	3,500	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	60	60	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	448	448	Redacted



CARE_CURR_DS D	Age/sex: 5-9 Male	1,034	1,034	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	146	146	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	60	60	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	60	60	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	448	448	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,034	1,034	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	150	150	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	60	60	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	3,500	3,500	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,542	1,542	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	206	206	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,542	1,542	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	210	210	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	3,500	3,500	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,970	250	Redacted



CARE_NEW_DSD	Age/sex: <1 Male	36	18	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	72	36	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	52	26	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	62	31	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	26	13	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	15		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	670		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	50		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	38	19	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	74	37	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	50	25	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	64	32	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	26	13	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	15		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	670		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	50		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,970	250	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	222	124	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	761		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	226	126	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	761		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,970	250	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted



CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of	2	2	Redacted



	PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	650	250	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	650	250	Redacted
FN_THER_DSD	Age: <1	80	40	Redacted
FN_THER_DSD	Age: 1-4	110	55	Redacted
FN_THER_DSD	Age: 5-14	270	135	Redacted
FN_THER_DSD	Age: 15-17	40	20	Redacted
FN_THER_DSD	Age: 18+	150		Redacted
FN_THER_DSD	Sum of Age disaggregates	650	250	Redacted
FN_THER_DSD	Aggregated Age: <18	650	250	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	650	250	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	700		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	700		Redacted
TB_ART_DSD	Age: 15+	700		Redacted
TB_ART_DSD	Male	295		Redacted
TB_ART_DSD	Female	405		Redacted
TB_ART_DSD	Sum of Sex disaggregates	700		Redacted
TB_ART_DSD	Known HIV-positive	700		Redacted



TB_ART_DSD	Sum of Test Status disaggregates	700		Redacted
TB_ART_DSD	Aggregated Age: 15+	700		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	700		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	1		Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1		Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	1		Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	1		Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	1		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,693	2,347	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	9,386	4,693	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,223	2,112	Redacted
PMTCT_EID_DSD	By infants who received their first	470	235	Redacted

	virologic HIV test between 2 and 12 months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,693	2,347	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	563	286	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,500	3,500	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	60	60	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	448	448	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,034	1,034	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	208	208	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	60	60	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	448	448	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,034	1,034	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	208	208	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,084	3,084	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	60	60	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	60	60	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,542	1,542	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	208	208	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,542	1,542	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	208	208	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,084	3,084	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	416	416	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,500	3,500	Redacted



TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,500	3,500	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	60	60	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	448	448	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,034	1,034	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	208	208	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	60	60	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	448	448	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,034	1,034	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	208	208	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	3,500	3,500	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	60	60	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	60	60	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,542	1,542	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	208	208	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,542	1,542	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	208	208	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	3,500	3,500	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	3,084	3,084	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	416	416	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,440	1,690	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	35	17	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	75	38	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	58	29	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	74	37	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	16	8	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	30	30	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	420	650	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	20	40	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	38	19	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	54	27	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	75	38	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	59	29	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	16	8	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	30	30	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	420	650	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	20	40	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,440	1,690	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	35	17	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	242	121	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	486	728	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	38	19	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	226	113	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	486	728	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,440	1,690	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	550	275	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	550	275	Redacted



	those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,400	1,200	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator:	0	0	Redacted



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,760	1,500	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,400	1,200	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after	2	2	Redacted



	ART initiation			
TX_SITE	Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	2	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1	1	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1	1	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1	1	Redacted
LAB_CAP_DSD	By clinical laboratories	1	1	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1	1	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted



LAB_CAP_DSD	Sum of Site Support Type disaggregates	1	1	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	1	1	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	1	Redacted

LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	4		Redacted
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	4		Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to conduct supply chain activities	4		Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	2		Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform supportive supervision	4		Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform quantification	4		Redacted



QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	1	1	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	1	1	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	1	1	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	1	1	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	1	1	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	1	1	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,500	3,500	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,500	3,500	Redacted



TB_SCREEN_DSD	Age: <1	0	0	Redacted
TB_SCREEN_DSD	Age: 1-4	0	0	Redacted
TB_SCREEN_DSD	Age: 5-9	0	0	Redacted
TB_SCREEN_DSD	Age: 10-14	0	0	Redacted
TB_SCREEN_DSD	Age: 15-19	350	350	Redacted
TB_SCREEN_DSD	Age: 20-24	392	392	Redacted
TB_SCREEN_DSD	Age: 25-49	1,949	1,949	Redacted
TB_SCREEN_DSD	Age: 50+	809	809	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	350	350	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	3,500	3,500	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,500	3,500	Redacted
TB_SCREEN_DSD	Sex: Male	1,454	1,454	Redacted
TB_SCREEN_DSD	Sex: Female	2,046	2,046	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	3,500	3,500	Redacted

Implementing Mechanism Details

Mechanism ID: 17500	Mechanism Name: UNZA M&E, Department of Population Studies
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 525,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 75,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	525,000

Sub Partner Name(s)

Approved



(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	450,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17500		
Mechanism Name:	UNZA M&E, Department of Population Studies		
Prime Partner Name:	University of Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	450,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17499	Mechanism Name: TDRC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tropical Diseases Research Centre	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 362,271	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 112,729	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	362,271

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	45,000
---------------------------	--------

Key Issues

TB

Budget Code Information

Mechanism ID:	17499		
Mechanism Name:	TDRC		
Prime Partner Name:	Tropical Diseases Research Centre		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	112,271	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	250,000	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	77	77	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	77	77	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	77	77	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted



LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	77	77	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	77	77	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	70	70	Redacted

Implementing Mechanism Details

Mechanism ID: 17497	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 17483	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17479	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17478	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17477	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17449	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17448	Mechanism Name: Stamping Out and Preventing Gender Based Violence (STOP GBV) : Access to Justice
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Women and Law in Southern Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

CARE International in Zambia	Women in Law and Development in Africa (WiLDAF)	
------------------------------	---	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research



Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Motor Vehicles: Purchased	100,000

Key Issues

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	17448		
Mechanism Name:	Stamping Out and Preventing Gender Based Violence (STOP GBV) :		
Prime Partner Name:	Access to Justice		
	Women and Law in Southern Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	8	8
GEND_GBVDSD	Number of people receiving post-GBV care	4,136	4,136
GEND_GBVDSD	Age: 0-9	1,280	1,280
GEND_GBVDSD	Age: 10-14	640	640
GEND_GBVDSD	Age: 15-17	480	480
GEND_GBVDSD	Age: 18-24	360	360
GEND_GBVDSD	Age: 25+	1,376	1,376
GEND_GBVDSD	Sum of Age disaggregates	4,136	4,136
GEND_GBVDSD	Sex: Male	786	786
GEND_GBVDSD	Sex: Female	3,350	3,350
GEND_GBVDSD	Sum of Sex disaggregates	4,136	4,136
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,267	3,267
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	869	869

Implementing Mechanism Details

Mechanism ID: 17441	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17440	TBD: Yes
REDACTED	

Implementing Mechanism Details

Approved



Mechanism ID: 17439	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17425	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17424	Mechanism Name: Human Resources Alliance for Africa
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: ECSA-HC/Health Resources for Alliance for Health (HRAA)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Eastern & Southern Management Institute	JHPIEGO	Regional Center for Quality of Health Care
---	---------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- End-of-Program Evaluation
- Family Planning

Budget Code Information

Mechanism ID: 17424			
Mechanism Name: Human Resources Alliance for Africa			
Prime Partner Name: ECSA-HC/Health Resources for Alliance for Health (HRAA)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17422	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17421	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17414	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17413	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17411	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17410	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17403	Mechanism Name: Gender Based Violence - Survivor Support Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 1,659,017	Total Mechanism Pipeline: Redacted

Approved



Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,659,017

Sub Partner Name(s)

Expanded Church Response (ECR)	Forum for African Women Educationalists of Zambia	
--------------------------------	---	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	1,000,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	50,000

Key Issues

End-of-Program Evaluation
Family Planning

Budget Code Information

Mechanism ID:	17403		
Mechanism Name:	Gender Based Violence - Survivor Support Project		
Prime Partner Name:	World Vision International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,023,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	186,017	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	8	16
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	8	16
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	8	10
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	8	16
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,504	4,382
HTC_TST_DSD	By Test Result: Negative	2,232	3,906
HTC_TST_DSD	By Test Result: Positive	272	476
HTC_TST_DSD	Sum of Test Result disaggregates	2,504	4,382



HTC_TST_DSD	Age/sex: <1 Male	36	66
HTC_TST_DSD	Age/sex: 1-4 Male	38	68
HTC_TST_DSD	Age/sex: 5-9 Male	40	70
HTC_TST_DSD	Age/sex: 10-14 Male	50	80
HTC_TST_DSD	Age/sex: 15-19 Male	50	80
HTC_TST_DSD	Age/sex: 20-24 Male	60	90
HTC_TST_DSD	Age/sex: 25-49 Male	75	135
HTC_TST_DSD	Age/sex: 50+ Male	75	135
HTC_TST_DSD	Age/sex: <1 Female	195	345
HTC_TST_DSD	Age/sex: 1-4 Female	195	345
HTC_TST_DSD	Age/sex: 5-9 Female	195	345
HTC_TST_DSD	Age/sex: 10-14 Female	249	429
HTC_TST_DSD	Age/sex: 15-19 Female	318	552
HTC_TST_DSD	Age/sex: 20-24 Female	328	562
HTC_TST_DSD	Age/sex: 25-49 Female	300	540
HTC_TST_DSD	Age/sex: 50+ Female	300	540
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,504	4,382
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	164	284
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	260	440
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	834	1,464
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,246	2,194
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	998	1,748
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,506	2,634
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,504	4,382
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,504	4,382
HTC_TST_NGI	By Test Result: Negative	2,232	3,906
HTC_TST_NGI	By Test Result: Positive	272	476



HTC_TST_NGI	Sum of Test Result disaggregates	2,504	4,382
HTC_TST_NGI	Age/sex: <1 Male	36	66
HTC_TST_NGI	Age/sex: 1-4 Male	38	68
HTC_TST_NGI	Age/sex: 5-9 Male	40	70
HTC_TST_NGI	Age/sex: 10-14 Male	50	80
HTC_TST_NGI	Age/sex: 15-19 Male	50	80
HTC_TST_NGI	Age/sex: 20-24 Male	60	90
HTC_TST_NGI	Age/sex: 25-49 Male	75	135
HTC_TST_NGI	Age/sex: 50+ Male	75	135
HTC_TST_NGI	Age/sex: <1 Female	195	345
HTC_TST_NGI	Age/sex: 1-4 Female	195	345
HTC_TST_NGI	Age/sex: 5-9 Female	195	345
HTC_TST_NGI	Age/sex: 10-14 Female	249	429
HTC_TST_NGI	Age/sex: 15-19 Female	318	552
HTC_TST_NGI	Age/sex: 20-24 Female	328	562
HTC_TST_NGI	Age/sex: 25-49 Female	300	540
HTC_TST_NGI	Age/sex: 50+ Female	300	540
HTC_TST_NGI	Sum of Age/Sex disaggregates	2,504	4,382
HTC_TST_NGI	Aggregated Age/sex: <15 Male	164	284
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	260	440
HTC_TST_NGI	Aggregated Age/sex: <15 Female	834	1,464
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,246	2,194
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	998	1,748
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,506	2,634
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	2,504	4,382
GEND_GBV_DSD	Number of people receiving post-GBV care	9,001	15,751
GEND_GBV_DSD	Age: 0-9	1,175	2,075
GEND_GBV_DSD	Age: 10-14	1,200	2,100
GEND_GBV_DSD	Age: 15-17	1,326	2,226
GEND_GBV_DSD	Age: 18-24	2,596	4,618
GEND_GBV_DSD	Age: 25+	2,704	4,732
GEND_GBV_DSD	Sum of Age disaggregates	9,001	15,751



GEND_GBVDSD	Sex: Male	903	1,575
GEND_GBVDSD	Sex: Female	8,098	14,176
GEND_GBVDSD	Sum of Sex disaggregates	9,001	15,751
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8,098	14,176
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	903	1,575
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	360	360

Implementing Mechanism Details

Mechanism ID: 17400	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17399	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17396	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17395	Mechanism Name: District OVC Systems Strengthening (DOSS) / Community Rising
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Luapula Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	



G2G: No	Managing Agency:
Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

Catholic Medical Mission Board		
--------------------------------	--	--

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	300,000

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID: 17395			
Mechanism Name: District OVC Systems Strengthening (DOSS) / Community Rising			
Prime Partner Name: Luapula Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	24	28
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	24	28
HRH_PRE	Number of new HCW who graduated from a	716	1,250



	pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		
HRH_PRE	By Graduates: Doctors	0	0
HRH_PRE	By Graduates: Nurses	0	0
HRH_PRE	By Graduates: Midwives	0	0
HRH_PRE	By Graduates: Social service workers	0	0
HRH_PRE	By Graduates: Laboratory professionals	0	0
HRH_PRE	By Graduates: Other	716	1,250
HRH_PRE	Sum of Graduates disaggreagtes	716	1,250
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	0
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	0
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	0
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	1,072	1,072

Implementing Mechanism Details

Mechanism ID: 17360	Mechanism Name: Time To Learn
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Education Development Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 4,250,000	Total Mechanism Pipeline: Redacted
---	---

Approved



Applied Pipeline Amount: 1,606,842	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	4,250,000

Sub Partner Name(s)

CAMFED	Forum for African Women Educationalists of Zambia	
--------	--	--

Cross-Cutting Budget Attribution(s)

Education	4,000,000
-----------	-----------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17360		
Mechanism Name:	Time To Learn		
Prime Partner Name:	Education Development Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	2,408	2,408



SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	2,408	2,408
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	88,000	88,000
OVC_SERV_DSD	Sex: Male	43,407	43,407
OVC_SERV_DSD	Sex: Female	44,593	44,593
OVC_SERV_DSD	Sum of Sex disaggregates	88,000	88,000
OVC_SERV_DSD	Age: 5-9	48,000	48,000
OVC_SERV_DSD	Age: 10-14	32,000	32,000
OVC_SERV_DSD	Age: 15-17	6,530	6,530
OVC_SERV_DSD	Age: 18+	1,470	1,470
OVC_SERV_DSD	Sum of Age disaggregates	88,000	88,000

Implementing Mechanism Details

Mechanism ID: 17356	Mechanism Name: Food and Nutrition Technical Assistance (FANTA III)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,292,384	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,292,384

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
Food and Nutrition: Policy, Tools, and Service Delivery	542,384
Water	50,000

Key Issues

Child Survival Activities
TB

Budget Code Information

Mechanism ID:	17356		
Mechanism Name:	Food and Nutrition Technical Assistance (FANTA III)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	142,384	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: Food and	25	47



	Nutrition Direct Service Delivery (DSD)		
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	12,764	15,792
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	15,792	15,792
FN_THER_DSD	Age: <1	345	426
FN_THER_DSD	Age: 1-4	1,800	2,227
FN_THER_DSD	Age: 5-14	3,446	4,264
FN_THER_DSD	Age: 15-17	1,174	1,453
FN_THER_DSD	Age: 18+	5,999	7,422
FN_THER_DSD	Sum of Age disaggregates	12,764	15,792
FN_THER_DSD	Aggregated Age: <18	6,764	8,369
FN_THER_DSD	Aggregated Age: 18+	6,000	7,423
FN_THER_DSD	Sum of Aggregated Age disaggregates	12,764	15,792

Implementing Mechanism Details

Mechanism ID: 17355	Mechanism Name: Applying Science to Strengthen & Improve Systems Project (ASSIST)/USAID Healthcare Improvement Project (HCI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: (ASSIST) - Applying Science to Strengthen and Improve Systems Project	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
Food and Nutrition: Policy, Tools, and Service Delivery	100,000

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID:	17355		
Mechanism Name:	Applying Science to Strengthen & Improve Systems Project		
Prime Partner Name:	(ASSIST)/USAID Healthcare Improvement Project (HCI)		
Prime Partner Name:	(ASSIST) - Applying Science to Strengthen and Improve Systems Project		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
------------------	-------	------	------



FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	8	26
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	49	49
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	8	26
FN_SITE	Sum of Numerator Support Type disaggregates	8	26
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	49	49
FN_SITE	Sum of Denominator Support Type disaggregates	49	49

Implementing Mechanism Details

Mechanism ID: 17354	Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount



GHP-State	300,000
-----------	---------

Sub Partner Name(s)

Care International	World Vision	
--------------------	--------------	--

Cross-Cutting Budget Attribution(s)

Economic Strengthening	88,065
------------------------	--------

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID:	17354		
Mechanism Name:	Livelihoods and Food Security Technical Assistance (LIFT) II		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	3	3
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening	21	21



	efforts, within the reporting period, by select cadre		
HRH_PRE	By Graduates: Doctors	0	0
HRH_PRE	By Graduates: Nurses	0	0
HRH_PRE	By Graduates: Midwives	0	0
HRH_PRE	By Graduates: Social service workers	0	0
HRH_PRE	By Graduates: Laboratory professionals	0	0
HRH_PRE	By Graduates: Other	21	21
HRH_PRE	Sum of Graduates disaggreagtes	21	21
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	0
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	0
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	0
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	21	21

Implementing Mechanism Details

Mechanism ID: 17168	Mechanism Name: Zambian OVC Management Information Systems (ZOMIS) / Data Rising
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Expanded Church Response Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

Futures Group		
---------------	--	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Motor Vehicles: Purchased	80,000

Key Issues

End-of-Program Evaluation

Budget Code Information



Mechanism ID: 17168			
Mechanism Name: Zambian OVC Management Information Systems (ZOMIS) / Data Rising			
Prime Partner Name: Expanded Church Response Trust			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	1,400
HRH_PRE	By Graduates: Doctors	0	0
HRH_PRE	By Graduates: Nurses	0	0
HRH_PRE	By Graduates: Midwives	0	0
HRH_PRE	By Graduates: Social service workers	0	0
HRH_PRE	By Graduates: Laboratory professionals	0	0
HRH_PRE	By Graduates: Other	0	1,400
HRH_PRE	Sum of Graduates disaggreagtes	0	1,400

Implementing Mechanism Details

Mechanism ID: 17100	Mechanism Name: Stamping Out and Preventing Gender-Based Violence (STOP GBV) : Prevention & Advocacy
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Zambia Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:



Total All Funding Sources: 700,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	700,000

Sub Partner Name(s)

CARE International in Zambia	LifeLine/ChildLine	Women in Law and Development in Africa (WILDAF)
------------------------------	--------------------	---

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	300,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Key Issues

Child Survival Activities

Family Planning



Budget Code Information

Mechanism ID:	17100		
Mechanism Name:	Stamping Out and Preventing Gender-Based Violence (STOP GBV) :		
Prime Partner Name:	Prevention & Advocacy Zambia Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	550,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	997	10,603
GEND_NORM_DSD	By Age: 0-9	50	529
GEND_NORM_DSD	By Age: 10-14	199	2,120
GEND_NORM_DSD	By Age: 15-19	249	2,652
GEND_NORM_DSD	By Age: 20-24	300	3,182
GEND_NORM_DSD	By Age: 25+	199	2,120
GEND_NORM_DSD	Sum of Age disaggregates	997	10,603
GEND_NORM_DSD	By Sex: Male	299	3,182
GEND_NORM_DSD	By Sex: Female	698	7,421
GEND_NORM_DSD	Sum of Sex disaggregates	997	10,603
GEND_NORM_DSD	By type of activity: Individual	245	2,602
GEND_NORM_DSD	By type of activity: Small Group	246	2,620
GEND_NORM_DSD	By type of activity: Community-level	506	5,381



Implementing Mechanism Details

Mechanism ID: 16903	Mechanism Name: Evaluation of Integrated Community-Based and Clinical HIV/AIDS Interventions in Sinazongwe, Zambia
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	200,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	114,320
---------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16903
Mechanism Name:	Evaluation of Integrated Community-Based and Clinical HIV/AIDS Interventions in Sinazongwe, Zambia
Prime Partner Name:	Interventions in Sinazongwe, Zambia



Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16833	Mechanism Name: Human Resource Information System (HRIS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 150,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	350,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
----------------------------	---------



Key Issues

Workplace Programs

Budget Code Information

Mechanism ID: 16833			
Mechanism Name: Human Resource Information System (HRIS)			
Prime Partner Name: Emory University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16690		Mechanism Name: SAVVY	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: New Partner			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: No			
G2G: Yes		Managing Agency: HHS/CDC	
Total All Funding Sources: 934,917		Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 400,083			
FY 2013 Burn Rate: Redacted			

Approved



Funding Source	Funding Amount
GHP-State	934,917

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16690			
Mechanism Name: SAVVY			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	934,917	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16656	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 16634	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 14507	Mechanism Name: Family Health International
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,888,509	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Military Population

Mobile Population

Safe Motherhood

TB



Family Planning

Budget Code Information

Mechanism ID: 14507			
Mechanism Name: Family Health International			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	43	43
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	43	43
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	33	35
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	33	35
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	33	33
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct	33	35



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	25	27
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	10
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	10	12
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who	200	400



	received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	500	500
PMTCT_ARV_NGI	Life-long ART (including Option B+)	200	400
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	50	100
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	150	300
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	65	30
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	36	18
PMTCT_ARV_NGI	Sum of Regimen disaggregates	301	448
PMTCT_ARV_NGI	Sum of New and Current disaggregates	200	400
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	200	400
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	500	500
PMTCT_ARV_TA	Life-long ART (including Option B+)	200	400
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	50	100
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	150	300

PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	65	30
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	36	18
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	301	448
PMTCT_ARV_TA	Sum of New and Current disaggregates	200	400
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,600	6,490
PMTCT_STAT_NGI	Number of new ANC and L&D clients	6,250	7,200
PMTCT_STAT_NGI	By: Known positives at entry	250	290
PMTCT_STAT_NGI	By: Number of new positives identified	900	1,035
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	1,150	1,325
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,600	6,490
PMTCT_STAT_TA	Number of new ANC and L&D clients	6,250	7,200
PMTCT_STAT_TA	By: Known positives at entry	250	290
PMTCT_STAT_TA	By: Number of new positives identified	900	1,035
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,150	1,325
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	43	25
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	174	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	33	0



VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	250	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0	25
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	150	25
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	100	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	200	250
VMMC_CIRC_DSD	By Age: 10-14	80	96
VMMC_CIRC_DSD	By Age: 15-19	35	44
VMMC_CIRC_DSD	By Age: 20-24	40	49



VMMC_CIRC_DSD	By Age: 25-49	35	44
VMMC_CIRC_DSD	By Age: 50+	10	17
VMMC_CIRC_DSD	Sum of age disaggregates	200	250
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	42	43
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	136	174
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	22	33
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	200	250
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	66	150
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	134	100
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,000	2,500
VMMC_CIRC_NGI	By Age: 10-14	844	964
VMMC_CIRC_NGI	By Age: 15-19	344	464
VMMC_CIRC_NGI	By Age: 20-24	394	514
VMMC_CIRC_NGI	By Age: 25-49	344	414
VMMC_CIRC_NGI	By Age: 50+	74	144
VMMC_CIRC_NGI	Sum of Age disaggregates	2,000	2,500
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	188	199
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients	1,780	2,109



	(tested HIV negative at VMMC program		
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	32	142
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	2,000	2,500
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,450	1,916
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	550	534
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,800	2,250
VMMC_CIRC_TA	By Age: <1	0	0
VMMC_CIRC_TA	By Age: 1-9	0	0
VMMC_CIRC_TA	By Age: 10-14	764	868
VMMC_CIRC_TA	By Age: 15-19	309	420
VMMC_CIRC_TA	By Age: 20-24	354	465
VMMC_CIRC_TA	By Age: 25-49	309	370
VMMC_CIRC_TA	By Age: 50+	64	127
VMMC_CIRC_TA	Sum of Age disaggregations	1,800	2,250
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	146	157
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program	1,644	1,973
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	10	120



VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	1,800	2,250
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,384	1,830
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	416	400
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,000	30,000
HTC_TST_NGI	By Test Result: Negative	24,000	25,800
HTC_TST_NGI	By Test Result: Positive	4,000	4,200
HTC_TST_NGI	Sum of Test Result disaggregates	28,000	30,000
HTC_TST_NGI	Age/sex: <1 Male	56	60
HTC_TST_NGI	Age/sex: 1-4 Male	140	150
HTC_TST_NGI	Age/sex: 5-9 Male	196	210
HTC_TST_NGI	Age/sex: 10-14 Male	1,204	1,290
HTC_TST_NGI	Age/sex: 15-19 Male	1,484	1,590
HTC_TST_NGI	Age/sex: 20-24 Male	2,688	2,880
HTC_TST_NGI	Age/sex: 25-49 Male	4,676	5,010
HTC_TST_NGI	Age/sex: 50+ Male	140	150
HTC_TST_NGI	Age/sex: <1 Female	252	270
HTC_TST_NGI	Age/sex: 1-4 Female	644	690
HTC_TST_NGI	Age/sex: 5-9 Female	896	960
HTC_TST_NGI	Age/sex: 10-14 Female	2,632	2,820
HTC_TST_NGI	Age/sex: 15-19 Female	2,464	2,640
HTC_TST_NGI	Age/sex: 20-24 Female	3,164	3,390
HTC_TST_NGI	Age/sex: 25-49 Female	6,860	7,350
HTC_TST_NGI	Age/sex: 50+ Female	504	540



HTC_TST_NGI	Sum of Age/Sex disaggregates	28,000	30,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,596	1,710
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	8,988	9,630
HTC_TST_NGI	Aggregated Age/sex: <15 Female	4,424	4,740
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	12,992	13,920
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	6,020	6,450
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	21,980	23,550
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	28,000	30,000
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,000	30,000
HTC_TST_TA	By Test Result: Negative	24,000	25,800
HTC_TST_TA	By Test Result: Positive	4,000	4,200
HTC_TST_TA	Sum of Test Result disaggregates	28,000	30,000
HTC_TST_TA	Age/sex: <1 Male	56	60
HTC_TST_TA	Age/sex: 1-4 Male	140	150
HTC_TST_TA	Age/sex: 5-9 Male	196	210
HTC_TST_TA	Age/sex: 10-14 Male	1,204	1,290
HTC_TST_TA	Age/sex: 15-19 Male	1,484	1,590
HTC_TST_TA	Age/sex: 20-24 Male	2,688	2,880
HTC_TST_TA	Age/sex: 25-49 Male	4,676	5,010
HTC_TST_TA	Age/sex: 50+ Male	140	150
HTC_TST_TA	Age/sex: <1 Female	252	270
HTC_TST_TA	Age/sex: 1-4 Female	644	690
HTC_TST_TA	Age/sex: 5-9 Female	896	960
HTC_TST_TA	Age/sex: 10-14 Female	2,632	2,820
HTC_TST_TA	Age/sex: 15-19 Female	2,464	2,640
HTC_TST_TA	Age/sex: 20-24 Female	3,164	3,390
HTC_TST_TA	Age/sex: 25-49 Female	6,860	7,350
HTC_TST_TA	Age/sex: 50+ Female	504	540
HTC_TST_TA	Sum of Age/Sex disaggregates	28,000	30,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	1,596	1,710



	PERMISSION ONLY: <15 Male		
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,988	9,630
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,424	4,740
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,992	13,920
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,020	6,450
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	21,980	23,550
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	28,000	30,000
GEND_GBV_DSD	Number of people receiving post-GBV care	400	500
GEND_GBV_DSD	Age: 0-9	50	50
GEND_GBV_DSD	Age: 10-14	150	200
GEND_GBV_DSD	Age: 15-17	100	100
GEND_GBV_DSD	Age: 18-24	50	100
GEND_GBV_DSD	Age: 25+	50	50
GEND_GBV_DSD	Sum of Age disaggregates	400	500
GEND_GBV_DSD	Sex: Male	2	5
GEND_GBV_DSD	Sex: Female	398	495
GEND_GBV_DSD	Sum of Sex disaggregates	400	500
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	150	200
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	250	300
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	80	100
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	11,200	
C2.1.D_NGI	By Age/Sex: <15 Female	248	
C2.1.D_NGI	By Age/Sex: <15 Male	200	
C2.1.D_NGI	By Age/Sex: 15+ Female	5,802	
C2.1.D_NGI	By Age/Sex: 15+ Male	4,950	
C2.1.D_NGI	Sum of Age/Sex disaggregates	11,200	



C2.1.D_NGI	By Age: <15	448	
C2.1.D_NGI	By Age: 15+	10,752	
C2.1.D_NGI	Sum of Age disaggregates	11,200	
C2.1.D_NGI	By Sex: Female	6,050	
C2.1.D_NGI	By Sex: Male	5,150	
C2.1.D_NGI	Sum of Sex disaggregates	11,200	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	11,200	0
C2.1.D_TA	By Age/Sex: <15 Female	248	0
C2.1.D_TA	By Age/Sex: <15 Male	200	0
C2.1.D_TA	By Age/Sex: 15+ Female	5,802	0
C2.1.D_TA	By Age/Sex: 15+ Male	4,950	0
C2.1.D_TA	Sum of Age/Sex disaggregates	11,200	0
C2.1.D_TA	By Age: <15	448	0
C2.1.D_TA	By Age: 15+	10,752	0
C2.1.D_TA	Sum of Age disaggregates	11,200	0
C2.1.D_TA	By Sex: Female	6,050	0
C2.1.D_TA	By Sex: Male	5,150	0
C2.1.D_TA	Sum of Sex disaggregates	11,200	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	200	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,900	6,000
CARE_CURR_TA	Age/sex: <1 Male	10	12
CARE_CURR_TA	Age/sex: 1-4 Male	24	30
CARE_CURR_TA	Age/sex: 5-9 Male	29	42
CARE_CURR_TA	Age/sex: 10-14 Male	109	138
CARE_CURR_TA	Age/sex: 15-19 Male	110	138
CARE_CURR_TA	Age/sex: 20-24 Male	350	216



CARE_CURR_TA	Age/sex: 25-49 Male	150	402
CARE_CURR_TA	Age/sex: 50+ Male	25	30
CARE_CURR_TA	Age/sex: <1 Female	43	54
CARE_CURR_TA	Age/sex: 1-4 Female	50	138
CARE_CURR_TA	Age/sex: 5-9 Female	150	192
CARE_CURR_TA	Age/sex: 10-14 Female	200	684
CARE_CURR_TA	Age/sex: 15-19 Female	250	708
CARE_CURR_TA	Age/sex: 20-24 Female	400	1,038
CARE_CURR_TA	Age/sex: 25-49 Female	900	2,070
CARE_CURR_TA	Age/sex: 50+ Female	100	108
CARE_CURR_TA	Sum of Age/Sex disaggregates	2,900	6,000
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	172	222
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	635	786
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	443	1,068
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,650	3,924
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,900	6,000
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	23	30
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	32	35
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	350	400
TB_ART_DSD	The number of registered new and relapse TB	500	550



	cases with documented HIV-positive status during TB treatment during the reporting period		
TB_ART_DSD	Age: 0-4	5	6
TB_ART_DSD	Age: 5-14	70	81
TB_ART_DSD	Age: 15+	275	313
TB_ART_DSD	Male	105	120
TB_ART_DSD	Female	245	280
TB_ART_DSD	Sum of Sex disaggregates	350	400
TB_ART_DSD	Newly tested	330	350
TB_ART_DSD	Known HIV-positive	20	50
TB_ART_DSD	Sum of Test Status disaggregates	350	400
TB_ART_DSD	Aggregated Age: <15	75	87
TB_ART_DSD	Aggregated Age: 15+	275	313
TB_ART_DSD	Sum of Aggregated Age disaggregates	350	400
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	200	350
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,150	1,250
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	100	150
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	100	200
PMTCT_EID_DSD	Sum of Infant Age disaggregates	200	350
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	10	15
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,100	10,200
TX_CURR_DSD	Age/Sex: <1 Male	5	10
TX_CURR_DSD	Age/Sex: 1-4 Male	75	80



TX_CURR_DSD	Age/Sex: 5-14 Male	140	150
TX_CURR_DSD	Age/Sex: 15+ Male	4,695	4,695
TX_CURR_DSD	Age/Sex: <1 Female	5	10
TX_CURR_DSD	Age/Sex: 1-4 Female	50	100
TX_CURR_DSD	Age/Sex: 5-14 Female	155	165
TX_CURR_DSD	Age/Sex: 15+ Female	4,975	4,990
TX_CURR_DSD	Sum of age/sex disaggregates	430	515
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	4	5
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	51	52
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	5	10
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	5	10
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	220	240
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,695	4,695
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	210	275
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,975	4,990
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	430	515
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,670	9,685
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,100	10,200
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	9,794	10,200
TX_CURR_NGI	Age/Sex: <1 Male	5	10
TX_CURR_NGI	Age/Sex: 1-4 Male	73	80
TX_CURR_NGI	Age/Sex: 5-14 Male	135	150
TX_CURR_NGI	Age/Sex: 15+ Male	4,553	4,695
TX_CURR_NGI	Age/Sex: <1 Female	5	10
TX_CURR_NGI	Age/Sex: 1-4 Female	48	100
TX_CURR_NGI	Age/Sex: 5-14 Female	151	165
TX_CURR_NGI	Age/Sex: 15+ Female	4,824	4,990



TX_CURR_NGI	Sum of Age/Sex disaggregates	9,794	10,200
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	5	10
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	5	10
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	213	240
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	4,553	4,695
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	204	275
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	4,824	4,990
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	9,794	10,200
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	417	515
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	9,377	9,685
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,794	10,200
TX_CURR_TA	Age/Sex: <1 Male	5	10
TX_CURR_TA	Age/Sex: 1-4 Male	73	80
TX_CURR_TA	Age/Sex: 5-14 Male	135	150
TX_CURR_TA	Age/Sex: 15+ Male	4,553	4,695
TX_CURR_TA	Age/Sex: <1 Female	5	10
TX_CURR_TA	Age/Sex: 1-4 Female	48	100
TX_CURR_TA	Age/Sex: 5-14 Female	151	165
TX_CURR_TA	Age/Sex: 15+ Female	4,824	4,990
TX_CURR_TA	Sum of Age/Sex disaggregations	417	515
TX_CURR_TA	Aggregated Age/Sex: <1 Male	5	10
TX_CURR_TA	Aggregated Age/Sex: <1 Female	5	10
TX_CURR_TA	Aggregated Age/Sex: <15 Male	213	240
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,553	4,695
TX_CURR_TA	Aggregated Age/Sex: <15 Female	204	275
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,824	4,990
TX_CURR_TA	Sum of Aggregated Age/Sex <15	417	515
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	9,377	9,685
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,794	10,200
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,900	5,000



TX_NEW_DSD	By Age/Sex: <1 Male	10	10
TX_NEW_DSD	By Age/Sex: 1-4 Male	24	25
TX_NEW_DSD	By Age/Sex: 5-9 Male	29	35
TX_NEW_DSD	By Age/Sex: 10-14 Male	109	115
TX_NEW_DSD	By Age/Sex: 15-19 Male	110	115
TX_NEW_DSD	By Age/Sex: 20-24 Male	350	180
TX_NEW_DSD	By Age/Sex: 25-49 Male	150	335
TX_NEW_DSD	By Age/Sex: 50+ Male	25	25
TX_NEW_DSD	By Age/Sex: <1 Female	43	45
TX_NEW_DSD	By Age/Sex: 1-4 Female	50	115
TX_NEW_DSD	By Age/Sex: 5-9 Female	150	160
TX_NEW_DSD	By Age/Sex: 10-14 Female	200	570
TX_NEW_DSD	By Age/Sex: 15-19 Female	250	590
TX_NEW_DSD	By Age/Sex: 20-24 Female	400	865
TX_NEW_DSD	By Age/Sex: 25-49 Female	900	1,725
TX_NEW_DSD	By Age/Sex: 50+ Female	100	90
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,900	5,000
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	10	10
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	172	185
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	635	655
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	43	45
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	443	890
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,650	3,270
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,900	5,000
TX_NEW_DSD	Pregnancy status	970	1,100
TX_NEW_DSD	Breastfeeding status	104	350
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,300	2,800
TX_RET_DSD	Total number of adults and children who	2,500	3,000



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200	300
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	600	800
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,700	1,900
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200	300
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	500	700
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,600	1,800
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	800	1,100
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of	1,700	1,900



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	700	1,000
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,600	1,800
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	500	600
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	600	700
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	10	12
LAB_CAP_DSD	By clinical laboratories	10	12
LAB_CAP_DSD	By Point-of-care testing sites	0	0
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	10	12
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0
LAB_CAP_DSD	Sum of Site Support Type disaggregates	10	12



Implementing Mechanism Details

Mechanism ID: 14452	Mechanism Name: Society for Family Health
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,156,239	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Military Population
 Mobile Population

Budget Code Information

Mechanism ID:	14452
Mechanism Name:	Society for Family Health
Prime Partner Name:	Population Services International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	12	12
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	12	12
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	12	12
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	12	12
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	11	5
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	4	2
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	4	2
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical	0	0



	intra-operative AE(s)		
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	7	3
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	7	3
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,000	5,400
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	779	1,404
VMMC_CIRC_DSD	By Age: 15-19	703	1,242
VMMC_CIRC_DSD	By Age: 20-24	927	1,674
VMMC_CIRC_DSD	By Age: 25-49	568	1,026



VMMC_CIRC_DSD	By Age: 50+	23	54
VMMC_CIRC_DSD	Sum of age disaggregates	3,000	5,400
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,000	5,400
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	3,000	5,400
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	2,850	5,130
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	150	270
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,000	5,400
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	779	1,404
VMMC_CIRC_NGI	By Age: 15-19	703	1,242
VMMC_CIRC_NGI	By Age: 20-24	927	1,674
VMMC_CIRC_NGI	By Age: 25-49	568	1,026
VMMC_CIRC_NGI	By Age: 50+	23	54
VMMC_CIRC_NGI	Sum of Age disaggregates	3,000	5,400
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0



VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,000	5,400
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	3,000	5,400
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	2,850	5,130
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	150	270
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,002	11,000
PP_PREV_DSD	Total number of people in the target population	14,089	14,511
PP_PREV_DSD	Age/sex: 10-14 Male	1,476	1,788
PP_PREV_DSD	Age/sex: 15-19 Male	1,329	1,626
PP_PREV_DSD	Age/sex: 20-24 Male	1,753	2,144
PP_PREV_DSD	Age/sex: 25-49 Male	1,111	1,358
PP_PREV_DSD	Age/sex: 50+ Male	9	11
PP_PREV_DSD	Age/sex: 10-14 Female	866	1,059
PP_PREV_DSD	Age/sex: 15-19 Female	781	954
PP_PREV_DSD	Age/sex: 20-24 Female	1,030	1,258
PP_PREV_DSD	Age/sex: 25-49 Female	641	797
PP_PREV_DSD	Age/sex: 50+ Female	6	5
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,002	11,000
PP_PREV_TA	Number of the target population who	9,002	11,000



	completed a standardized HIV prevention intervention including the minimum components during the reporting period.		
PP_PREV_TA	Total number of people in the target population	14,089	14,511
PP_PREV_TA	Age/sex: 10-14 Male	1,476	1,788
PP_PREV_TA	Age/sex: 15-19 Male	1,329	1,626
PP_PREV_TA	Age/sex: 20-24 Male	1,753	2,144
PP_PREV_TA	Age/sex: 25-49 Male	1,111	1,358
PP_PREV_TA	Age/sex: 50+ Male	9	11
PP_PREV_TA	Age/sex: 10-14 Female	866	1,059
PP_PREV_TA	Age/sex: 15-19 Female	781	954
PP_PREV_TA	Age/sex: 20-24 Female	1,030	1,258
PP_PREV_TA	Age/sex: 25-49 Female	641	797
PP_PREV_TA	Age/sex: 50+ Female	6	5
PP_PREV_TA	Sum of Age/Sex disaggregates	9,002	11,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,000	5,400
HTC_TST_DSD	Age/sex: 10-14 Male	779	1,404
HTC_TST_DSD	Age/sex: 15-19 Male	703	1,242
HTC_TST_DSD	Age/sex: 20-24 Male	927	1,674
HTC_TST_DSD	Age/sex: 25-49 Male	568	1,026
HTC_TST_DSD	Age/sex: 50+ Male	23	54
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,000	5,400
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	12	12
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and	12	12



	HTC		
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	12	12
QI_SITE	Sum of Numerator Site Support Type disaggregates	12	12
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	12	12
QI_SITE	Sum of Denominator Site Support Type disaggregates	12	12

Implementing Mechanism Details

Mechanism ID: 14421	Mechanism Name: SPMO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Southern Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,978,564	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,157,381	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,978,564

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Renovation	150,000
Motor Vehicles: Purchased	577,778

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID: 14421			
Mechanism Name: SPMO			
Prime Partner Name: Southern Provincial Health Office			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	323,019	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	170,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,345,545	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets



SITE_SUPP	Number of unique sites supported by PEPFAR	248	284	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	21	39	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	227	245	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	21	39	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	22	24	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	21	39	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	22	39	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	6	8	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	21	39	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	21	39	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	215	233	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	22	24	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	21	23	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	22	39	Redacted



SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	20	22	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	74	76	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	282	310	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	286	316	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	282	310	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	175	192	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	107	118	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	282	310	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	282	310	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	855	941	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	868	955	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	855	941	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	530	583	Redacted



	pregnancy			
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	325	358	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	855	941	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	855	941	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	573	631	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	582	639	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	573	631	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	355	391	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	218	240	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted



PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	573	631	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	573	631	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	27	45	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	27	45	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	6	8	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	21	37	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	27	45	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	6		Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	21	37	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	27	37	Redacted
PMTCT_STAT_DS	Number of pregnant women with known	3,627	3,990	Redacted



D	HIV status (includes women who were tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	3,627	3,990	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	101	111	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	183	201	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	284	312	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,990	7,980	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	10,990	7,980	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	307	338	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	554	609	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	861	947	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,363	3,990	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	7,363	3,990	Redacted
PMTCT_STAT_TA	By: Known positives at entry	206	227	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	371	408	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	577	635	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe	21	19	Redacted

	adverse event(s) (AEs)			
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,899	19,686	Redacted
VMMC_CIRC_DS D	By Age: <1	280	308	Redacted
VMMC_CIRC_DS D	By Age: 1-9	25	28	Redacted
VMMC_CIRC_DS D	By Age: 10-14	3,789	4,168	Redacted
VMMC_CIRC_DS D	By Age: 15-19	5,406	5,947	Redacted
VMMC_CIRC_DS D	By Age: 20-24	4,011	4,412	Redacted
VMMC_CIRC_DS D	By Age: 25-49	3,997	4,397	Redacted
VMMC_CIRC_DS D	By Age: 50+	391	430	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	17,899	19,690	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	260	286	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	17,218	18,940	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	418	460	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	17,899	19,686	Redacted
VMMC_CIRC_DS	By follow-up status: Number of	17,877	19,665	Redacted

D	surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	22	21	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,899	19,686	Redacted
VMMC_CIRC_NGI	By Age: <1	280	308	Redacted
VMMC_CIRC_NGI	By Age: 1-9	25	28	Redacted
VMMC_CIRC_NGI	By Age: 10-14	3,789	4,168	Redacted
VMMC_CIRC_NGI	By Age: 15-19	5,406	5,947	Redacted
VMMC_CIRC_NGI	By Age: 20-24	4,011	4,412	Redacted
VMMC_CIRC_NGI	By Age: 25-49	3,997	4,397	Redacted
VMMC_CIRC_NGI	By Age: 50+	391	430	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	17,899	19,690	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	260	286	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	17,218	18,940	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	418	460	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	17,899	19,690	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of	17,877	19,665	Redacted

	surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	22	25	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	18,089	20,127	Redacted
VMMC_CIRC_TA	By Age: 10-14	3,926	4,341	Redacted
VMMC_CIRC_TA	By Age: 15-19	5,531	6,076	Redacted
VMMC_CIRC_TA	By Age: 20-24	4,223	4,723	Redacted
VMMC_CIRC_TA	By Age: 25-49	4,003	4,447	Redacted
VMMC_CIRC_TA	By Age: 50+	406	540	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	18,089	20,127	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	261	301	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	15,644	17,639	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	35,770	161	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	18,089	20,127	Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care	17,225	19,409	Redacted



	within 14 days of circumcision surgery			
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	23	15	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	224,834	224,840	Redacted
PP_PREV_DSD	Total number of people in the target population	352,979	352,980	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	7,669	7,670	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	10,537	10,540	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	17,200	17,200	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	27,139	27,140	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	11,751	11,750	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	44,138	44,140	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	15,649	15,650	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	18,462	18,460	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	60,497	60,500	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	11,790	11,790	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	224,832	224,840	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	456,480	502,128	Redacted
PP_PREV_TA	Total number of people in the target population	716,653	1,141,297	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	15,572	24,798	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	21,395	34,071	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	34,920	55,612	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	55,102	87,751	Redacted



PP_PREV_TA	Age/sex: 50+ Male	23,859	37,996	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	89,615	142,714	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	31,771	50,597	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	37,483	59,693	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	122,829	195,609	Redacted
PP_PREV_TA	Age/sex: 50+ Female	23,936	38,120	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	456,482	726,961	Redacted
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	87	115	Redacted
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	34	49	Redacted
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21	22	Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21	22	Redacted
KP_PREV_TA	By key population type: Men who have	11	22	Redacted



	sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21	21	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	46,835	51,518	Redacted
HTC_TST_DSD	By Test Result: Negative	40,906	44,997	Redacted
HTC_TST_DSD	By Test Result: Positive	5,928	6,521	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	46,834	51,518	Redacted
HTC_TST_DSD	Age/sex: <1 Male	163	179	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	346	381	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	526	579	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	839	922	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,110	2,321	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	5,659	6,224	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,088	8,897	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,881	2,069	Redacted
HTC_TST_DSD	Age/sex: <1 Female	186	205	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	416	457	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	643	707	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,233	1,357	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,930	3,223	Redacted



HTC_TST_DSD	Age/sex: 20-24 Female	7,764	8,541	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	12,112	13,323	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,939	2,133	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	46,835	51,518	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,853	2,038	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,716	19,487	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,487	2,735	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,779	27,258	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,340	4,773	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	42,495	46,745	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	46,835	51,518	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	141,923	156,115	Redacted
HTC_TST_NGI	By Test Result: Negative	123,958	136,354	Redacted
HTC_TST_NGI	By Test Result: Positive	17,965	19,762	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	141,923	156,116	Redacted
HTC_TST_NGI	Age/sex: <1 Male	493	542	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,049	1,154	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,595	1,755	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,541	2,795	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	6,393	7,032	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	17,147	18,862	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	24,510	26,961	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,700	6,270	Redacted
HTC_TST_NGI	Age/sex: <1 Female	565	622	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,260	1,386	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,947	2,142	Redacted



HTC_TST_NGI	Age/sex: 10-14 Female	3,737	4,111	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	8,880	9,768	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	23,528	25,881	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	36,703	40,373	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,875	6,463	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	141,923	156,117	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,615	6,177	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	53,684	59,052	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	7,535	8,289	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	75,089	82,598	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	13,150	14,466	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	128,773	141,650	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	141,923	156,116	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95,088	104,597	Redacted
HTC_TST_TA	By Test Result: Negative	83,051	91,357	Redacted
HTC_TST_TA	By Test Result: Positive	12,037	13,241	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	95,088	104,598	Redacted
HTC_TST_TA	Age/sex: <1 Male	330	363	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	703	773	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,069	1,176	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	1,702	1,873	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	4,283	4,712	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	11,488	12,637	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	16,422	18,064	Redacted
HTC_TST_TA	Age/sex: 50+ Male	3,819	4,201	Redacted
HTC_TST_TA	Age/sex: <1 Female	379	416	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	844	929	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,304	1,435	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	2,504	2,754	Redacted

HTC_TST_TA	Age/sex: 15-19 Female	5,950	6,545	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	15,764	17,340	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	24,591	27,050	Redacted
HTC_TST_TA	Age/sex: 50+ Female	3,936	4,330	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	95,088	104,598	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,762	4,138	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	35,968	39,565	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,048	5,553	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50,310	55,342	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	8,810	9,691	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	86,278	94,907	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	95,088	104,598	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	40,145	44,160	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,454	2,700	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	2,346	2,580	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	19,760	21,736	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	15,585	17,143	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	40,145	44,159	Redacted
C2.1.D_DSD	By Age: <15	4,801	5,281	Redacted
C2.1.D_DSD	By Age: 15+	35,344	38,878	Redacted
C2.1.D_DSD	Sum of Age disaggregates	40,145	44,159	Redacted
C2.1.D_DSD	By Sex: Female	22,465	24,712	Redacted
C2.1.D_DSD	By Sex: Male	17,680	19,448	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	40,145	44,160	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical	59,918	65,910	Redacted

	service			
C2.1.D_NGI	By Age/Sex: <15 Female	3,663	4,029	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	3,501	3,851	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	29,493	32,442	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	23,261	25,587	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	59,918	65,909	Redacted
C2.1.D_NGI	By Age: <15	7,166	7,883	Redacted
C2.1.D_NGI	By Age: 15+	52,752	58,027	Redacted
C2.1.D_NGI	Sum of Age disaggregates	59,918	65,910	Redacted
C2.1.D_NGI	By Sex: Female	33,530	36,883	Redacted
C2.1.D_NGI	By Sex: Male	26,388	29,027	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	59,918	65,910	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	19,773	21,750	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	1,209	1,330	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	1,155	1,271	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	9,733	10,706	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	7,676	8,444	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	19,773	21,751	Redacted
C2.1.D_TA	By Age: <15	2,365	2,601	Redacted
C2.1.D_TA	By Age: 15+	17,408	19,149	Redacted
C2.1.D_TA	Sum of Age disaggregates	19,773	21,750	Redacted
C2.1.D_TA	By Sex: Female	11,065	12,171	Redacted
C2.1.D_TA	By Sex: Male	8,708	9,579	Redacted
C2.1.D_TA	Sum of Sex disaggregates	19,773	21,750	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	27,069	29,776	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	40,145	44,160	Redacted
CARE_CURR_DS	Number of HIV positive adults and	53,275		Redacted



D	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	240		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	640		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	1,057		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,524		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	3,553		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	6,879		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	8,110		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	981		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	311		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	829		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,305		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,918		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	4,644		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	7,810		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	11,625		Redacted



CARE_CURR_DS D	Age/sex: 50+ Female	1,849		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	53,275		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,483		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,243		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,551		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,993		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	53,270		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	37,015		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	75		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	220		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	499		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	1,001		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	2,015		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	3,543		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	7,979		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	886		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	98		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	267		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	625		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	1,044		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	2,058		Redacted



CARE_NEW_DSD	Age/sex: 20-24 Female	5,347		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	10,367		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	991		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	37,015		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,839		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	14,640		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	2,057		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	19,117		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	37,653		Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	53		Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	50		Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	3		Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	3		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	12		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be	130		Redacted

	clinically undernourished.			
FN_THER_DSD	Age: <1	1		Redacted
FN_THER_DSD	Age: 1-4	1		Redacted
FN_THER_DSD	Age: 5-14	2		Redacted
FN_THER_DSD	Age: 15-17	2		Redacted
FN_THER_DSD	Age: 18+	6		Redacted
FN_THER_DSD	Sum of Age disaggregates	12		Redacted
FN_THER_DSD	Aggregated Age: <18	1		Redacted
FN_THER_DSD	Aggregated Age: 18+	1		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,922		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	8,342		Redacted
TB_ART_DSD	Age: 0-4	127		Redacted
TB_ART_DSD	Age: 5-14	285		Redacted
TB_ART_DSD	Age: 15+	1,201		Redacted
TB_ART_DSD	Male	417		Redacted
TB_ART_DSD	Female	1,073		Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,490		Redacted
TB_ART_DSD	Newly tested	801		Redacted
TB_ART_DSD	Known HIV-positive	698		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,499		Redacted
TB_ART_DSD	Aggregated Age: <15	1,614		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,839		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,453		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80%	73	80	Redacted

	of registered TB cases who are HIV-positive are on ART, during the reporting period			
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	87	96	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	49	54	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	24	26	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	73	80	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	58	64	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	29	32	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	87	96	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	237	261	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant	1,288	1,417	Redacted



	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	84	92	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	171	188	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	255	280	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	40	44	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	59,140	65,054	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	202	222	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	765	842	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	2,014	2,215	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	21,017	23,119	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	309	340	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	990	1,089	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	2,837	3,121	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	31,006	34,106	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	7,117	7,829	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	202	222	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	309	340	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,981	3,279	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	21,017	23,119	Redacted



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,136	4,550	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	31,006	34,106	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,117	7,829	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	52,023	57,225	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	59,140	65,054	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	88,269	97,097	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	301	331	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	1,142	1,256	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	3,006	3,307	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	31,369	34,506	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	461	507	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	1,478	1,626	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	4,235	4,659	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	46,277	50,905	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	88,269	97,097	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	301	331	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	461	507	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	4,449	4,894	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	31,369	34,506	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	6,174	6,792	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	46,277	50,905	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	88,269	97,097	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	10,623	11,686	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	77,646	85,411	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	29,129	32,042	Redacted
TX_CURR_TA	Age/Sex: <1 Male	99	109	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	377	415	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	992	1,091	Redacted



TX_CURR_TA	Age/Sex: 15+ Male	10,352	11,387	Redacted
TX_CURR_TA	Age/Sex: <1 Female	152	167	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	488	537	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	1,398	1,537	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	15,271	16,799	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	3,506	3,856	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	99	109	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	152	167	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,468	1,615	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	10,352	11,387	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,038	2,241	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	15,271	16,799	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,506	3,856	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	25,623	28,186	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	29,129	32,042	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,435	12,578	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	104	114	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	140	154	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	203	223	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	324	356	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	681	749	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,178	1,296	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,918	2,110	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	392	431	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	121	133	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	192	211	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	277	305	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	432	475	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,057	1,163	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,545	1,700	Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Female	2,458	2,704	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	413	454	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,435	12,578	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	104	114	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	771	847	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,169	4,586	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	121	133	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,022	1,124	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,473	6,021	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,435	12,578	Redacted
TX_NEW_DSD	Pregnancy status	401	441	Redacted
TX_NEW_DSD	Breastfeeding status	57	63	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,165	2,382	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,229	2,452	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,179	1,227	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	3,331	3,493	Redacted



	initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,622	13,492	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,738	1,827	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,100	3,266	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,734	14,265	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,325	4,414	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,533	14,007	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children	405	460	Redacted



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	436	499	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,673	4,820	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,901	12,942	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	60	66	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	76	84	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	40	44	Redacted
TX_SITE	By support type: Technical Assistance	20	22	Redacted



	(TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation			
TX_SITE	Sum of Numerator Site Support Type disaggregates	60	66	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	51	56	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	25	28	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	76	84	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8	10	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	8	10	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	8	10	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	185	204	Redacted
LAB_CAP_DSD	By clinical laboratories	20	22	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	74	81	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	91	100	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	91	100	Redacted

SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	2	0	Redacted
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	2	0	Redacted
SC_TRAIN	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to conduct supply chain activities	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to develop distribution plans	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform supportive supervision	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform quantification	1	0	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	18	20	Redacted
QI_SITE	Total number of PEPFAR-supported	21	42	Redacted



	sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC			
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	12	13	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	6	7	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	18	20	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	14	15	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	7	8	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	21	23	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility	23,411		Redacted



	during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	53,275		Redacted
TB_SCREEN_DSD	Age: <1	287		Redacted
TB_SCREEN_DSD	Age: 1-4	570		Redacted
TB_SCREEN_DSD	Age: 5-9	855		Redacted
TB_SCREEN_DSD	Age: 10-14	1,593		Redacted
TB_SCREEN_DSD	Age: 15-19	3,474		Redacted
TB_SCREEN_DSD	Age: 20-24	7,928		Redacted
TB_SCREEN_DSD	Age: 25-49	7,173		Redacted
TB_SCREEN_DSD	Age: 50+	1,190		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	6,779		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,581		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	19,332		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	22,913		Redacted
TB_SCREEN_DSD	Sex: Male	9,022		Redacted
TB_SCREEN_DSD	Sex: Female	12,891		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	21,913		Redacted

Implementing Mechanism Details

Mechanism ID: 14420	Mechanism Name: LPHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lusaka Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Approved



Total All Funding Sources: 1,245,590	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,798,742	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,245,590

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Renovation	50,000
Motor Vehicles: Purchased	285,000
Water	10,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	14420		
Mechanism Name:	LPHO		
Prime Partner Name:	Lusaka Provincial Health Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	160,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	135,658	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	699,932	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	250,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	104	104	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	104	104	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	44	55	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	44	55	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	30	70	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	35	45	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	17	25	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	79	90	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	79	90	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	15	32	Redacted

PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,080	4,080	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,244	4,244	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	3,080	4,080	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,314	2,038	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,766	2,042	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	330	490	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,180	2,290	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	778	145	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	5,368	7,005	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	3,080	4,080	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,080	4,080	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,244	4,244	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	3,080	4,080	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly	1,314	2,038	Redacted



	initiated on treatment during the current pregnancy			
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,766	2,042	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	330	490	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,180	2,290	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	778	145	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	5,368	7,005	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	3,080	4,080	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	30	70	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	30	70	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	30	70	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	30	149	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	30	70	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	30	149	Redacted



PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,200	19,000	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	12,780	20,000	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	563	836	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	843	1,254	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,406	2,090	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,950	24,828	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	26,558	29,338	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	1,280	591	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,964	885	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	3,244	1,476	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,950	24,828	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	26,558	29,338	Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,280	591	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,964	885	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,244	1,476	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced	74	80	Redacted



	at least one moderate or severe adverse event(s) (AEs)			
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	74	80	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,184	7,382	Redacted
VMMC_CIRC_NGI	By Age: <1	116	541	Redacted
VMMC_CIRC_NGI	By Age: 1-9	492	1,295	Redacted
VMMC_CIRC_NGI	By Age: 10-14	1,178	1,550	Redacted
VMMC_CIRC_NGI	By Age: 15-19	1,046	1,350	Redacted
VMMC_CIRC_NGI	By Age: 20-24	1,228	1,410	Redacted
VMMC_CIRC_NGI	By Age: 25-49	1,092	1,201	Redacted
VMMC_CIRC_NGI	By Age: 50+	32	35	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	5,184	7,382	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	484	532	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,066	4,472	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	634	2,378	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	5,184	7,382	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	660	768	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care	4,147	5,905	Redacted

	within 14 days of circumcision surgery			
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,184	7,382	Redacted
VMMC_CIRC_TA	By Age: <1	116	541	Redacted
VMMC_CIRC_TA	By Age: 1-9	492	1,295	Redacted
VMMC_CIRC_TA	By Age: 10-14	1,178	1,550	Redacted
VMMC_CIRC_TA	By Age: 15-19	1,046	1,350	Redacted
VMMC_CIRC_TA	By Age: 20-24	1,228	1,410	Redacted
VMMC_CIRC_TA	By Age: 25-49	1,092	1,201	Redacted
VMMC_CIRC_TA	By Age: 50+	32	35	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	5,184	7,382	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	484	532	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,066	4,472	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	634	2,378	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	5,184	7,382	Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	660	768	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care	4,147	5,905	Redacted



	within 14 days of circumcision surgery			
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,000	25,000	Redacted
PP_PREV_TA	Total number of people in the target population	20,000	35,000	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	500	2,500	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	2,000	3,000	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	2,100	3,100	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	2,600	2,900	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	1,300	2,300	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	2,000	3,000	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	2,000	3,700	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	2,500	4,500	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	15,000	25,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	100,000	150,000	Redacted
HTC_TST_NGI	By Test Result: Negative	90,000	110,000	Redacted
HTC_TST_NGI	By Test Result: Positive	10,000	40,000	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	100,000	150,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	2,000	4,000	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	2,000	4,000	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	500	1,000	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,500	3,000	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	6,000	9,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	6,000	10,000	Redacted



HTC_TST_NGI	Age/sex: 25-49 Male	4,000	8,799	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	3,000	3,500	Redacted
HTC_TST_NGI	Age/sex: <1 Female	600	7,000	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	900	1,900	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	899	8,000	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,800	3,800	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	6,780	6,780	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	23,800	30,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	30,221	30,221	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	9,000	19,000	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	100,000	150,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	10,000	35,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	30,000	40,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	20,000	30,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	40,000	45,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	30,000	65,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	70,000	85,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	100,000	150,000	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	100,000	150,000	Redacted
HTC_TST_TA	By Test Result: Negative	90,000	110,000	Redacted
HTC_TST_TA	By Test Result: Positive	10,000	40,000	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	100,000	150,000	Redacted
HTC_TST_TA	Age/sex: <1 Male	2,000	4,000	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	2,000	4,000	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	500	1,000	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	1,500	3,000	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	6,000	9,000	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	6,000	10,000	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	4,000	8,799	Redacted



HTC_TST_TA	Age/sex: 50+ Male	3,000	3,500	Redacted
HTC_TST_TA	Age/sex: <1 Female	600	7,000	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	900	1,900	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	899	8,000	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	2,800	3,800	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	6,780	6,780	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	23,800	30,000	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	30,221	30,221	Redacted
HTC_TST_TA	Age/sex: 50+ Female	9,000	19,000	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	100,000	150,000	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,000	35,000	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,000	40,000	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	20,000	30,000	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	40,000	45,000	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	30,000	65,000	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	70,000	85,000	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	100,000	150,000	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	17,986	18,884	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	566	594	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	496	520	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	10,542	11,069	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	6,382	6,701	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	17,986	18,884	Redacted
C2.1.D_NGI	By Age: <15	3,352	3,518	Redacted
C2.1.D_NGI	By Age: 15+	14,634	15,366	Redacted
C2.1.D_NGI	Sum of Age disaggregates	17,986	18,884	Redacted



C2.1.D_NGI	By Sex: Female	9,494	11,663	Redacted
C2.1.D_NGI	By Sex: Male	8,492	7,221	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	17,986	18,884	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	17,986	18,884	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	566	594	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	496	520	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	10,542	11,069	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	6,382	6,701	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	17,986	18,884	Redacted
C2.1.D_TA	By Age: <15	3,352	3,518	Redacted
C2.1.D_TA	By Age: 15+	14,634	15,366	Redacted
C2.1.D_TA	Sum of Age disaggregates	17,986	18,884	Redacted
C2.1.D_TA	By Sex: Female	9,494	11,663	Redacted
C2.1.D_TA	By Sex: Male	8,492	7,221	Redacted
C2.1.D_TA	Sum of Sex disaggregates	17,986	18,884	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,796	1,891	Redacted
CARE_CURR_TA	Age/sex: <1 Male	26	28	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	28	30	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	32	34	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	112	118	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	16	18	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	180	190	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	30	32	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	44	46	Redacted
CARE_CURR_TA	Age/sex: <1 Female	100	105	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	90	96	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	68	71	Redacted



CARE_CURR_TA	Age/sex: 10-14 Female	224	235	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	230	241	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	218	229	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	222	233	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	176	185	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	1,796	1,891	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	198	210	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	500	286	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	470	507	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	628	888	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,796	1,891	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	26,600	30,000	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	1,000	1,000	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	1,200	1,200	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	1,000	2,000	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	1,200	2,200	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1,400	2,400	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	1,000	1,400	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,000	1,000	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	1,400	1,400	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	1,200	1,200	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	1,000	1,000	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	2,800	2,800	Redacted



CARE_NEW_DSD	Age/sex: 10-14 Female	3,000	3,000	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	2,400	2,400	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	2,000	2,000	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,000	3,000	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	2,000	2,000	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	26,600	30,000	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	4,400	5,400	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	4,800	4,800	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	8,000	10,000	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	9,400	9,800	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	26,600	30,000	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	46	46	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	48	48	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	46	46	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	46	46	Redacted
CARE_SITE	By site support type: Technical	48	48	Redacted



	Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services			
CARE_SITE	Sum of Denominator Site Support Type disaggregates	48	48	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,000	3,500	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	12,159	26,496	Redacted
TB_ART_DSD	Age: 0-4	50	100	Redacted
TB_ART_DSD	Age: 5-14	400	1,500	Redacted
TB_ART_DSD	Age: 15+	550	1,900	Redacted
TB_ART_DSD	Male	400	1,400	Redacted
TB_ART_DSD	Female	600	2,100	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,000	3,500	Redacted
TB_ART_DSD	Newly tested	300	1,000	Redacted
TB_ART_DSD	Known HIV-positive	700	2,500	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,000	3,500	Redacted
TB_ART_DSD	Aggregated Age: <15	8	28	Redacted
TB_ART_DSD	Aggregated Age: 15+	992	3,472	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,000	3,500	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	35	35	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	35	35	Redacted
TB_ARTSITE	By site support type: Technical	35	35	Redacted

	Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	35	35	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	15	20	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	35	35	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	50	55	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,674	2,674	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,244	3,244	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,218	1,218	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,456	1,456	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,674	2,674	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	30	30	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	12,424	13,663	Redacted



TX_CURR_NGI	Age/Sex: <1 Male	48	52	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	116	128	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	502	552	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	4,036	4,439	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	26	28	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	114	125	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	368	404	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	7,214	7,935	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	12,424	13,663	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	48	52	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	26	28	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	666	732	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	4,036	4,439	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	508	557	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	7,214	7,935	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	12,424	13,663	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,174	1,289	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	11,250	12,374	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,424	13,663	Redacted
TX_CURR_TA	Age/Sex: <1 Male	48	52	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	116	128	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	502	552	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	4,036	4,439	Redacted
TX_CURR_TA	Age/Sex: <1 Female	26	28	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	114	125	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	368	404	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	7,214	7,935	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	1,174	1,289	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	48	52	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	26	28	Redacted



TX_CURR_TA	Aggregated Age/Sex: <15 Male	666	732	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,036	4,439	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	508	557	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	7,214	7,935	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,174	1,289	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	11,250	12,374	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,424	13,663	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	7	8	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	8	8	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,600	34,650	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	6	1,003	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	14	1,007	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	34	1,017	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	128	1,064	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	180	1,090	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	170	1,085	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	626	1,313	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	130	1,065	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	2	1,001	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	18	1,009	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	52	1,026	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	126	1,063	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	406	7,203	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	604	7,202	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,764	7,302	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	340	200	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,600	34,650	Redacted

TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	6	1,003	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	182	4,091	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,106	4,553	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	1,001	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	198	4,099	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,114	21,907	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,600	34,650	Redacted
TX_NEW_DSD	Pregnancy status	236	21,907	Redacted
TX_NEW_DSD	Breastfeeding status	232	21,907	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,944	7,000	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	25,438	30,000	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50	1,333	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,000	1,220	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	1,922	3,022	Redacted



	ART)			
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	255	2,233	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,500	3,256	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,964	11,343	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,050	16,832	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,922	2,200	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	3,755	2,553	Redacted

	those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,964	3,022	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,972	5,575	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,719	5,575	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	28	35	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	44	44	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	28	35	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	28	35	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of	44	44	Redacted



	PEPFAR-supported ART sites			
TX_SITE	Sum of Denominator Site Support Type disaggregates	44	44	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	3	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	2	3	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	2	3	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	15	32	Redacted
LAB_CAP_DSD	By clinical laboratories	15	12	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	15	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	15	27	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	2	3	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	17	30	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	10,486	25,253	Redacted
TB_SCREEN_DSD	Age: 1-4	500	1,250	Redacted
TB_SCREEN_DSD	Age: 5-9	1,000	3,500	Redacted
TB_SCREEN_DSD	Age: 10-14	2,400	4,700	Redacted
TB_SCREEN_DSD	Age: 15-19	3,000	4,500	Redacted
TB_SCREEN_DSD	Age: 20-24	2,500	10,000	Redacted
TB_SCREEN_DSD	Age: 25-49	2,600	10,000	Redacted



TB_SCREEN_DSD	Age: 50+	3,950	12,000	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	6,900	14,000	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,900	9,500	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	12,050	36,500	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	15,950	46,000	Redacted
TB_SCREEN_DSD	Sex: Male	6,380	18,400	Redacted
TB_SCREEN_DSD	Sex: Female	9,570	27,600	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	15,950	46,000	Redacted

Implementing Mechanism Details

Mechanism ID: 14392	Mechanism Name: Jhpiego (Eastern)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 495,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	495,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	495,000
----------------------------	---------



Key Issues

TB

Budget Code Information

Mechanism ID: 14392			
Mechanism Name: Jhpiego (Eastern)			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	115,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	140,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14339	Mechanism Name: PEPFAR Prevention Small Grants
----------------------------	---

Approved



Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 150,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	14339		
Mechanism Name:	PEPFAR Prevention Small Grants		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	5	5
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	810	810
PP_PREV_DSD	Total number of people in the target population	22,800	22,800
PP_PREV_DSD	Age/sex: 10-14 Male	71	71
PP_PREV_DSD	Age/sex: 15-19 Male	291	291
PP_PREV_DSD	Age/sex: 20-24 Male	158	158
PP_PREV_DSD	Age/sex: 25-49 Male	30	30
PP_PREV_DSD	Age/sex: 50+ Male	54	54
PP_PREV_DSD	Age/sex: 10-14 Female	31	31
PP_PREV_DSD	Age/sex: 15-19 Female	33	33
PP_PREV_DSD	Age/sex: 20-24 Female	50	50



PP_PREV_DSD	Age/sex: 25-49 Female	48	48
PP_PREV_DSD	Age/sex: 50+ Female	44	44
PP_PREV_DSD	Sum of Age/Sex disaggregates	810	810
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	389	389
PP_PREV_TA	Total number of people in the target population	22,800	22,800
PP_PREV_TA	Age/sex: 10-14 Male	21	21
PP_PREV_TA	Age/sex: 15-19 Male	87	87
PP_PREV_TA	Age/sex: 20-24 Male	40	40
PP_PREV_TA	Age/sex: 25-49 Male	7	7
PP_PREV_TA	Age/sex: 50+ Male	14	14
PP_PREV_TA	Age/sex: 10-14 Female	72	72
PP_PREV_TA	Age/sex: 15-19 Female	76	76
PP_PREV_TA	Age/sex: 20-24 Female	26	26
PP_PREV_TA	Age/sex: 25-49 Female	24	24
PP_PREV_TA	Age/sex: 50+ Female	22	22
PP_PREV_TA	Sum of Age/Sex disaggregates	389	389
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,170	9,170
HTC_TST_DSD	By Test Result: Negative	200	200
HTC_TST_DSD	By Test Result: Positive	8,970	8,970
HTC_TST_DSD	Sum of Test Result disaggregates	9,170	9,170
HTC_TST_DSD	Age/sex: <1 Male	42	42
HTC_TST_DSD	Age/sex: 1-4 Male	8	8
HTC_TST_DSD	Age/sex: 5-9 Male	423	423
HTC_TST_DSD	Age/sex: 10-14 Male	644	644
HTC_TST_DSD	Age/sex: 15-19 Male	1,033	1,033
HTC_TST_DSD	Age/sex: 20-24 Male	664	664
HTC_TST_DSD	Age/sex: 25-49 Male	296	296



HTC_TST_DSD	Age/sex: 50+ Male	400	400
HTC_TST_DSD	Age/sex: <1 Female	15	15
HTC_TST_DSD	Age/sex: 1-4 Female	35	35
HTC_TST_DSD	Age/sex: 5-9 Female	477	477
HTC_TST_DSD	Age/sex: 10-14 Female	715	715
HTC_TST_DSD	Age/sex: 15-19 Female	1,258	1,258
HTC_TST_DSD	Age/sex: 20-24 Female	485	485
HTC_TST_DSD	Age/sex: 25-49 Female	307	307
HTC_TST_DSD	Age/sex: 50+ Female	2,368	2,368
HTC_TST_DSD	Sum of Age/Sex disaggregates	9,170	9,170
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,389	2,389
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,658	3,658
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,653	1,653
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,470	1,470
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,042	4,042
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,128	5,128
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	9,170	9,170
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,170	9,170
HTC_TST_NGI	By Test Result: Negative	200	200
HTC_TST_NGI	By Test Result: Positive	8,970	8,970
HTC_TST_NGI	Sum of Test Result disaggregates	9,170	9,170
HTC_TST_NGI	Age/sex: <1 Male	42	42
HTC_TST_NGI	Age/sex: 1-4 Male	8	8
HTC_TST_NGI	Age/sex: 5-9 Male	423	423
HTC_TST_NGI	Age/sex: 10-14 Male	644	644
HTC_TST_NGI	Age/sex: 15-19 Male	1,033	1,033
HTC_TST_NGI	Age/sex: 20-24 Male	664	664



HTC_TST_NGI	Age/sex: 25-49 Male	296	296
HTC_TST_NGI	Age/sex: 50+ Male	400	400
HTC_TST_NGI	Age/sex: <1 Female	15	15
HTC_TST_NGI	Age/sex: 1-4 Female	35	35
HTC_TST_NGI	Age/sex: 5-9 Female	477	477
HTC_TST_NGI	Age/sex: 10-14 Female	715	715
HTC_TST_NGI	Age/sex: 15-19 Female	1,258	1,258
HTC_TST_NGI	Age/sex: 20-24 Female	485	485
HTC_TST_NGI	Age/sex: 25-49 Female	307	307
HTC_TST_NGI	Age/sex: 50+ Female	2,368	2,368
HTC_TST_NGI	Sum of Age/Sex disaggregates	9,170	9,170
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,150	2,150
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,350	1,350
HTC_TST_NGI	Aggregated Age/sex: <15 Female	2,510	2,510
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,160	3,160
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	4,660	4,660
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	4,510	4,510
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	9,170	9,170

Implementing Mechanism Details

Mechanism ID: 14338	Mechanism Name: Sustainability Through Economic strengthening, Prevention, and Support for Orphans, and Vulnerable Children, youth and other vulnerable populations (STEPS OVC) program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted

Approved



Applied Pipeline Amount: 4,150,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Archdiocese of Kasama	Chipata Diocese	Copperbelt Health Education Project
Development Aid from People to People Humana Zambia	Diocese of Mongu	Diocese of Mpika
Diocese of Solwezi	Expanded Church Response	Futures Group
Jesus Cares Ministries	Ndola Catholic Diocese	Salvation Army
Zambia Open Community Schools		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood
Family Planning

Budget Code Information

Mechanism ID:	14338		
Mechanism Name:	Sustainability Through Economic strengthening, Prevention, and Support for Orphans, and Vulnerable Children, youth and other vulnerable populations (STEPS OVC) program		
Prime Partner Name:	World Vision International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	749	469
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	749	469
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	749	469
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	749	469
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery	749	469



	(DSD)		
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	749	469
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	86,409	0
PP_PREV_DSD	Total number of people in the target population	627,526	0
PP_PREV_DSD	Age/sex: 10-14 Male	15,141	0
PP_PREV_DSD	Age/sex: 15-19 Male	13,802	0
PP_PREV_DSD	Age/sex: 20-24 Male	1,902	0
PP_PREV_DSD	Age/sex: 25-49 Male	5,938	0
PP_PREV_DSD	Age/sex: 50+ Male	3,118	0
PP_PREV_DSD	Age/sex: 10-14 Female	15,319	0
PP_PREV_DSD	Age/sex: 15-19 Female	12,313	0
PP_PREV_DSD	Age/sex: 20-24 Female	2,058	0
PP_PREV_DSD	Age/sex: 25-49 Female	11,545	0
PP_PREV_DSD	Age/sex: 50+ Female	5,273	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	86,409	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	77,936	19,484
HTC_TST_DSD	By Test Result: Negative	62,349	15,587
HTC_TST_DSD	By Test Result: Positive	15,587	3,897
HTC_TST_DSD	Sum of Test Result disaggregates	77,936	19,484
HTC_TST_DSD	Age/sex: <1 Male	23	5
HTC_TST_DSD	Age/sex: 1-4 Male	2,236	559
HTC_TST_DSD	Age/sex: 5-9 Male	6,895	1,724
HTC_TST_DSD	Age/sex: 10-14 Male	10,409	2,602
HTC_TST_DSD	Age/sex: 15-19 Male	9,488	2,372
HTC_TST_DSD	Age/sex: 20-24 Male	1,307	327
HTC_TST_DSD	Age/sex: 25-49 Male	4,082	1,021



HTC_TST_DSD	Age/sex: 50+ Male	2,143	536
HTC_TST_DSD	Age/sex: <1 Female	23	5
HTC_TST_DSD	Age/sex: 1-4 Female	2,322	581
HTC_TST_DSD	Age/sex: 5-9 Female	7,035	1,759
HTC_TST_DSD	Age/sex: 10-14 Female	10,531	2,633
HTC_TST_DSD	Age/sex: 15-19 Female	8,465	2,116
HTC_TST_DSD	Age/sex: 20-24 Female	1,415	354
HTC_TST_DSD	Age/sex: 25-49 Female	7,937	1,984
HTC_TST_DSD	Age/sex: 50+ Female	3,625	906
HTC_TST_DSD	Sum of Age/Sex disaggregates	77,936	19,484
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	19,563	4,891
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,021	4,255
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,910	4,977
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,442	5,361
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	39,473	9,868
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	38,463	9,616
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	77,936	19,484
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	77,936	19,484
HTC_TST_NGI	By Test Result: Negative	62,349	15,587
HTC_TST_NGI	By Test Result: Positive	15,587	3,897
HTC_TST_NGI	Sum of Test Result disaggregates	77,936	19,484
HTC_TST_NGI	Age/sex: <1 Male	23	5
HTC_TST_NGI	Age/sex: 1-4 Male	2,236	559
HTC_TST_NGI	Age/sex: 5-9 Male	6,895	1,724
HTC_TST_NGI	Age/sex: 10-14 Male	10,409	2,602
HTC_TST_NGI	Age/sex: 15-19 Male	9,488	2,372
HTC_TST_NGI	Age/sex: 20-24 Male	1,307	327



HTC_TST_NGI	Age/sex: 25-49 Male	4,082	1,021
HTC_TST_NGI	Age/sex: 50+ Male	2,143	536
HTC_TST_NGI	Age/sex: <1 Female	23	5
HTC_TST_NGI	Age/sex: 1-4 Female	2,322	581
HTC_TST_NGI	Age/sex: 5-9 Female	7,035	1,759
HTC_TST_NGI	Age/sex: 10-14 Female	10,531	2,633
HTC_TST_NGI	Age/sex: 15-19 Female	8,465	2,116
HTC_TST_NGI	Age/sex: 20-24 Female	1,415	354
HTC_TST_NGI	Age/sex: 25-49 Female	7,937	1,984
HTC_TST_NGI	Age/sex: 50+ Female	3,625	906
HTC_TST_NGI	Sum of Age/Sex disaggregates	77,936	19,484
HTC_TST_NGI	Aggregated Age/sex: <15 Male	19,563	4,891
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	17,021	4,255
HTC_TST_NGI	Aggregated Age/sex: <15 Female	19,910	4,977
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	21,442	5,361
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	39,473	9,868
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	38,463	9,616
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	77,936	19,484
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	559,872	345,739
OVC_SERV_DSD	Sex: Male	263,523	161,178
OVC_SERV_DSD	Sex: Female	296,349	184,561
OVC_SERV_DSD	Sum of Sex disaggregates	559,872	345,739
OVC_SERV_DSD	Age: <1	427	264
OVC_SERV_DSD	Age: 1-4	43,292	26,734
OVC_SERV_DSD	Age: 5-9	132,370	81,743
OVC_SERV_DSD	Age: 10-14	199,034	122,910
OVC_SERV_DSD	Age: 15-17	122,294	75,521
OVC_SERV_DSD	Age: 18+	62,455	38,567
OVC_SERV_DSD	Sum of Age disaggregates	559,872	345,739

Implementing Mechanism Details

Approved



Mechanism ID: 14276	Mechanism Name: NYS AIDS INSTITUTE/ HEALTHQUAL
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: New York AIDS Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

Key Issues

Safe Motherhood

Budget Code Information

Mechanism ID:	14276		
Mechanism Name:	NYS AIDS INSTITUTE/ HEALTHQUAL		
Prime Partner Name:	New York AIDS Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	150,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13792	Mechanism Name: Support to the HIV/AIDS Response in Zambia II (SHARe II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,608,500	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,450,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,608,500

Sub Partner Name(s)

LEAD	Zambia Health Education and Communication Trust	ZINGO
------	---	-------

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance

Key Issues

- Malaria (PMI)
- Mobile Population
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID: 13792			
Mechanism Name: Support to the HIV/AIDS Response in Zambia II (SHARe II)			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	508,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	600,000	0
------------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	36	36
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	58	58
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	29	29
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,186	9,973
PP_PREV_TA	Total number of people in the target population	53,812	53,812
PP_PREV_TA	Age/sex: 10-14 Male	0	0
PP_PREV_TA	Age/sex: 15-19 Male	212	110
PP_PREV_TA	Age/sex: 20-24 Male	782	478
PP_PREV_TA	Age/sex: 25-49 Male	9,093	4,740
PP_PREV_TA	Age/sex: 10-14 Female	1,188	594
PP_PREV_TA	Age/sex: 15-19 Female	1,757	880
PP_PREV_TA	Age/sex: 20-24 Female	2,101	996
PP_PREV_TA	Age/sex: 25-49 Female	4,053	2,175
PP_PREV_TA	Sum of Age/Sex disaggregates	19,186	9,973
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,966	12,550
HTC_TST_TA	By Test Result: Negative	22,284	11,672



HTC_TST_TA	By Test Result: Positive	1,682	878
HTC_TST_TA	Sum of Test Result disaggregates	23,966	12,550
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	0	0
HTC_TST_TA	Age/sex: 5-9 Male	0	0
HTC_TST_TA	Age/sex: 10-14 Male	242	134
HTC_TST_TA	Age/sex: 15-19 Male	1,749	912
HTC_TST_TA	Age/sex: 20-24 Male	2,825	1,497
HTC_TST_TA	Age/sex: 25-49 Male	10,467	5,458
HTC_TST_TA	Age/sex: 50+ Male	0	0
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	0	0
HTC_TST_TA	Age/sex: 5-9 Female	0	0
HTC_TST_TA	Age/sex: 10-14 Female	258	145
HTC_TST_TA	Age/sex: 15-19 Female	1,695	884
HTC_TST_TA	Age/sex: 20-24 Female	1,999	1,048
HTC_TST_TA	Age/sex: 25-49 Female	4,731	2,472
HTC_TST_TA	Age/sex: 50+ Female	0	0
HTC_TST_TA	Sum of Age/Sex disaggregates	23,966	12,550
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	242	134
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,041	7,867
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	258	145
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,425	4,404
HTC_TST_TA	Sum of Aggregated Age/Sex <15	500	279
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	23,466	12,271
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	23,966	12,550
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	2,989	1,500



GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	675	338
GEND_NORM_DSD	By Age: 15-19	975	487
GEND_NORM_DSD	By Age: 20-24	750	376
GEND_NORM_DSD	By Age: 25+	589	299
GEND_NORM_DSD	Sum of Age disaggregates	2,989	1,500
GEND_NORM_DSD	By Sex: Male	1,137	571
GEND_NORM_DSD	By Sex: Female	1,852	929
GEND_NORM_DSD	Sum of Sex disaggregates	2,989	1,500
GEND_NORM_DSD	By type of activity: Individual	2,989	1,500

Implementing Mechanism Details

Mechanism ID: 13787	Mechanism Name: CHAZ
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Churches Health Association of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 5,201,714	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 331,637	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,201,714

Sub Partner Name(s)

Chikuni Mission Hospital	Chilonga Mission Hospital	Coptic Hospital
Expanded Church Response (ECR)	Kamoto Mission Hospital	Katondwe Mission Hospital
Mtendere Mission Hospital	Mukinge Mission Hospital	Mwandi Mission Hospital
New Partner	Sichili Mission Hospital	St Francis Mission Hospital



St Theresa Mission Hospital	YOUTH ALIVE	
-----------------------------	-------------	--

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	162,014
Gender: GBV	208,480
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	208,480
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	817,890
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs

Key Issues

- Child Survival Activities
- Safe Motherhood
- TB
- Workplace Programs

Budget Code Information

Mechanism ID:	13787		
Mechanism Name:	CHAZ		
Prime Partner Name:	Churches Health Association of Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	396,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	375,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,963,929	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	465,900	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	9	11	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	9	11	Redacted



SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	9	11	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	9	11	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	9	11	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	9	11	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	9	11	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	11	7	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	11	11	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	9	11	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	658	930	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	731	1,033	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	658	930	Redacted



PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	283	400	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	375	530	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	658	930	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	658	930	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	946	930	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,050	1,033	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	946	930	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	283	400	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	663	530	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	946	930	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	946	930	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	8	10	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	9	11	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of	8	10	Redacted

	PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women			
PMTCT_SITE	Sum of Numerator Support Type disaggregates	8	10	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	9	10	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	9	10	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	731	1,033	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	8,500	12,000	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	417	620	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	314	413	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	731	1,033	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	731	1,033	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	8,500	12,000	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	417	620	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	314	413	Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	731	1,033	Redacted

I				
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	60	68	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	60	68	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	60	68	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	4,500	6,000	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,002	1,336	Redacted
VMMC_CIRC_DS D	By Age: 15-19	1,500	2,000	Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,112	1,482	Redacted
VMMC_CIRC_DS D	By Age: 25-49	877	1,169	Redacted
VMMC_CIRC_DS D	By Age: 50+	9	13	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	4,500	6,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	392	523	Redacted
VMMC_CIRC_DS	By HIV status: Number of HIV-negative	3,966	5,288	Redacted



D	clients (tested HIV negative at VMMC program)			
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	142	189	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	4,500	6,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	4,500	6,000	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	4,500	6,000	Redacted
VMMC_CIRC_NGI	By Age: 10-14	1,002	1,336	Redacted
VMMC_CIRC_NGI	By Age: 15-19	1,500	2,000	Redacted
VMMC_CIRC_NGI	By Age: 20-24	1,112	1,482	Redacted
VMMC_CIRC_NGI	By Age: 25-49	877	1,169	Redacted
VMMC_CIRC_NGI	By Age: 50+	9	13	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	4,500	6,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	392	523	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,966	5,288	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	142	189	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	4,500	6,000	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of	4,500	6,000	Redacted



	surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery			
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	30,000	30,000	Redacted
PP_PREV_DSD	Total number of people in the target population	622,338	674,383	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	750	750	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	7,500	7,500	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	4,500	4,500	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,800	1,800	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	250	250	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	750	750	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	7,950	7,950	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	4,500	4,500	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,800	1,800	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	200	200	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	30,000	30,000	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,000	5,000	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,000	5,000	Redacted
HTC_TST_DSD	Number of individuals who received	33,000	40,000	Redacted



	T&C services for HIV and received their test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	29,370	35,600	Redacted
HTC_TST_DSD	By Test Result: Positive	3,630	4,400	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	33,000	40,000	Redacted
HTC_TST_DSD	Age/sex: <1 Male	660	800	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,535	1,860	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	787	954	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,358	2,858	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,720	5,721	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,931	4,765	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,912	2,317	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	11	134	Redacted
HTC_TST_DSD	Age/sex: <1 Female	690	934	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	825	1,000	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	448	543	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,752	1,906	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,397	2,906	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	6,291	7,626	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	3,931	4,765	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	752	911	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	33,000	40,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,340	6,472	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,574	12,937	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,715	4,383	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,371	16,208	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,055	10,855	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,945	29,145	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	33,000	40,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,000	40,000	Redacted
HTC_TST_NGI	By Test Result: Negative	29,370	35,600	Redacted
HTC_TST_NGI	By Test Result: Positive	3,630	4,400	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	33,000	40,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	660	800	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,535	1,860	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	787	954	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,358	2,858	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,720	5,721	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	3,931	4,765	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,912	2,317	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	11	134	Redacted
HTC_TST_NGI	Age/sex: <1 Female	690	934	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	825	1,000	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	448	543	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,752	1,906	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	2,397	2,906	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	6,291	7,626	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	3,931	4,765	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	752	911	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	33,000	40,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,340	6,472	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	10,574	12,937	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	3,715	4,383	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	13,371	16,208	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	9,055	10,855	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	23,945	29,145	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex	33,000	40,000	Redacted



	disaggregates			
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	24,049	33,500	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,170	1,631	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,207	1,682	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	13,501	18,804	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	8,171	11,383	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	24,049	33,500	Redacted
C2.1.D_DSD	By Age: <15	2,377	3,313	Redacted
C2.1.D_DSD	By Age: 15+	21,672	30,187	Redacted
C2.1.D_DSD	Sum of Age disaggregates	24,049	33,500	Redacted
C2.1.D_DSD	By Sex: Female	14,671	20,435	Redacted
C2.1.D_DSD	By Sex: Male	9,378	13,065	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	24,049	33,500	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	24,049	33,500	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,170	1,631	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,207	1,682	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	13,501	18,804	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	8,171	11,383	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	24,049	33,500	Redacted
C2.1.D_NGI	By Age: <15	2,377	3,313	Redacted
C2.1.D_NGI	By Age: 15+	21,672	30,187	Redacted
C2.1.D_NGI	Sum of Age disaggregates	24,049	33,500	Redacted
C2.1.D_NGI	By Sex: Female	14,671	20,435	Redacted
C2.1.D_NGI	By Sex: Male	9,378	13,065	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	24,049	33,500	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	21,644	30,150	Redacted
C2.4.D_DSD	Number of HIV-positive individuals	24,049	33,500	Redacted



	receiving a minimum of one clinical service			
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	24,049	33,500	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	379	528	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	315	439	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	283	395	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	230	320	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	219	305	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	2,672	3,722	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	4,804	6,693	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	476	663	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	283	395	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	337	469	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	310	432	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	240	335	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	305	424	Redacted
CARE_CURR_DS	Age/sex: 20-24 Female	4,056	5,650	Redacted



D				
CARE_CURR_DS D	Age/sex: 25-49 Female	5,398	7,519	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	3,742	5,211	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	24,049	33,500	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,207	1,682	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,171	11,383	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,170	1,631	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,501	18,804	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	24,049	33,500	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	5,563	8,662	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	250	391	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	470	734	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	267	417	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	470	734	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	598	933	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	507	790	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	197	308	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	25	39	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	262	408	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	271	422	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	266	415	Redacted



CARE_NEW_DSD	Age/sex: 10-14 Female	479	748	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	315	491	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	647	1,009	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	500	780	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	39	43	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	5,563	8,662	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,457	2,275	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,327	2,070	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,278	1,994	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,501	2,323	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	5,563	8,662	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	11	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	9	11	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	11	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	9	11	Redacted
CARE_SITE	By site support type: Direct Service	9	11	Redacted



	Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services			
CARE_SITE	Sum of Denominator Site Support Type disaggregates	9	11	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	11	11	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	11	11	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	11	11	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	11	11	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	11	11	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	11	11	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	585	883	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	731	1,033	Redacted

PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	351	530	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	234	353	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	585	883	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	29	44	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	23,900	31,500	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	743	979	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	108	143	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	207	273	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	7,687	10,131	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	743	979	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	112	148	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	205	270	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	14,095	18,577	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,118	2,792	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	743	979	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	743	979	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,058	1,395	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,687	10,131	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,060	1,397	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	14,095	18,577	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,118	2,792	Redacted



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,782	28,708	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	23,900	31,500	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	23,900	31,500	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	743	979	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	108	143	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	207	273	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	7,687	10,131	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	743	979	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	112	148	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	205	270	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	14,095	18,577	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	23,900	31,500	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	743	978	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	743	979	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,058	1,395	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	7,687	10,131	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,060	1,397	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	14,095	18,577	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	23,900	31,500	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,118	2,792	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	21,782	28,708	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,900	7,643	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	221	442	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	415	830	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	236	472	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	415	830	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	528	598	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	447	506	Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Male	174	197	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	22	25	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	231	462	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	239	478	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	235	470	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	423	846	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	278	315	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	571	646	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	441	500	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	24	26	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,900	7,643	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	221	442	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,287	2,574	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,171	1,326	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	231	462	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,128	2,256	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,314	1,487	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,900	7,643	Redacted
TX_NEW_DSD	Pregnancy status	283	400	Redacted
TX_NEW_DSD	Breastfeeding status	90	150	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	896	24,180	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	1,149	31,000	Redacted



	those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	293	347	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76	82	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,315	3,941	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	375	3,941	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99	116	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,247	4,637	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator:	3,315	3,941	Redacted



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,247	4,637	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	366	440	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	473	515	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	366	440	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	473	515	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after	4	5	Redacted



	ART initiation			
TX_SITE	Total number of PEPFAR-supported ART sites	9	11	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	4	5	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	4	5	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	9	11	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	9	11	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	9	11	Redacted
LAB_CAP_DSD	By clinical laboratories	9	11	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	9	11	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	9	11	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	4	4	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	11	11	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family	4	4	Redacted



	planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	4	4	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	11	11	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	11	11	Redacted
FPINT_SITE_DSD	Service delivery type: Community	0	0	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	4	4	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	4	4	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	11	5	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	11	11	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	11	5	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	11	5	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV	11	11	Redacted



	clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	Sum of Denominator Site Support Type disaggregates	11	11	Redacted

Implementing Mechanism Details

Mechanism ID: 13731	Mechanism Name: DAPP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People Humana Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,057,143	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 195,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,057,143

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Condom programming	25,000
Food and Nutrition: Commodities	15,000
Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Water	15,000

Key Issues

- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	13731		
Mechanism Name:	DAPP		
Prime Partner Name:	Development Aid from People to People Humana Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	942,143	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	115,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	33	33	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	33	33	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	33	33	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	12	12	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	202,937	206,129	Redacted
PP_PREV_DSD	Total number of people in the target population	354,158	454,160	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	22,044	17,242	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	22,404	21,451	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	14,399	14,791	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	31,710	35,546	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	8,834	10,095	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	21,147	16,574	Redacted



PP_PREV_DSD	Age/sex: 15-19 Female	21,307	21,159	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	15,480	16,760	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	35,161	40,473	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	10,451	12,038	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	202,937	206,129	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	350	350	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	350	350	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations	247	247	Redacted



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,337	60,300	Redacted
HTC_TST_DSD	By Test Result: Negative	54,302	54,270	Redacted
HTC_TST_DSD	By Test Result: Positive	6,035	6,030	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	60,337	60,300	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	15	15	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	378	378	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	5,411	5,408	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,702	5,699	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,460	4,457	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	10,152	10,146	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,736	2,734	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	18	18	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	372	372	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	5,368	5,365	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,208	6,204	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,340	5,337	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	11,125	11,118	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,052	3,049	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	60,337	60,300	Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,804	5,801	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,050	23,036	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,758	5,755	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,725	25,708	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,562	11,556	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	48,775	48,744	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	60,337	60,300	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,337	60,300	Redacted
HTC_TST_NGI	By Test Result: Negative	54,302	54,270	Redacted
HTC_TST_NGI	By Test Result: Positive	6,035	6,030	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	60,337	60,300	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	15	15	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	378	378	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	5,411	5,408	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,702	5,699	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	4,460	4,457	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	10,152	10,146	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	2,736	2,734	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	18	18	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	372	372	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	5,368	5,365	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	6,208	6,204	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	5,340	5,337	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	11,125	11,118	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	3,052	3,049	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	60,337	60,300	Redacted



HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,804	5,801	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	23,050	23,036	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	5,758	5,755	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	25,725	25,708	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	11,562	11,556	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	48,775	48,744	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	60,337	60,300	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	301	252	Redacted
HRH_PRE	By Graduates: Doctors	0	0	Redacted
HRH_PRE	By Graduates: Nurses	0	0	Redacted
HRH_PRE	By Graduates: Midwives	0	0	Redacted
HRH_PRE	By Graduates: Social service workers	153	252	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	148	0	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	301	252	Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	153	252	Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	148	0	Redacted



Implementing Mechanism Details

Mechanism ID: 13684	Mechanism Name: UNZA ZEPACT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 875,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	875,000

Sub Partner Name(s)

Centre for Infectious Diseases Research in Zambia (CIDRZ)	University of Alabama, Birmingham	University of Maryland Baltimore
Vanderbilt University		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

Key Issues

Child Survival Activities
Safe Motherhood



Budget Code Information

Mechanism ID:	13684		
Mechanism Name:	UNZA ZEPACT		
Prime Partner Name:	University of Zambia School of Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	600,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1	1	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	335	335	Redacted
HRH_PRE	By Graduates: Doctors	8	8	Redacted
HRH_PRE	By Graduates: Nurses	10	10	Redacted
HRH_PRE	By Graduates: Midwives	10	10	Redacted



HRH_PRE	By Graduates: Social service workers	20	20	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	287	287	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	335	335	Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	8	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	0	Redacted

Implementing Mechanism Details

Mechanism ID: 13653	Mechanism Name: National Alliance of State and Territorial AIDS Directors (NASTAD)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 30,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	30,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	20,000
Key Populations: MSM and TG	30,000
Focus Area:	Collection and use of strategic information



Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	30,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13653		
Mechanism Name:	National Alliance of State and Territorial AIDS Directors (NASTAD)		
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13580	Mechanism Name: CIDRZ (HiLo)
----------------------------	-------------------------------------

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Centre for Infectious Diseases Research in Zambia (CIDRZ)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 15,334,723	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 50,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	15,334,723

Sub Partner Name(s)

University of Alabama at Birmingham/CIDRZ	University of North Carolina at Chapel Hill, Carolina Population Center	
---	---	--

Cross-Cutting Budget Attribution(s)

Renovation	202,045
Motor Vehicles: Purchased	416,150

Key Issues

Child Survival Activities
Safe Motherhood
TB
Family Planning



Budget Code Information

Mechanism ID: 13580			
Mechanism Name: CIDRZ (HiLo)			
Prime Partner Name: Centre for Infectious Diseases Research in Zambia (CIDRZ)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,449,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,505,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,682,362	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,397,861	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	1,000,000	0
-----------	------	-----------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	412	412	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	100	61	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	336	336	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	78	78	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	78	78	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	78	78	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	78	78	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	100	61	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	336	336	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	23	23	Redacted
SITE_SUPP	By program area/support type: TB/HIV	67	67	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	23	25	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	78	78	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	78	78	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	336	3	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	7	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	71	71	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	17,957	21,671	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	20,076	24,089	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	9,103	10,860	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	10	10	Redacted



PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	8,844	10,711	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	13	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	17,957	21,594	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	17,656	19,759	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	19,616	19,759	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	17,666	21,370	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	9,178	13,897	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	8,488	7,473	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	10	10	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	6,997	10,711	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	13	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	24,673	32,104	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	17,666	21,370	Redacted

PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	17,656	19,759	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	19,616	19,759	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	17,666	21,370	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	9,178	13,897	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	8,488	7,473	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	6,997		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	24,663	21,370	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	17,666	21,370	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	336	336	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	336	336	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	336	336	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	336	336	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of	336	336	Redacted



	PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	Sum of Denominator Support Type disaggregates	336	336	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	142,448	177,021	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	175,304	186,072	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	6,762	8,107	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	13,314	15,982	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	20,076	24,089	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	156,915	159,712	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	164,429	166,073	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	7,273	7,293	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	12,343	12,466	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	19,616	19,759	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	156,915	159,712	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	164,429	166,073	Redacted



PMTCT_STAT_TA	By: Known positives at entry	7,273	7,293	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	12,343	12,466	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	19,616	19,759	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	30	50	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	30	50	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	30	50	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	32	39	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe	0	0	Redacted

	medical device-related AE(s)			
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	32	40	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	10	10	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,000	25,000	Redacted
VMMC_CIRC_DS D	By Age: 1-9	1,500	2,000	Redacted
VMMC_CIRC_DS D	By Age: 10-14	6,000	8,000	Redacted
VMMC_CIRC_DS D	By Age: 15-19	5,000	7,000	Redacted
VMMC_CIRC_DS D	By Age: 20-24	3,100	4,000	Redacted
VMMC_CIRC_DS D	By Age: 25-49	3,000	3,400	Redacted
VMMC_CIRC_DS D	By Age: 50+	400	600	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	19,000	25,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	300	400	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC	11,000	15,000	Redacted

	program)			
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	7,700	9,600	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	19,000	25,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	11,000	19,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	8,000	6,000	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,000	25,000	Redacted
VMMC_CIRC_NGI	By Age: 1-9	1,500	2,000	Redacted
VMMC_CIRC_NGI	By Age: 10-14	6,000	8,000	Redacted
VMMC_CIRC_NGI	By Age: 15-19	5,000	7,000	Redacted
VMMC_CIRC_NGI	By Age: 20-24	3,100	4,000	Redacted
VMMC_CIRC_NGI	By Age: 25-49	3,000	3,400	Redacted
VMMC_CIRC_NGI	By Age: 50+	400	600	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	19,000	25,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	300	400	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	11,000	15,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV	7,700	9,600	Redacted

	status or not tested for HIV at site			
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	19,000	25,000	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	328	355	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	11,000	19,000	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	8,000	6,000	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,091	7,080	Redacted
VMMC_CIRC_TA	By Age: 10-14	1,567	1,856	Redacted
VMMC_CIRC_TA	By Age: 15-19	1,554	1,811	Redacted
VMMC_CIRC_TA	By Age: 20-24	1,264	1,481	Redacted
VMMC_CIRC_TA	By Age: 25-49	1,089	1,241	Redacted
VMMC_CIRC_TA	By Age: 50+	617	691	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	6,091	7,080	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical	0	0	Redacted



	VMMC			
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	328	355	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	6,360	6,868	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	2,662	2,878	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	375	475	Redacted
PP_PREV_TA	Total number of people in the target population	0	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 50+ Male	375	475	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	375	475	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	289,873	307,886	Redacted
HTC_TST_NGI	By Test Result: Negative	263,784	278,724	Redacted
HTC_TST_NGI	By Test Result: Positive	26,089	29,162	Redacted



HTC_TST_NGI	Sum of Test Result disaggregates	289,873	307,886	Redacted
HTC_TST_NGI	Age/sex: <1 Male	7,454	7,826	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	21,168	23,109	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	115,950	123,154	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	70,102	88,022	Redacted
HTC_TST_NGI	Age/sex: <1 Female	7,454	7,826	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,691	1,775	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	25,369	27,517	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	54,120	57,706	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	173,923	184,732	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	139,407	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	616,638	521,667	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	7,454	7,826	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	105,839	111,130	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	9,145	9,601	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	167,435	179,329	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	16,599	17,427	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	273,274	290,459	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	289,873	307,886	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	289,873	307,886	Redacted
HTC_TST_TA	By Test Result: Negative	263,784	278,724	Redacted
HTC_TST_TA	By Test Result: Positive	26,089	29,162	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	289,873	307,886	Redacted



HTC_TST_TA	Age/sex: <1 Male	7,454	7,826	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	21,168	23,109	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	115,950	123,154	Redacted
HTC_TST_TA	Age/sex: 50+ Male	70,102	88,022	Redacted
HTC_TST_TA	Age/sex: <1 Female	7,454	7,826	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	1,691	1,775	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	25,369	27,517	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	54,120	57,706	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	173,923	184,732	Redacted
HTC_TST_TA	Age/sex: 50+ Female	139,407	0	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	616,638	521,667	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,454	7,826	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	105,839	111,130	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,145	9,601	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	167,435	179,329	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	16,599	17,427	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	273,274	290,459	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	289,873	307,886	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	181,619		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	5,381		Redacted



C2.1.D_DSD	By Age/Sex: <15 Male	5,251		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	106,735		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	64,252		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	181,619		Redacted
C2.1.D_DSD	By Age: <15	10,632		Redacted
C2.1.D_DSD	By Age: 15+	171,007		Redacted
C2.1.D_DSD	Sum of Age disaggregates	181,639		Redacted
C2.1.D_DSD	By Sex: Female	114,741		Redacted
C2.1.D_DSD	By Sex: Male	66,898		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	181,639		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	230,000	0	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	6,821	0	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	6,704	0	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	133,808	0	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	82,667	0	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	230,000	0	Redacted
C2.1.D_NGI	By Age: <15	13,525	0	Redacted
C2.1.D_NGI	By Age: 15+	216,475	0	Redacted
C2.1.D_NGI	Sum of Age disaggregates	230,000	0	Redacted
C2.1.D_NGI	By Sex: Female	140,629	0	Redacted
C2.1.D_NGI	By Sex: Male	89,371	0	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	230,000	0	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	230,000		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	6,821		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	6,704		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	133,808		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	82,667		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	230,000		Redacted

C2.1.D_TA	By Age: <15	13,525		Redacted
C2.1.D_TA	By Age: 15+	216,475		Redacted
C2.1.D_TA	Sum of Age disaggregates	230,000		Redacted
C2.1.D_TA	By Sex: Female	140,629		Redacted
C2.1.D_TA	By Sex: Male	89,371		Redacted
C2.1.D_TA	Sum of Sex disaggregates	230,000		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	181,619		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	146,230	158,571	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	183	202	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	517	566	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	1,638	1,739	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,379	1,467	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,008	1,087	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	847	902	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	35,848	38,558	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	11,896	12,897	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	162	183	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	718	779	Redacted



CARE_CURR_DS D	Age/sex: 5-9 Female	1,885	2,030	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,573	1,699	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,569	1,701	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	3,337	3,637	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	67,316	73,214	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	16,354	17,910	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	146,230	158,571	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,717	3,974	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,599	53,444	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,338	4,691	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	88,576	96,462	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	146,230	158,571	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	201,759	215,882	Redacted
CARE_CURR_TA	Age/sex: <1 Male	217	232	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	726	777	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	2,317	2,479	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	1,986	2,125	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	1,391	1,488	Redacted



CARE_CURR_TA	Age/sex: 20-24 Male	1,105	1,182	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	49,262	52,710	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	16,775	17,949	Redacted
CARE_CURR_TA	Age/sex: <1 Female	186	199	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	1,007	1,078	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	2,711	2,901	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	2,235	2,391	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	2,124	2,273	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	4,443	4,754	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	92,324	98,787	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	22,950	24,557	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	201,759	215,882	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,246	5,613	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	68,533	73,329	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,139	6,569	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	121,841	130,371	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	201,759	215,882	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	31,784	44,000	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	29	41	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	341	472	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	180	250	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	141	195	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	147	204	Redacted



CARE_NEW_DSD	Age/sex: 20-24 Male	518	717	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	9,903	13,709	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	1,206	1,670	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	37	52	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	355	491	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	202	279	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	221	306	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	736	1,019	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	2,750	3,807	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	13,671	18,923	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,347	1,865	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	31,784	44,000	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	691	958	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	11,774	16,300	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	815	1,128	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	18,504	25,614	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	31,784	44,000	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	78	78	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	78	78	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment	78	78	Redacted

	(WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	78	78	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	78	78	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	78	78	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	8,878	8,878	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	10,445	10,445	Redacted
TB_ART_DSD	Age: 15+	8,878	8,878	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	14,908	15,807	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	18,635	19,759	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	13,417	14,226	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,491	1,581	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	14,908	15,807	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test	5,963	6,323	Redacted



	result within 12 months of birth			
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	165,058	198,069	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	39	46	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	1,052	1,262	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	5,031	6,038	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	55,532	66,639	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	1,507	1,809	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	967	1,161	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	5,216	6,259	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	95,714	114,855	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	13,812	16,575	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	39	46	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1,507	1,809	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,122	7,346	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	55,532	66,639	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	7,690	9,229	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	95,714	114,855	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	13,812	16,575	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	151,246	181,494	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	165,058	198,069	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	165,058	198,069	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	39	46	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	1,052	1,262	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	5,031	6,038	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	55,532	66,639	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	1,507	1,809	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	967	1,161	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	5,216	6,259	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	95,714	114,855	Redacted



TX_CURR_NGI	Sum of Age/Sex disaggregates	165,058	198,069	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	39	46	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	1,507	1,809	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	6,122	7,346	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	55,532	66,639	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	7,690	9,229	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	95,714	114,855	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	165,058	198,069	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	13,812	16,575	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	151,246	181,494	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	165,058	198,069	Redacted
TX_CURR_TA	Age/Sex: <1 Male	39	46	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	1,052	1,262	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	5,031	6,038	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	55,532	66,639	Redacted
TX_CURR_TA	Age/Sex: <1 Female	1,507	1,809	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	967	1,161	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	5,216	6,259	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	95,714	114,855	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	13,812	16,575	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	165,058	198,069	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	39	46	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,507	1,809	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,122	7,346	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	55,532	66,639	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	7,690	9,229	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	57,039	68,448	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	13,812	16,575	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	70,851	85,023	Redacted



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	37,864	44,000	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	56	64	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	287	334	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	376	437	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	352	409	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	239	278	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	341	397	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	10,628	12,350	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	2,794	3,247	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	147	171	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	325	377	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	364	423	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	448	521	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	490	569	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,566	1,820	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	15,596	18,123	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	3,855	4,480	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	37,864	44,000	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	56	64	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,071	1,244	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	14,002	16,272	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	147	171	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,284	1,492	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	21,507	24,992	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	37,864	44,000	Redacted
TX_NEW_DSD	Pregnancy status	6,100	8,207	Redacted



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	25,490	26,505	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	36,651	37,864	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	645	645	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number	0	0	Redacted



	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	18	58	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	78	78	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of	18	58	Redacted



	PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation			
TX_SITE	Sum of Numerator Site Support Type disaggregates	18	58	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	78	78	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	78	78	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	78	78	Redacted
LAB_CAP_DSD	By clinical laboratories	57	57	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	21	21	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	78	78	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	78	78	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	78	78	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	49	49	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	46	46	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	36	36	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	20	20	Redacted
LAB_PT_DSD	CD4: Number of laboratories that	20	20	Redacted

	achieve acceptable successful passing criteria in this PT program			
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2	2	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	22	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	2	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	62	64	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	47	50	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	47	50	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by	14	14	Redacted

	select cadre			
HRH_PRE	By Graduates: Nurses	14	14	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	14	14	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	103	309	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	103	309	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	103	309	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	103	309	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	412	412	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	412	412	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	160,000	200,000	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and	146,230	158,571	Redacted



	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
TB_SCREEN_DSD	Age: 25-49	160,000	200,000	Redacted

Implementing Mechanism Details

Mechanism ID: 13562	Mechanism Name: CHRESO Ministries
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Chreso Ministries	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,644,125	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 111,083	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,644,125

Sub Partner Name(s)

Chreso Lusaka	Chreso-Kabwe	Chreso-Livingstone
Circle of Hope		

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	400,000
Condom procurement	100,000
Condom programming	10,000
Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Gender: GBV	2,000



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Human Resources for Health	2,264,225

Key Issues

Malaria (PMI)

Child Survival Activities

Military Population

Custom

Approved



Mobile Population
 Safe Motherhood
 TB
 Workplace Programs
 End-of-Program Evaluation
 Family Planning

Budget Code Information

Mechanism ID: 13562			
Mechanism Name: CHRESO Ministries			
Prime Partner Name: Chreso Ministries			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	908,860	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	272,973	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	48,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,488,792	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	5	5	Redacted



SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	1	1	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	1	1	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	1	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	1	1	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	1	1	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	1	1	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	5	5	Redacted



SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	5	5	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	533	640	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	553	664	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	256	307	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	52	62	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	204	245	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	256	307	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	256	307	Redacted
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	263	304	Redacted
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	272	352	Redacted
PMTCT_ARV_NA	Life-long ART (including Option B+)	263	304	Redacted
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly	43	69	Redacted

	initiated on treatment during the current pregnancy			
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	220	235	Redacted
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NA	Sum of Regimen disaggregates	263	304	Redacted
PMTCT_ARV_NA	Sum of New and Current disaggregates	263	304	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	256	307	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	553	664	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	256	307	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	52	62	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	204	245	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy	0	0	Redacted



	and delivery)			
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	256	307	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	256	307	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	5	5	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	5	5	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	5	5	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	6	6	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	5	4	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	6	5	Redacted

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	987	1,184	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,027	1,232	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	391	469	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	162	194	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	553	663	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	987	1,184	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	1,027	1,232	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	391	469	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	162	194	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	553	663	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	24		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,072	884	Redacted
VMMC_CIRC_DS D	By Age: 10-14	158	200	Redacted

VMMC_CIRC_DS D	By Age: 15-19	229	222	Redacted
VMMC_CIRC_DS D	By Age: 20-24	286	237	Redacted
VMMC_CIRC_DS D	By Age: 25-49	303	225	Redacted
VMMC_CIRC_DS D	By Age: 50+	96	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	1,072	884	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	150	128	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	937	791	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	762	865	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,073	865	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting	1,072	884	Redacted

	period			
VMMC_CIRC_NGI	By Age: 10-14	158	200	Redacted
VMMC_CIRC_NGI	By Age: 15-19	229	222	Redacted
VMMC_CIRC_NGI	By Age: 20-24	286	237	Redacted
VMMC_CIRC_NGI	By Age: 25-49	303	225	Redacted
VMMC_CIRC_NGI	By Age: 50+	96	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	1,072	884	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	150	128	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	937	791	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	13,100	0	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	1,072	884	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,072	884	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	312	330	Redacted
VMMC_CIRC_TA	By Age: <1	0	0	Redacted

VMMC_CIRC_TA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_TA	By Age: 10-14	48	50	Redacted
VMMC_CIRC_TA	By Age: 15-19	72	80	Redacted
VMMC_CIRC_TA	By Age: 20-24	96	100	Redacted
VMMC_CIRC_TA	By Age: 25-49	96	100	Redacted
VMMC_CIRC_TA	By Age: 50+	0	0	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	312	330	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	43	46	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	269	284	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	312	330	Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	312	330	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	37,290	44,748	Redacted
PP_PREV_DSD	Total number of people in the target	98,000	101,136	Redacted



	population			
PP_PREV_DSD	Age/sex: 10-14 Male	700	840	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	3,000	3,600	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	6,700	8,040	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	4,540	5,448	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	200	240	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	700	840	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	6,500	7,800	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	5,500	6,600	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	9,250	11,100	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	200	240	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	37,290	44,748	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,000	6,000	Redacted
PP_PREV_TA	Total number of people in the target population	16,000	16,000	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	100	250	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	500	1,000	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	550	1,150	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	450	500	Redacted
PP_PREV_TA	Age/sex: 50+ Male	100	300	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	700	1,000	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	900	1,200	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	400	530	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	120	160	Redacted
PP_PREV_TA	Age/sex: 50+ Female	80	110	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	3,900	6,200	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are	650	780	Redacted



	based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	650	780	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual	0	0	Redacted



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	100	100	Redacted
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	100	Redacted
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	0	0	Redacted

	interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,046	8,455	Redacted
HTC_TST_DSD	By Test Result: Negative	4,600	5,820	Redacted
HTC_TST_DSD	By Test Result: Positive	2,446	2,635	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	7,046	8,455	Redacted
HTC_TST_DSD	Age/sex: <1 Male	255	306	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	43	52	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	119	143	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	154	185	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	470	564	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	865	1,038	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,155	1,386	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	260	312	Redacted
HTC_TST_DSD	Age/sex: <1 Female	265	318	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	47	56	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	145	174	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	160	192	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	477	572	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,080	1,296	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,180	1,416	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	371	445	Redacted

HTC_TST_DSD	Sum of Age/Sex disaggregates	7,046	8,455	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	357	686	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,750	3,300	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	397	740	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,542	3,729	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	754	1,426	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,292	7,029	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,046	8,455	Redacted
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,200	11,181	Redacted
HTC_TST_NA	By Test Result: Negative	6,300	7,716	Redacted
HTC_TST_NA	By Test Result: Positive	2,900	3,465	Redacted
HTC_TST_NA	Sum of Test Result disaggregates	9,200	11,181	Redacted
HTC_TST_NA	Age/sex: <1 Male	56	81	Redacted
HTC_TST_NA	Age/sex: 1-4 Male	58	85	Redacted
HTC_TST_NA	Age/sex: 5-9 Male	164	190	Redacted
HTC_TST_NA	Age/sex: 10-14 Male	199	239	Redacted
HTC_TST_NA	Age/sex: 15-19 Male	590	950	Redacted
HTC_TST_NA	Age/sex: 20-24 Male	1,215	1,620	Redacted
HTC_TST_NA	Age/sex: 25-49 Male	1,645	1,767	Redacted
HTC_TST_NA	Age/sex: 50+ Male	360	392	Redacted
HTC_TST_NA	Age/sex: <1 Female	62	97	Redacted
HTC_TST_NA	Age/sex: 1-4 Female	64	100	Redacted
HTC_TST_NA	Age/sex: 5-9 Female	195	220	Redacted
HTC_TST_NA	Age/sex: 10-14 Female	210	245	Redacted
HTC_TST_NA	Age/sex: 15-19 Female	602	1,080	Redacted
HTC_TST_NA	Age/sex: 20-24 Female	1,480	1,614	Redacted



HTC_TST_NA	Age/sex: 25-49 Female	1,680	2,000	Redacted
HTC_TST_NA	Age/sex: 50+ Female	532	577	Redacted
HTC_TST_NA	Sum of Age/Sex disaggregates	9,112	11,257	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Male	479		Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Male	4,340		Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Female	597		Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Female	4,888		Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex <15	1,076		Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	9,228		Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	10,304		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,046	8,455	Redacted
HTC_TST_NGI	By Test Result: Negative	4,600	5,820	Redacted
HTC_TST_NGI	By Test Result: Positive	2,446	2,635	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	7,046	8,455	Redacted
HTC_TST_NGI	Age/sex: <1 Male	255	306	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	43	52	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	119	143	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	154	185	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	470	564	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	865	1,038	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,155	1,386	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	260	312	Redacted
HTC_TST_NGI	Age/sex: <1 Female	265	318	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	47	56	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	145	174	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	160	192	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	477	572	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	1,080	1,296	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	1,180	1,416	Redacted

HTC_TST_NGI	Age/sex: 50+ Female	371	445	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	7,046	8,455	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	357	686	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	2,750	3,300	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	397	740	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,542	3,729	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	754	1,426	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	6,292	7,029	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	7,046	8,455	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,164	1,476	Redacted
HTC_TST_TA	By Test Result: Negative	850	1,020	Redacted
HTC_TST_TA	By Test Result: Positive	400	430	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	1,250	1,450	Redacted
HTC_TST_TA	Age/sex: <1 Male	7	10	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	7	10	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	22	25	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	22	26	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	60	100	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	140	225	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	200	227	Redacted
HTC_TST_TA	Age/sex: 50+ Male	50	52	Redacted
HTC_TST_TA	Age/sex: <1 Female	8	15	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	8	15	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	25	27	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	25	27	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	60	130	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	200	202	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	250	300	Redacted
HTC_TST_TA	Age/sex: 50+ Female	80	85	Redacted



HTC_TST_TA	Sum of Age/Sex disaggregates	1,164	1,476	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	58		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	450		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	66		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	590		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	124		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,040		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,164		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	19,743	23,692	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,444	1,733	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	3,253	3,904	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	7,540	9,048	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	7,506	9,007	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	19,743	23,692	Redacted
C2.1.D_DSD	By Age: <15	4,697	5,637	Redacted
C2.1.D_DSD	By Age: 15+	15,046	18,055	Redacted
C2.1.D_DSD	Sum of Age disaggregates	19,743	23,692	Redacted
C2.1.D_DSD	By Sex: Female	8,984	10,781	Redacted
C2.1.D_DSD	By Sex: Male	10,759	12,911	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	19,743	23,692	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	19,743	23,692	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,444	1,733	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	3,253	3,904	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	7,540	9,048	Redacted



C2.1.D_NGI	By Age/Sex: 15+ Male	7,506	9,007	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	19,743	23,692	Redacted
C2.1.D_NGI	By Age: <15	4,697	5,637	Redacted
C2.1.D_NGI	By Age: 15+	15,046	18,055	Redacted
C2.1.D_NGI	Sum of Age disaggregates	19,743	23,692	Redacted
C2.1.D_NGI	By Sex: Female	8,984	10,781	Redacted
C2.1.D_NGI	By Sex: Male	10,759	12,911	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	19,743	23,692	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	2,500		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	150		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	150		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	1,200		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	1,000		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	2,500		Redacted
C2.1.D_TA	By Age: <15	300		Redacted
C2.1.D_TA	By Age: 15+	2,200		Redacted
C2.1.D_TA	Sum of Age disaggregates	2,500		Redacted
C2.1.D_TA	By Sex: Female	1,350		Redacted
C2.1.D_TA	By Sex: Male	1,150		Redacted
C2.1.D_TA	Sum of Sex disaggregates	2,500		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	25,729	23,692	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	19,743	23,692	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,729	30,875	Redacted



CARE_CURR_DS D	Age/sex: <1 Male	351	421	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	529	635	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	705	846	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	881	1,057	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,234	1,481	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	2,820	3,384	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	3,525	4,230	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	705	846	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	529	635	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	881	1,057	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,410	1,692	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	2,114	2,537	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	2,996	3,595	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	4,405	5,286	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	2,290	2,748	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	354	425	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	25,729	30,875	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,466	2,959	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,284	9,941	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,934	5,921	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,045	12,054	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	25,729	30,875	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,500	2,500	Redacted
CARE_CURR_TA	Age/sex: <1 Male	9	9	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	28	28	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	30	30	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	52	52	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	185	185	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	250	250	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	400	400	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	66	66	Redacted
CARE_CURR_TA	Age/sex: <1 Female	10	10	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	25	25	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	110	110	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	225	225	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	400	400	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	150	150	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	500	500	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	60	60	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	2,500	2,500	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ	119	119	Redacted



	PERMISSION ONLY: <15 Male			
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	901	901	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	370	370	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,110	1,110	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,500	2,500	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,651	3,182	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	3	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	8	10	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	24	29	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	78	94	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	118	142	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	474	569	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	425	510	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	100	120	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	3	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	10	12	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	32	38	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	102	122	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	137	164	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	502	602	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	503	604	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	132	158	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,651	3,182	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	113	137	Redacted



CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,117	1,340	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	147	176	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,274	1,529	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,651	3,182	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	5	5	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	5	5	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	5	5	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	5	5	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	5	5	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	5	5	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of	5	5	Redacted



	malnutrition			
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	5	5	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	5	5	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	5	5	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	5	5	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	5	5	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	323	323	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	322	322	Redacted
FN_THER_DSD	Age: <1	0	0	Redacted
FN_THER_DSD	Age: 1-4	10	10	Redacted
FN_THER_DSD	Age: 5-14	158	158	Redacted
FN_THER_DSD	Age: 15-17	145	145	Redacted
FN_THER_DSD	Age: 18+	10	10	Redacted
FN_THER_DSD	Sum of Age disaggregates	323	323	Redacted
FN_THER_DSD	Aggregated Age: <18	313	313	Redacted

FN_THER_DSD	Aggregated Age: 18+	10	10	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	323	323	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	152	152	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	152	152	Redacted
TB_ART_DSD	Age: 0-4	0	0	Redacted
TB_ART_DSD	Age: 5-14	13	13	Redacted
TB_ART_DSD	Age: 15+	139	139	Redacted
TB_ART_DSD	Male	13	13	Redacted
TB_ART_DSD	Female	139	139	Redacted
TB_ART_DSD	Sum of Sex disaggregates	152	152	Redacted
TB_ART_DSD	Newly tested	67	67	Redacted
TB_ART_DSD	Known HIV-positive	85	85	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	152	152	Redacted
TB_ART_DSD	Aggregated Age: <15	127	127	Redacted
TB_ART_DSD	Aggregated Age: 15+	25	25	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	152	152	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	5	5	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	5	5	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of	5	5	Redacted

	registered TB cases who are HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	5	5	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	5	5	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	5	5	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	520	642	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	553	680	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	165	198	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	355	444	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	520	642	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	23	28	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,209	16,633	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	150	141	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	112	105	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	300	284	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,732	6,050	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	155	162	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	135	109	Redacted

TX_CURR_DSD	Age/Sex: 5-14 Female	325	282	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	10,300	9,500	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,177	1,083	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	150	141	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	155	162	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	562	530	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,732	6,050	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	615	553	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,300	9,500	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,177	1,083	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	17,032	15,550	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,209	16,633	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	18,209	16,633	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	150	141	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	112	105	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	300	284	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	6,732	6,050	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	155	162	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	135	109	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	325	282	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	10,300	9,500	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	18,209	16,633	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	150	141	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	155	162	Redacted



TX_CURR_NGI	Aggregated Age/Sex: <15 Male	562	530	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	6,732	6,050	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	615	553	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	10,300	9,500	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	18,209	16,633	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,177	1,083	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	17,032	15,550	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,173	2,608	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	7	8	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	15	18	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	26	31	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	69	83	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	88	106	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	180	216	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	344	413	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	56	67	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	8	10	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	17	20	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	38	46	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	165	198	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	141	169	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	345	414	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	601	721	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	73	88	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,173	2,608	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	7	8	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	117	140	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	668	802	Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	8	10	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	228	274	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,160	1,392	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,173	2,608	Redacted
TX_NEW_DSD	Pregnancy status	244	293	Redacted
TX_NEW_DSD	Breastfeeding status	32	38	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	236	283	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	256	307	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	397	477	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	606	660	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,361	15,709	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	410	485	Redacted



	who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	484	529	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,959	16,398	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	889	1,017	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,749	16,168	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	0	0	Redacted



	period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	991	1,115	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,331	15,674	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	5	5	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	5	5	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	5	5	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	5	5	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	5	5	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	5	5	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are	5	5	Redacted



	recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	5	5	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	5	5	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	5	5	Redacted
LAB_CAP_DSD	By clinical laboratories	5	5	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	5	6	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5	5	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	5	5	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	5	5	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	5	5	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	5	5	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	5	5	Redacted
FPINT_SITE_DSD	By site support type: Direct Service	5	5	Redacted



	Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	5	5	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	5	5	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	5	5	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	5	5	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	5	5	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	5	5	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	5	5	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	5	5	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	5	5	Redacted



TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	29,966	30,559	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,729	30,875	Redacted
TB_SCREEN_DSD	Age: <1	26	26	Redacted
TB_SCREEN_DSD	Age: 1-4	174	178	Redacted
TB_SCREEN_DSD	Age: 5-9	459	462	Redacted
TB_SCREEN_DSD	Age: 10-14	893	911	Redacted
TB_SCREEN_DSD	Age: 15-19	2,945	3,004	Redacted
TB_SCREEN_DSD	Age: 20-24	12,040	12,281	Redacted
TB_SCREEN_DSD	Age: 25-49	9,998	10,198	Redacted
TB_SCREEN_DSD	Age: 50+	3,431	3,499	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	4,497	4,581	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,552	1,577	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	28,414	28,982	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	29,966	30,559	Redacted
TB_SCREEN_DSD	Sex: Male	12,899	12,224	Redacted
TB_SCREEN_DSD	Sex: Female	17,067	18,335	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	29,966	30,559	Redacted

Implementing Mechanism Details

Mechanism ID: 13409	Mechanism Name: University of North Carolina at Chapel Hill - PS10-10108
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	13409		
Mechanism Name:	University of North Carolina at Chapel Hill - PS10-10108		
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13258	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13096	Mechanism Name: Zambia-led Prevention Initiative (ZPI)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0



Sub Partner Name(s)

Afya Mzuri	Catholic Medical Mission Board	CHAMP Services Ltd
Population Council	ZHECT	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation

Budget Code Information

Mechanism ID: 13096			
Mechanism Name: Zambia-led Prevention Initiative (ZPI)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	185	
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	185	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	12	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	120,000	10,000
PP_PREV_DSD	Total number of people in the target population	1,791,242	228,000
PP_PREV_DSD	Age/sex: 10-14 Male	3,019	1,000
PP_PREV_DSD	Age/sex: 15-19 Male	6,702	1,500
PP_PREV_DSD	Age/sex: 20-24 Male	14,906	1,500
PP_PREV_DSD	Age/sex: 25-49 Male	18,900	0
PP_PREV_DSD	Age/sex: 50+ Male	3,008	0
PP_PREV_DSD	Age/sex: 10-14 Female	3,016	1,000
PP_PREV_DSD	Age/sex: 15-19 Female	9,540	2,000
PP_PREV_DSD	Age/sex: 20-24 Female	25,423	3,000
PP_PREV_DSD	Age/sex: 25-49 Female	32,547	0
PP_PREV_DSD	Age/sex: 50+ Female	2,939	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	120,000	10,000
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,000	
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key	2,000	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	
HTC_TST_NA	By Test Result: Negative	17,000	
HTC_TST_NA	By Test Result: Positive	3,000	



HTC_TST_NA	Sum of Test Result disaggregates	20,000	
HTC_TST_NA	Age/sex: <1 Male	0	
HTC_TST_NA	Age/sex: 1-4 Male	0	
HTC_TST_NA	Age/sex: 5-9 Male	0	
HTC_TST_NA	Age/sex: 10-14 Male	470	
HTC_TST_NA	Age/sex: 15-19 Male	1,177	
HTC_TST_NA	Age/sex: 20-24 Male	2,500	
HTC_TST_NA	Age/sex: 25-49 Male	3,614	
HTC_TST_NA	Age/sex: 50+ Male	502	
HTC_TST_NA	Age/sex: <1 Female	0	
HTC_TST_NA	Age/sex: 1-4 Female	0	
HTC_TST_NA	Age/sex: 5-9 Female	0	
HTC_TST_NA	Age/sex: 10-14 Female	479	
HTC_TST_NA	Age/sex: 15-19 Female	1,425	
HTC_TST_NA	Age/sex: 20-24 Female	4,007	
HTC_TST_NA	Age/sex: 25-49 Female	5,354	
HTC_TST_NA	Age/sex: 50+ Female	472	
HTC_TST_NA	Sum of Age/Sex disaggregates	20,000	
HTC_TST_NA	Aggregated Age/sex: <15 Male	470	
HTC_TST_NA	Aggregated Age/sex: 15+ Male	7,793	
HTC_TST_NA	Aggregated Age/sex: <15 Female	479	
HTC_TST_NA	Aggregated Age/sex: 15+ Female	11,258	
HTC_TST_NA	Sum of Aggregated Age/Sex <15	949	
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	19,051	
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	20,000	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	
HTC_TST_NGI	By Test Result: Negative	17,000	
HTC_TST_NGI	By Test Result: Positive	3,000	
HTC_TST_NGI	Sum of Test Result disaggregates	20,000	
HTC_TST_NGI	Age/sex: <1 Male	0	



HTC_TST_NGI	Age/sex: 1-4 Male	0	
HTC_TST_NGI	Age/sex: 5-9 Male	0	
HTC_TST_NGI	Age/sex: 10-14 Male	470	
HTC_TST_NGI	Age/sex: 15-19 Male	1,177	
HTC_TST_NGI	Age/sex: 20-24 Male	2,500	
HTC_TST_NGI	Age/sex: 25-49 Male	3,614	
HTC_TST_NGI	Age/sex: 50+ Male	502	
HTC_TST_NGI	Age/sex: <1 Female	0	
HTC_TST_NGI	Age/sex: 1-4 Female	0	
HTC_TST_NGI	Age/sex: 5-9 Female	0	
HTC_TST_NGI	Age/sex: 10-14 Female	479	
HTC_TST_NGI	Age/sex: 15-19 Female	1,425	
HTC_TST_NGI	Age/sex: 20-24 Female	4,007	
HTC_TST_NGI	Age/sex: 25-49 Female	5,354	
HTC_TST_NGI	Age/sex: 50+ Female	472	
HTC_TST_NGI	Sum of Age/Sex disaggregates	20,000	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	470	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	7,793	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	479	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	11,258	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	949	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	19,051	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	20,000	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	2,900	
GEND_NORM_DSD	By Age: 0-9	100	
GEND_NORM_DSD	By Age: 10-14	200	
GEND_NORM_DSD	By Age: 15-19	500	
GEND_NORM_DSD	By Age: 20-24	900	
GEND_NORM_DSD	By Age: 25+	1,200	
GEND_NORM_DSD	Sum of Age disaggregates	2,900	



GEND_NORM_DSD	By Sex: Male	1,450	
GEND_NORM_DSD	By Sex: Female	1,450	
GEND_NORM_DSD	Sum of Sex disaggregates	2,900	
GEND_NORM_DSD	By type of activity: Individual	0	
GEND_NORM_DSD	By type of activity: Small Group	2,900	
GEND_NORM_DSD	By type of activity: Community-level	0	

Implementing Mechanism Details

Mechanism ID: 13076		Mechanism Name: JSI Logistics Services	
Funding Agency: DOD		Procurement Type: Grant	
Prime Partner Name: John Snow, Inc.			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: No			
G2G: No		Managing Agency:	

Total All Funding Sources: 0		Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 977,991			
FY 2013 Burn Rate: Redacted			
Funding Source		Funding Amount	
GHP-State		0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)
Child Survival Activities



Military Population
 Mobile Population
 Safe Motherhood
 Family Planning

Budget Code Information

Mechanism ID: 13076			
Mechanism Name: JSI Logistics Services			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	26	30
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	53	53
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	26	26
LAB_ACC_DSD	By site support type: Direct Service Delivery	0	0



	(DSD)		
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	26	26
LAB_ACC_DSD	Sum of Support Type disaggregates	26	26
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	26	26
LAB_CAP_DSD	By clinical laboratories	26	26
LAB_CAP_DSD	By Point-of-care testing sites	0	0
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	26
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0	26
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	145	153
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	153	161
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	145	153

Implementing Mechanism Details

Mechanism ID: 13071	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13033	Mechanism Name: POPULATION COUNCIL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 663,427	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 410,073	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	663,427

Sub Partner Name(s)

Tropical Diseases Research Centre	University of California at San Francisco	
-----------------------------------	---	--

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	13,500
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	13,500
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID:	13033		
Mechanism Name:	POPULATION COUNCIL		
Prime Partner Name:	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	580,134	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	53,293	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	30,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,051		Redacted
PP_PREV_DSD	Total number of people in the target population	36,888		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	519		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	399		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	251		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	1,668		Redacted



PP_PREV_DSD	Age/sex: 10-14 Female	1,579		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	2,980		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	2,655		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,051		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,584	3,600	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,524	1,200	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12	1,080	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12	120	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small	24	840	Redacted



	group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12	360	Redacted

Implementing Mechanism Details

Mechanism ID: 13016	Mechanism Name: CMMB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 575,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	575,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	13016		
Mechanism Name:	CMMB		
Prime Partner Name:	Catholic Medical Mission Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	225,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	11	11	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	11	11	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	11	11	Redacted



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,000	0	Redacted
PP_PREV_DSD	Total number of people in the target population	53,940	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	996	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	954	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	3,318	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	912	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,823	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	2,215	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	4,849	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	933	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	16,000	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,000	0	Redacted
HTC_TST_DSD	By Test Result: Negative	8,600	0	Redacted
HTC_TST_DSD	By Test Result: Positive	1,400	0	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	10,000	0	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	623	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	596	0	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	2,074	0	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	570	0	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted



HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,139	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,385	0	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	3,030	0	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	583	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,000	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,862	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,138	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,000	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,000	0	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,000	0	Redacted
HTC_TST_NGI	By Test Result: Negative	8,600	0	Redacted
HTC_TST_NGI	By Test Result: Positive	1,400	0	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	10,000	0	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	623	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	596	0	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	2,074	0	Redacted



HTC_TST_NGI	Age/sex: 50+ Male	570	0	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,139	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	1,385	0	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	3,030	0	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	583	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	10,000	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	3,862	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	6,138	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	10,000	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	10,000	0	Redacted

Implementing Mechanism Details

Mechanism ID: 13006	Mechanism Name: CIDRZ - Community Compact
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 615,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	615,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Water	5,000

Key Issues

Family Planning

Budget Code Information

Mechanism ID: 13006			
Mechanism Name: CIDRZ - Community Compact			
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	520,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	MTCT	95,000	0
------------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	2	2	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	2	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	54,000	54,000	Redacted
HTC_TST_DSD	By Test Result: Negative	46,278	46,278	Redacted
HTC_TST_DSD	By Test Result: Positive	7,722	7,722	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	54,000	54,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	29,700	29,700	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	24,300	24,300	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	54,000	54,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,700	29,700	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,300	24,300	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	54,000	54,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	54,000	54,000	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	54,000	54,000	Redacted
HTC_TST_NGI	By Test Result: Negative	46,278	46,278	Redacted
HTC_TST_NGI	By Test Result: Positive	7,722	7,722	Redacted



HTC_TST_NGI	Sum of Test Result disaggregates	54,000	54,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	29,700	29,700	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	24,300	24,300	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	54,000	54,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	29,700	29,700	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	24,300	24,300	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	54,000	54,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	54,000	54,000	Redacted

Implementing Mechanism Details

Mechanism ID: 12988	Mechanism Name: CARE
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 604,460	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 45,540	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	604,460

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Safe Motherhood

TB

Family Planning

Budget Code Information

Mechanism ID: 12988			
Mechanism Name: CARE			
Prime Partner Name: Care International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	154,460	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	210,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	66	66	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	66	66	Redacted

Implementing Mechanism Details

Mechanism ID: 12942	Mechanism Name: PROJECT CONCERN
----------------------------	--



	INTERNATIONAL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 725,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	725,000

Sub Partner Name(s)

Evangelical Fellowship of Zambia	Zambia Episcopal Conference	
----------------------------------	-----------------------------	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Gender: Gender Equality	25,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

Child Survival Activities
 Safe Motherhood

Budget Code Information

Mechanism ID: 12942			
Mechanism Name: PROJECT CONCERN INTERNATIONAL			
Prime Partner Name: Project Concern International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	110,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	225,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	190,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	5	5	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	2	2	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only	0	0	Redacted



	(TA)			
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	26	19	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration	0	0	Redacted

	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	5,197	Redacted
PP_PREV_DSD	Total number of people in the target population	0	5,729	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	331	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	0	662	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	0	357	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	0	1,019	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0	178	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	345	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0	689	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	0	370	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0	1,060	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0	186	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	5,197	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,934	0	Redacted
PP_PREV_TA	Total number of people in the target population	7,652	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	441	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	883	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	476	0	Redacted



PP_PREV_TA	Age/sex: 25-49 Male	1,359	0	Redacted
PP_PREV_TA	Age/sex: 50+ Male	238	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	460	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	920	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	495	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	1,415	0	Redacted
PP_PREV_TA	Age/sex: 50+ Female	247	0	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	6,934	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	600	480	Redacted
HTC_TST_DSD	By Test Result: Negative	516	413	Redacted
HTC_TST_DSD	By Test Result: Positive	84	67	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	600	480	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	38	31	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	76	61	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	41	33	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	118	94	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	21	16	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	40	32	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	80	64	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	43	34	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	122	98	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	21	17	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	600	480	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	38	31	Redacted

	PERMISSION ONLY: <15 Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	256	204	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40	32	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	266	213	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	78	63	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	522	417	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	600	480	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,000	717	Redacted
HTC_TST_NGI	By Test Result: Negative	860	617	Redacted
HTC_TST_NGI	By Test Result: Positive	140	100	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	1,000	717	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	63	46	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	127	92	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	68	49	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	196	140	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	35	24	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	67	48	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	133	95	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	72	51	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	204	146	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	35	26	Redacted

HTC_TST_NGI	Sum of Age/Sex disaggregates	1,000	717	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	63	46	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	426	305	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	67	48	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	444	318	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	130	94	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	870	623	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	1,000	717	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	400	237	Redacted
HTC_TST_TA	By Test Result: Negative	344	204	Redacted
HTC_TST_TA	By Test Result: Positive	56	33	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	400	237	Redacted
HTC_TST_TA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	25	15	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	51	31	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	27	16	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	78	46	Redacted
HTC_TST_TA	Age/sex: 50+ Male	14	8	Redacted
HTC_TST_TA	Age/sex: <1 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	27	16	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	53	31	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	29	17	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	82	48	Redacted
HTC_TST_TA	Age/sex: 50+ Female	14	9	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	400	237	Redacted



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	25	15	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	170	101	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	27	16	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	178	105	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	52	31	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	348	206	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	400	237	Redacted

Implementing Mechanism Details

Mechanism ID: 12821	Mechanism Name: STEP UP
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,827,376	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

American Institute of Research		
--------------------------------	--	--

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Key Issues

Workplace Programs

Budget Code Information

Mechanism ID: 12821			
Mechanism Name: STEP UP			
Prime Partner Name: Chemonics International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,000	
HTC_TST_NA	Aggregated Age/sex: 15+ Male	6,504	
HTC_TST_NA	Aggregated Age/sex: 15+ Female	6,496	
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	13,000	
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	13,000	
HTC_TST_NGI	Number of individuals who received T&C	13,000	10,000



	services for HIV and received their test results during the past 12 months		
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	6,504	5,000
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	6,496	5,000
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	13,000	10,000
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	13,000	10,000
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000	1,000
C2.1.D_NA	By Sex: Female	500	500
C2.1.D_NA	By Sex: Male	500	500
C2.1.D_NA	Sum of Sex disaggregates	1,000	1,000
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,000	
C2.1.D_NGI	By Sex: Female	500	
C2.1.D_NGI	By Sex: Male	500	
C2.1.D_NGI	Sum of Sex disaggregates	1,000	

Implementing Mechanism Details

Mechanism ID: 12283	Mechanism Name: NASTAD - HQ
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 40,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	40,000

Sub Partner Name(s)

Approved



(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	40,000
----------------------------	--------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12283		
Mechanism Name:	NASTAD - HQ		
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12276	Mechanism Name: Macha Research Trust, Inc
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Macha Research Trust, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Elizabeth Glaser Pediatric AIDS Foundation	LinkNet	
--	---------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12276		
Mechanism Name:	Macha Research Trust, Inc		
Prime Partner Name:	Macha Research Trust, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	26	30	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	26	30	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	2	2	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	11	11	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	26	30	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	110	125	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	135	150	Redacted
PMTCT_ARV_DS	Life-long ART (including Option B+)	110	125	Redacted



D				
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	45	50	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	65	75	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	110	125	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	110	125	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	110	125	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	135	150	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	110	125	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	45	50	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	65	75	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	110	125	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	110	125	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted

PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0		Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	600	660	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	700	770	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	90	100	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	45	45	Redacted
PMTCT_STAT_DS	Sum of Positives Status disaggregates	135	145	Redacted



D				
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	600	660	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	700	770	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	90	100	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	45	45	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	135	145	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	135		Redacted

Implementing Mechanism Details

Mechanism ID: 12272	Mechanism Name: PEPFAR OVC Small Grants
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	150,000

Sub Partner Name(s)

Approved



(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	30,000
Education	30,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12272			
Mechanism Name: PEPFAR OVC Small Grants			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	8	8
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	500	500
OVC_SERV_DSD	Sex: Male	250	250
OVC_SERV_DSD	Sex: Female	250	250
OVC_SERV_DSD	Sum of Sex disaggregates	500	500
OVC_SERV_DSD	Age: <1	10	10



OVC_SERV_DSD	Age: 1-4	30	30
OVC_SERV_DSD	Age: 5-9	150	150
OVC_SERV_DSD	Age: 10-14	210	210
OVC_SERV_DSD	Age: 15-17	50	50
OVC_SERV_DSD	Age: 18+	50	50
OVC_SERV_DSD	Sum of Age disaggregates	500	500

Implementing Mechanism Details

Mechanism ID: 12271	Mechanism Name: Community Compacts
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	20,000
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Operation Research

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID: 12271			
Mechanism Name: Community Compacts			
Prime Partner Name: Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	350,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	6	6
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	6	6



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,051	4,349
PP_PREV_DSD	Total number of people in the target population	36,888	14,400
PP_PREV_DSD	Age/sex: 10-14 Male	0	0
PP_PREV_DSD	Age/sex: 15-19 Male	251	370
PP_PREV_DSD	Age/sex: 20-24 Male	1,579	1,000
PP_PREV_DSD	Age/sex: 25-49 Male	2,655	830
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	519	367
PP_PREV_DSD	Age/sex: 15-19 Female	399	395
PP_PREV_DSD	Age/sex: 20-24 Female	1,668	715
PP_PREV_DSD	Age/sex: 25-49 Female	2,980	672
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,051	4,349

Implementing Mechanism Details

Mechanism ID: 12267	Mechanism Name: Mawa (formerly ZERS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,500,000

Sub Partner Name(s)



(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	1,500,000
------------------------	-----------

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID:	12267		
Mechanism Name:	Mawa (formerly ZERS)		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	2	3
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	2	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	83,708	30,882
OVC_SERV_DSD	Sex: Male	41,078	15,155
OVC_SERV_DSD	Sex: Female	42,630	15,727



OVC_SERV_DSD	Sum of Sex disaggregates	83,708	30,882
OVC_SERV_DSD	Age: <1	1,365	504
OVC_SERV_DSD	Age: 1-4	12,822	4,730
OVC_SERV_DSD	Age: 5-9	15,177	5,599
OVC_SERV_DSD	Age: 10-14	12,182	4,494
OVC_SERV_DSD	Age: 15-17	5,320	1,963
OVC_SERV_DSD	Age: 18+	36,842	13,592
OVC_SERV_DSD	Sum of Age disaggregates	83,708	30,882

Implementing Mechanism Details

Mechanism ID: 11694	Mechanism Name: CDC Technical Assistance - SMDP & FETP
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	11694		
Mechanism Name:	CDC Technical Assistance - SMDP & FETP		
Prime Partner Name:	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11627	Mechanism Name: DAO Lusaka
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 4,660,894	



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Military Population
- Mobile Population
- Safe Motherhood

Budget Code Information

Mechanism ID: 11627			
Mechanism Name: DAO Lusaka			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Approved



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11626	Mechanism Name: Jhpiego
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,550,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Military Population
Mobile Population
Safe Motherhood
TB



Family Planning

Budget Code Information

Mechanism ID: 11626			
Mechanism Name: Jhpiego			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	15	15
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	15	15
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	7	8
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	13	13
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	13	13
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	13	13
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	6	6
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	13	13
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	259	314
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	336	376



PMTCT_ARV_NGI	Life-long ART (including Option B+)	150	210
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	89	135
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	61	75
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	109	104
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	259	314
PMTCT_ARV_NGI	Sum of New and Current disaggregates	150	210
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	259	314
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	336	376
PMTCT_ARV_TA	Life-long ART (including Option B+)	259	314
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	144	187
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	115	127
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0



PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	259	314
PMTCT_ARV_TA	Sum of New and Current disaggregates	259	314
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	11	12
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	13	13
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	11	12
PMTCT_SITE	Sum of Numerator Support Type disaggregates	11	12
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	13	13
PMTCT_SITE	Sum of Denominator Support Type disaggregates	13	13
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,000	3,130
PMTCT_STAT_NGI	Number of new ANC and L&D clients	3,000	3,130
PMTCT_STAT_NGI	By: Known positives at entry	87	109
PMTCT_STAT_NGI	By: Number of new positives identified	249	267
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	336	376
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,000	3,130
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,000	3,130
PMTCT_STAT_TA	By: Known positives at entry	87	109
PMTCT_STAT_TA	By: Number of new positives identified	249	267

PMTCT_STAT_TA	Sum of Positives Status disaggregates	336	376
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	84	68
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	42	34
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	32	30
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	10	4
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical	0	0

	device-related AE(s)		
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,000	7,001
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	1,661	2,171
VMMC_CIRC_DSD	By Age: 15-19	1,209	1,572
VMMC_CIRC_DSD	By Age: 20-24	969	1,607
VMMC_CIRC_DSD	By Age: 25-49	1,144	1,633
VMMC_CIRC_DSD	By Age: 50+	17	18
VMMC_CIRC_DSD	Sum of age disaggregates	5,000	7,001
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	49	49
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,069	5,589
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	882	1,363
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	5,000	7,001
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	4,514	5,600
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision	486	1,400



	surgery		
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,345	11,001
HTC_TST_NGI	By Test Result: Negative	8,979	10,591
HTC_TST_NGI	By Test Result: Positive	366	410
HTC_TST_NGI	Sum of Test Result disaggregates	9,345	11,001
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	0	1,176
HTC_TST_NGI	Age/sex: 5-9 Male	104	2,208
HTC_TST_NGI	Age/sex: 10-14 Male	2,338	1,382
HTC_TST_NGI	Age/sex: 15-19 Male	1,074	1,344
HTC_TST_NGI	Age/sex: 20-24 Male	1,194	981
HTC_TST_NGI	Age/sex: 25-49 Male	735	9
HTC_TST_NGI	Age/sex: 50+ Male	9	0
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	0	0
HTC_TST_NGI	Age/sex: 5-9 Female	0	444
HTC_TST_NGI	Age/sex: 10-14 Female	444	1,063
HTC_TST_NGI	Age/sex: 15-19 Female	1,063	1,954
HTC_TST_NGI	Age/sex: 20-24 Female	1,944	440
HTC_TST_NGI	Age/sex: 25-49 Female	440	0
HTC_TST_NGI	Age/sex: 50+ Female	0	0
HTC_TST_NGI	Sum of Age/Sex disaggregates	9,345	11,001
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,442	3,384
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	3,012	3,716
HTC_TST_NGI	Aggregated Age/sex: <15 Female	444	444
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,447	3,457
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	2,886	3,828
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	6,459	7,173
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	9,345	11,001
HTC_TST_TA	Number of individuals who received T&C	9,345	11,001



	services for HIV and received their test results during the past 12 months		
HTC_TST_TA	By Test Result: Negative	8,979	10,591
HTC_TST_TA	By Test Result: Positive	366	410
HTC_TST_TA	Sum of Test Result disaggregates	9,345	11,001
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	0	1,176
HTC_TST_TA	Age/sex: 5-9 Male	104	2,208
HTC_TST_TA	Age/sex: 10-14 Male	2,338	1,382
HTC_TST_TA	Age/sex: 15-19 Male	1,074	1,344
HTC_TST_TA	Age/sex: 20-24 Male	1,194	981
HTC_TST_TA	Age/sex: 25-49 Male	735	9
HTC_TST_TA	Age/sex: 50+ Male	9	0
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	0	0
HTC_TST_TA	Age/sex: 5-9 Female	0	444
HTC_TST_TA	Age/sex: 10-14 Female	444	1,063
HTC_TST_TA	Age/sex: 15-19 Female	1,063	1,954
HTC_TST_TA	Age/sex: 20-24 Female	1,944	440
HTC_TST_TA	Age/sex: 25-49 Female	440	0
HTC_TST_TA	Age/sex: 50+ Female	0	0
HTC_TST_TA	Sum of Age/Sex disaggregates	9,345	11,001
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,442	3,384
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,012	3,716
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	444	444
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,447	3,457
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,886	3,828
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	6,459	7,173



HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	9,345	11,001
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	3,810	
C2.1.D_NGI	By Age/Sex: <15 Female	178	
C2.1.D_NGI	By Age/Sex: <15 Male	128	
C2.1.D_NGI	By Age/Sex: 15+ Female	1,969	
C2.1.D_NGI	By Age/Sex: 15+ Male	1,535	
C2.1.D_NGI	Sum of Age/Sex disaggregates	3,810	
C2.1.D_NGI	By Age: <15	306	
C2.1.D_NGI	By Age: 15+	3,504	
C2.1.D_NGI	Sum of Age disaggregates	3,810	
C2.1.D_NGI	By Sex: Female	2,147	
C2.1.D_NGI	By Sex: Male	1,663	
C2.1.D_NGI	Sum of Sex disaggregates	3,810	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	3,810	3,810
C2.1.D_TA	By Age/Sex: <15 Female	178	178
C2.1.D_TA	By Age/Sex: <15 Male	128	128
C2.1.D_TA	By Age/Sex: 15+ Female	1,969	1,969
C2.1.D_TA	By Age/Sex: 15+ Male	1,535	1,535
C2.1.D_TA	Sum of Age/Sex disaggregates	3,810	3,810
C2.1.D_TA	By Age: <15	306	306
C2.1.D_TA	By Age: 15+	3,504	3,504
C2.1.D_TA	Sum of Age disaggregates	3,810	3,810
C2.1.D_TA	By Sex: Female	2,147	2,147
C2.1.D_TA	By Sex: Male	1,663	1,663
C2.1.D_TA	Sum of Sex disaggregates	3,810	3,810
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible,	13	13



	cotrimoxazole		
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	13	13
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	13	13
CARE_SITE	Sum of Denominator Site Support Type disaggregates	13	13
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,810	4,803
TX_CURR_NGI	Age/Sex: <1 Male	6	6
TX_CURR_NGI	Age/Sex: 1-4 Male	0	0
TX_CURR_NGI	Age/Sex: 5-14 Male	116	116
TX_CURR_NGI	Age/Sex: 15+ Male	1,447	2,000
TX_CURR_NGI	Age/Sex: <1 Female	2	2
TX_CURR_NGI	Age/Sex: 1-4 Female	10	10
TX_CURR_NGI	Age/Sex: 5-14 Female	169	169
TX_CURR_NGI	Age/Sex: 15+ Female	2,060	2,500
TX_CURR_NGI	Sum of Age/Sex disaggregates	3,810	4,803
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	6	6
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	2	2
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	122	122
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,447	2,000
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	181	181
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	2,060	2,500
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	3,810	4,803
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	303	303
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	3,507	4,500
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	3,810	4,803
TX_CURR_TA	Age/Sex: <1 Male	6	6
TX_CURR_TA	Age/Sex: 1-4 Male	0	0



TX_CURR_TA	Age/Sex: 5-14 Male	116	116
TX_CURR_TA	Age/Sex: 15+ Male	1,447	2,000
TX_CURR_TA	Age/Sex: <1 Female	2	2
TX_CURR_TA	Age/Sex: 1-4 Female	10	10
TX_CURR_TA	Age/Sex: 5-14 Female	169	169
TX_CURR_TA	Age/Sex: 15+ Female	2,060	2,500
TX_CURR_TA	Sum of Age/Sex disaggregations	303	303
TX_CURR_TA	Aggregated Age/Sex: <1 Male	6	6
TX_CURR_TA	Aggregated Age/Sex: <1 Female	2	2
TX_CURR_TA	Aggregated Age/Sex: <15 Male	122	122
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,447	2,000
TX_CURR_TA	Aggregated Age/Sex: <15 Female	181	181
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,060	2,500
TX_CURR_TA	Sum of Aggregated Age/Sex <15	303	303
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,507	4,500
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	3,810	4,803
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	7	7
TX_DIST	Total number of PEPFAR supported District Health Offices	7	7
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	8
TX_SITE	Total number of PEPFAR-supported ART sites	7	8
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported	7	8



	ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
TX_SITE	Sum of Numerator Site Support Type disaggregates	7	8
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	0
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	7	8
TX_SITE	Sum of Denominator Site Support Type disaggregates	7	8
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	14	14
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	14	14
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	14	14
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	14	14
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	0



FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	14	14
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	14	14
FPINT_SITE_DSD	Service delivery type: Community	0	0
FPINT_SITE_DSD	Service delivery type: Clinical	14	14
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	14	14
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	14	14
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	14	14
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	14	14
QI_SITE	Sum of Numerator Site Support Type disaggregates	14	14
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV	15	15



	Care, HIV Treatment, TB care, PMTCT, VMMC, HTC		
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	15	15
QI_SITE	Sum of Denominator Site Support Type disaggregates	30	30
SI_HIS	Existence of a national registry of health facilities that is updated annually	0	0
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	14	14

Implementing Mechanism Details

Mechanism ID: 11027	Mechanism Name: National AIDS Council Joint Financing Arrangement
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: Yes	Managing Agency: State/AF

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 100,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Workplace Programs

Budget Code Information

Mechanism ID: 11027			
Mechanism Name: National AIDS Council Joint Financing Arrangement			
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10984	Mechanism Name: DOD Project Concern International PCI
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,129,685	

Approved



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	300,000
------------------------	---------

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Military Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	10984		
Mechanism Name:	DOD Project Concern International PCI		
Prime Partner Name:	Project Concern International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	55	55
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	53	55
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	3	5
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	24	24
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	22	22
SITE_SUPP	By program area/support type: PMTCT	3	5



	Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	24	24
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	53	55
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	27	35
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	10	20
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	129	239
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	161	299
PMTCT_ARV_NGI	Life-long ART (including Option B+)	129	239
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	102	191
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	27	48
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	129	239
PMTCT_ARV_NGI	Sum of New and Current disaggregates	129	239
PMTCT_ARV_TA	Number of HIV-positive pregnant women who	129	239



	received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	161	299
PMTCT_ARV_TA	Life-long ART (including Option B+)	129	239
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	102	191
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	27	48
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	129	239
PMTCT_ARV_TA	Sum of New and Current disaggregates	129	239
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	3	5
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	3	5
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	3	5
PMTCT_SITE	Sum of Numerator Support Type disaggregates	3	5
PMTCT_SITE	By site support type: Technical	3	5



	Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		
PMTCT_SITE	Sum of Denominator Support Type disaggregates	3	5
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	983	1,819
PMTCT_STAT_NGI	Number of new ANC and L&D clients	1,035	1,915
PMTCT_STAT_NGI	By: Known positives at entry	32	60
PMTCT_STAT_NGI	By: Number of new positives identified	129	239
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	161	299
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	983	1,819
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,035	1,915
PMTCT_STAT_TA	By: Known positives at entry	32	60
PMTCT_STAT_TA	By: Number of new positives identified	129	239
PMTCT_STAT_TA	Sum of Positives Status disaggregates	161	299
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,034	20,536
PP_PREV_TA	Total number of people in the target population	22,543	25,670
PP_PREV_TA	Age/sex: 10-14 Male	708	805
PP_PREV_TA	Age/sex: 15-19 Male	1,591	1,811
PP_PREV_TA	Age/sex: 20-24 Male	1,237	1,409
PP_PREV_TA	Age/sex: 25-49 Male	5,518	6,284
PP_PREV_TA	Age/sex: 50+ Male	0	0
PP_PREV_TA	Age/sex: 10-14 Female	736	838
PP_PREV_TA	Age/sex: 15-19 Female	1,655	1,885
PP_PREV_TA	Age/sex: 20-24 Female	1,287	1,466



PP_PREV_TA	Age/sex: 25-49 Female	5,302	6,038
PP_PREV_TA	Age/sex: 50+ Female	0	0
PP_PREV_TA	Sum of Age/Sex disaggregates	18,034	20,536
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,508	14,575
HTC_TST_DSD	By Test Result: Negative	11,033	12,860
HTC_TST_DSD	By Test Result: Positive	1,475	1,715
HTC_TST_DSD	Sum of Test Result disaggregates	12,508	14,575
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	735	858
HTC_TST_DSD	Age/sex: 5-9 Male	491	572
HTC_TST_DSD	Age/sex: 10-14 Male	123	143
HTC_TST_DSD	Age/sex: 15-19 Male	552	644
HTC_TST_DSD	Age/sex: 20-24 Male	552	643
HTC_TST_DSD	Age/sex: 25-49 Male	3,681	4,286
HTC_TST_DSD	Age/sex: 50+ Male	0	0
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	765	891
HTC_TST_DSD	Age/sex: 5-9 Female	510	594
HTC_TST_DSD	Age/sex: 10-14 Female	127	148
HTC_TST_DSD	Age/sex: 15-19 Female	574	669
HTC_TST_DSD	Age/sex: 20-24 Female	573	668
HTC_TST_DSD	Age/sex: 25-49 Female	3,825	4,459
HTC_TST_DSD	Age/sex: 50+ Female	0	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	12,508	14,575
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,349	1,573
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,785	5,573
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,402	1,633



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,972	5,796
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,751	3,206
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,757	11,369
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	12,508	14,575
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,650	18,605
HTC_TST_NGI	By Test Result: Negative	12,941	16,448
HTC_TST_NGI	By Test Result: Positive	1,709	2,157
HTC_TST_NGI	Sum of Test Result disaggregates	14,650	18,605
HTC_TST_NGI	Age/sex: <1 Male	56	103
HTC_TST_NGI	Age/sex: 1-4 Male	1,002	1,351
HTC_TST_NGI	Age/sex: 5-9 Male	491	572
HTC_TST_NGI	Age/sex: 10-14 Male	123	143
HTC_TST_NGI	Age/sex: 15-19 Male	773	1,085
HTC_TST_NGI	Age/sex: 20-24 Male	552	643
HTC_TST_NGI	Age/sex: 25-49 Male	3,681	4,286
HTC_TST_NGI	Age/sex: 50+ Male	0	0
HTC_TST_NGI	Age/sex: <1 Female	58	107
HTC_TST_NGI	Age/sex: 1-4 Female	1,041	1,403
HTC_TST_NGI	Age/sex: 5-9 Female	510	594
HTC_TST_NGI	Age/sex: 10-14 Female	127	148
HTC_TST_NGI	Age/sex: 15-19 Female	803	1,128
HTC_TST_NGI	Age/sex: 20-24 Female	987	1,434
HTC_TST_NGI	Age/sex: 25-49 Female	4,446	5,608
HTC_TST_NGI	Age/sex: 50+ Female	0	0
HTC_TST_NGI	Sum of Age/Sex disaggregates	14,650	18,605
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,672	2,169
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	5,006	6,014
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,736	2,252
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	6,236	8,170



HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3,408	4,421
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	11,242	14,184
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	14,650	18,605
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,142	4,030
HTC_TST_TA	By Test Result: Negative	1,908	3,588
HTC_TST_TA	By Test Result: Positive	234	442
HTC_TST_TA	Sum of Test Result disaggregates	2,142	4,030
HTC_TST_TA	Age/sex: <1 Male	56	103
HTC_TST_TA	Age/sex: 1-4 Male	267	493
HTC_TST_TA	Age/sex: 5-9 Male	0	0
HTC_TST_TA	Age/sex: 10-14 Male	0	0
HTC_TST_TA	Age/sex: 15-19 Male	221	441
HTC_TST_TA	Age/sex: 20-24 Male	0	0
HTC_TST_TA	Age/sex: 25-49 Male	0	0
HTC_TST_TA	Age/sex: 50+ Male	0	0
HTC_TST_TA	Age/sex: <1 Female	58	107
HTC_TST_TA	Age/sex: 1-4 Female	276	512
HTC_TST_TA	Age/sex: 5-9 Female	0	0
HTC_TST_TA	Age/sex: 10-14 Female	0	0
HTC_TST_TA	Age/sex: 15-19 Female	229	459
HTC_TST_TA	Age/sex: 20-24 Female	414	766
HTC_TST_TA	Age/sex: 25-49 Female	621	1,149
HTC_TST_TA	Age/sex: 50+ Female	0	0
HTC_TST_TA	Sum of Age/Sex disaggregates	2,142	4,030
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	323	596
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	221	441
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	334	619



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,264	2,374
HTC_TST_TA	Sum of Aggregated Age/Sex <15	657	1,215
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,485	2,815
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,142	4,030
GEND_GBV_DSD	Number of people receiving post-GBV care	64	161
GEND_GBV_DSD	Age: 0-9	20	52
GEND_GBV_DSD	Age: 10-14	8	23
GEND_GBV_DSD	Age: 15-17	7	19
GEND_GBV_DSD	Age: 18-24	5	14
GEND_GBV_DSD	Age: 25+	24	56
GEND_GBV_DSD	Sum of Age disaggregates	64	164
GEND_GBV_DSD	Sex: Male	6	16
GEND_GBV_DSD	Sex: Female	58	145
GEND_GBV_DSD	Sum of Sex disaggregates	64	161
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	129	129
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	25	64
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	25	64
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	24,835	30,256
GEND_NORM_DSD	By Age: 0-9	2,644	3,788
GEND_NORM_DSD	By Age: 10-14	3,333	4,343
GEND_NORM_DSD	By Age: 15-19	4,003	4,768
GEND_NORM_DSD	By Age: 20-24	4,035	5,035
GEND_NORM_DSD	By Age: 25+	10,820	12,322
GEND_NORM_DSD	Sum of Age disaggregates	24,835	30,256
GEND_NORM_DSD	By Sex: Male	12,386	15,072
GEND_NORM_DSD	By Sex: Female	12,449	15,184
GEND_NORM_DSD	Sum of Sex disaggregates	24,835	30,256



GEND_NORM_DSD	By type of activity: Individual	5,772	6,571
GEND_NORM_DSD	By type of activity: Small Group	11,573	16,226
GEND_NORM_DSD	By type of activity: Community-level	24,835	30,256
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,736	2,153
OVC_ACC_DSD	Sex: Male	851	1,055
OVC_ACC_DSD	Sex: Female	885	1,098
OVC_ACC_DSD	Sum of Sex disaggregates	1,736	2,153
OVC_ACC_DSD	Age: <1	19	28
OVC_ACC_DSD	Age: 1-4	735	858
OVC_ACC_DSD	Age: 5-9	491	572
OVC_ACC_DSD	Age: 10-14	123	143
OVC_ACC_DSD	Age: 15-17	152	243
OVC_ACC_DSD	Age: 18+	216	309
OVC_ACC_DSD	Sum of Age disaggregates	1,736	2,153
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,067	12,960
OVC_SERV_TA	Sex: Male	4,308	6,156
OVC_SERV_TA	Sex: Female	4,759	6,804
OVC_SERV_TA	Sum of Sex disaggregates	9,067	12,960
OVC_SERV_TA	Age: <1	377	540
OVC_SERV_TA	Age: 1-4	1,889	2,700
OVC_SERV_TA	Age: 5-9	2,644	3,788
OVC_SERV_TA	Age: 10-14	1,889	2,700
OVC_SERV_TA	Age: 15-17	757	1,072
OVC_SERV_TA	Age: 18+	1,511	2,160
OVC_SERV_TA	Sum of Age disaggregates	9,067	12,960
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,751	
C2.1.D_DSD	By Age/Sex: <15 Female	286	



C2.1.D_DSD	By Age/Sex: <15 Male	281	
C2.1.D_DSD	By Age/Sex: 15+ Female	638	
C2.1.D_DSD	By Age/Sex: 15+ Male	546	
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,751	
C2.1.D_DSD	By Age: <15	567	
C2.1.D_DSD	By Age: 15+	1,184	
C2.1.D_DSD	Sum of Age disaggregates	1,751	
C2.1.D_DSD	By Sex: Female	924	
C2.1.D_DSD	By Sex: Male	827	
C2.1.D_DSD	Sum of Sex disaggregates	1,751	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,751	
C2.1.D_NGI	By Age/Sex: <15 Female	286	
C2.1.D_NGI	By Age/Sex: <15 Male	281	
C2.1.D_NGI	By Age/Sex: 15+ Female	638	
C2.1.D_NGI	By Age/Sex: 15+ Male	546	
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,751	
C2.1.D_NGI	By Age: <15	567	
C2.1.D_NGI	By Age: 15+	1,184	
C2.1.D_NGI	Sum of Age disaggregates	1,751	
C2.1.D_NGI	By Sex: Female	924	
C2.1.D_NGI	By Sex: Male	827	
C2.1.D_NGI	Sum of Sex disaggregates	1,751	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	1,663	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,751	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,751	2,238



CARE_CURR_DSD	Age/sex: <1 Male	12	25
CARE_CURR_DSD	Age/sex: 1-4 Male	150	168
CARE_CURR_DSD	Age/sex: 5-9 Male	65	89
CARE_CURR_DSD	Age/sex: 10-14 Male	54	68
CARE_CURR_DSD	Age/sex: 15-19 Male	145	219
CARE_CURR_DSD	Age/sex: 20-24 Male	101	123
CARE_CURR_DSD	Age/sex: 25-49 Male	300	332
CARE_CURR_DSD	Age/sex: 50+ Male	0	0
CARE_CURR_DSD	Age/sex: <1 Female	14	29
CARE_CURR_DSD	Age/sex: 1-4 Female	152	170
CARE_CURR_DSD	Age/sex: 5-9 Female	66	70
CARE_CURR_DSD	Age/sex: 10-14 Female	54	56
CARE_CURR_DSD	Age/sex: 15-19 Female	148	184
CARE_CURR_DSD	Age/sex: 20-24 Female	149	198
CARE_CURR_DSD	Age/sex: 25-49 Female	341	507
CARE_CURR_DSD	Age/sex: 50+ Female	0	0
CARE_CURR_DSD	Sun of Age/Sex disaggregates	1,751	2,238
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	281	350
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	546	674
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	286	325
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	638	889
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,751	2,238
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	967	1,344
CARE_NEW_DSD	Age/sex: <1 Male	1	2



CARE_NEW_DSD	Age/sex: 1-4 Male	50	68
CARE_NEW_DSD	Age/sex: 5-9 Male	25	29
CARE_NEW_DSD	Age/sex: 10-14 Male	14	16
CARE_NEW_DSD	Age/sex: 15-19 Male	85	119
CARE_NEW_DSD	Age/sex: 20-24 Male	61	71
CARE_NEW_DSD	Age/sex: 25-49 Male	200	232
CARE_NEW_DSD	Age/sex: 50+ Male	0	0
CARE_NEW_DSD	Age/sex: <1 Female	1	2
CARE_NEW_DSD	Age/sex: 1-4 Female	52	70
CARE_NEW_DSD	Age/sex: 5-9 Female	26	30
CARE_NEW_DSD	Age/sex: 10-14 Female	14	16
CARE_NEW_DSD	Age/sex: 15-19 Female	88	124
CARE_NEW_DSD	Age/sex: 20-24 Female	109	158
CARE_NEW_DSD	Age/sex: 25-49 Female	241	407
CARE_NEW_DSD	Age/sex: 50+ Female	0	0
CARE_NEW_DSD	Sum of Age/sex disaggregates	967	1,344
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	90	115
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	346	422
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	93	118
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	438	689
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	967	1,344
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	20	22
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	24	24
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of	20	22



	PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Sum of Numerator Site Support Type disaggregates	20	22
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	20	22
CARE_SITE	Sum of Denominator Site Support Type disaggregates	20	22
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	20	22
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	22	22
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	20	22
FN_SITE	Sum of Numerator Support Type disaggregates	20	22
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	22	22
FN_SITE	Sum of Denominator Support Type disaggregates	22	22
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	644	821

FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	678	864
FN_THER_DSD	Age: <1	11	24
FN_THER_DSD	Age: 1-4	134	149
FN_THER_DSD	Age: 5-14	102	125
FN_THER_DSD	Age: 15-17	120	177
FN_THER_DSD	Age: 18+	277	346
FN_THER_DSD	Sum of Age disaggregates	644	821
FN_THER_DSD	Aggregated Age: <18	368	475
FN_THER_DSD	Aggregated Age: 18+	276	346
FN_THER_DSD	Sum of Aggregated Age disaggregates	644	821
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	114	210
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	161	239
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	114	210
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	114	210
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	2	4
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	22	23
TX_SITE	Total number of PEPFAR-supported ART sites	24	24
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for	22	23



	patients 12 months after ART initiation		
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Sum of Numerator Site Support Type disaggregates	22	23
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	24	24
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0
TX_SITE	Sum of Denominator Site Support Type disaggregates	24	24
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	10	20
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	10	20
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	10	20
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	10	20
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	10	20
FPINT_SITE_DSD	Sum of Denominator Site Support Type	10	20



	disaggregates		
FPINT_SITE_DSD	Service delivery type: Community	7	15
FPINT_SITE_DSD	Service delivery type: Clinical	3	5
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	10	20
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	17	20
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	24	24
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	17	20
QI_SITE	Sum of Numerator Site Support Type disaggregates	17	20
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	17	20
QI_SITE	Sum of Denominator Site Support Type disaggregates	17	20
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	1,663	2,126
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	1,751	2,238



	OR viral load		
TB_SCREEN_DSD	Age: <1	18	18
TB_SCREEN_DSD	Age: 1-4	62	62
TB_SCREEN_DSD	Age: 5-9	66	66
TB_SCREEN_DSD	Age: 10-14	62	62
TB_SCREEN_DSD	Age: 15-19	49	49
TB_SCREEN_DSD	Age: 20-24	40	40
TB_SCREEN_DSD	Age: 25-49	115	115
TB_SCREEN_DSD	Age: 50+	31	31
TB_SCREEN_DSD	Sum of Age disaggregates	257	257
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	208	208
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	235	235
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	443	443
TB_SCREEN_DSD	Sex: Male	217	217
TB_SCREEN_DSD	Sex: Female	226	226
TB_SCREEN_DSD	Sum of Sex disaggregates	443	443

Implementing Mechanism Details

Mechanism ID: 10875	Mechanism Name: United Nations High Commissioner for Refugees/PRM
Funding Agency: State/PRM	Procurement Type: Umbrella Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 50,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Approved



GHP-State	150,000
-----------	---------

Sub Partner Name(s)

Action Africa Health	Ministry of Community Development and Social Services	
----------------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population

Budget Code Information

Mechanism ID: 10875			
Mechanism Name: United Nations High Commissioner for Refugees/PRM			
Prime Partner Name: United Nations High Commissioner for Refugees			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	150,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	3	3
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	3	3
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	3	3
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	730	730
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	250	250
VMMC_CIRC_DSD	By Age: 15-19	300	300
VMMC_CIRC_DSD	By Age: 20-24	150	150
VMMC_CIRC_DSD	By Age: 25-49	20	20
VMMC_CIRC_DSD	By Age: 50+	10	10
VMMC_CIRC_DSD	Sum of age disaggregates	730	730
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	730	730



VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	730	730
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	730	730
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	730	730
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	250	250
VMMC_CIRC_NGI	By Age: 15-19	300	300
VMMC_CIRC_NGI	By Age: 20-24	150	150
VMMC_CIRC_NGI	By Age: 25-49	20	20
VMMC_CIRC_NGI	By Age: 50+	10	10
VMMC_CIRC_NGI	Sum of Age disaggregates	730	730
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	730	730
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	730	730



VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	730	730
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,500	7,500
PP_PREV_DSD	Total number of people in the target population	35,874	35,874
PP_PREV_DSD	Age/sex: 10-14 Male	100	100
PP_PREV_DSD	Age/sex: 15-19 Male	200	200
PP_PREV_DSD	Age/sex: 20-24 Male	420	420
PP_PREV_DSD	Age/sex: 25-49 Male	2,000	2,000
PP_PREV_DSD	Age/sex: 50+ Male	80	80
PP_PREV_DSD	Age/sex: 10-14 Female	150	150
PP_PREV_DSD	Age/sex: 15-19 Female	250	250
PP_PREV_DSD	Age/sex: 20-24 Female	1,200	1,200
PP_PREV_DSD	Age/sex: 25-49 Female	3,000	3,000
PP_PREV_DSD	Age/sex: 50+ Female	100	100
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,500	7,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,500	3,500
HTC_TST_DSD	By Test Result: Negative	3,255	3,255
HTC_TST_DSD	By Test Result: Positive	245	245
HTC_TST_DSD	Sum of Test Result disaggregates	3,500	3,500
HTC_TST_DSD	Age/sex: <1 Male	50	50



HTC_TST_DSD	Age/sex: 1-4 Male	100	100
HTC_TST_DSD	Age/sex: 5-9 Male	100	100
HTC_TST_DSD	Age/sex: 10-14 Male	100	100
HTC_TST_DSD	Age/sex: 15-19 Male	130	130
HTC_TST_DSD	Age/sex: 20-24 Male	300	300
HTC_TST_DSD	Age/sex: 25-49 Male	700	700
HTC_TST_DSD	Age/sex: 50+ Male	20	20
HTC_TST_DSD	Age/sex: <1 Female	50	50
HTC_TST_DSD	Age/sex: 1-4 Female	100	100
HTC_TST_DSD	Age/sex: 5-9 Female	100	100
HTC_TST_DSD	Age/sex: 10-14 Female	100	100
HTC_TST_DSD	Age/sex: 15-19 Female	150	150
HTC_TST_DSD	Age/sex: 20-24 Female	480	480
HTC_TST_DSD	Age/sex: 25-49 Female	1,000	1,000
HTC_TST_DSD	Age/sex: 50+ Female	20	20
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,500	3,500
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	350	350
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,150	1,150
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	350	350
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,650	1,650
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	700	700
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,800	2,800
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,500	3,500
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,500	3,500
HTC_TST_NGI	By Test Result: Negative	3,255	3,255
HTC_TST_NGI	By Test Result: Positive	245	245
HTC_TST_NGI	Sum of Test Result disaggregates	3,500	3,500

HTC_TST_NGI	Age/sex: <1 Male	50	50
HTC_TST_NGI	Age/sex: 1-4 Male	100	100
HTC_TST_NGI	Age/sex: 5-9 Male	100	100
HTC_TST_NGI	Age/sex: 10-14 Male	100	100
HTC_TST_NGI	Age/sex: 15-19 Male	130	130
HTC_TST_NGI	Age/sex: 20-24 Male	300	300
HTC_TST_NGI	Age/sex: 25-49 Male	700	700
HTC_TST_NGI	Age/sex: 50+ Male	20	20
HTC_TST_NGI	Age/sex: <1 Female	50	50
HTC_TST_NGI	Age/sex: 1-4 Female	100	100
HTC_TST_NGI	Age/sex: 5-9 Female	100	100
HTC_TST_NGI	Age/sex: 10-14 Female	100	100
HTC_TST_NGI	Age/sex: 15-19 Female	150	150
HTC_TST_NGI	Age/sex: 20-24 Female	480	480
HTC_TST_NGI	Age/sex: 25-49 Female	1,000	1,000
HTC_TST_NGI	Age/sex: 50+ Female	20	20
HTC_TST_NGI	Sum of Age/Sex disaggregates	3,500	3,500
HTC_TST_NGI	Aggregated Age/sex: <15 Male	350	350
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,150	1,150
HTC_TST_NGI	Aggregated Age/sex: <15 Female	350	350
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,650	1,650
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	700	700
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	2,800	2,800
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	3,500	3,500
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	650	650
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	800	800
FN_THER_DSD	Age: <1	0	0
FN_THER_DSD	Age: 1-4	0	0

Approved



FN_THER_DSD	Age: 5-14	0	0
FN_THER_DSD	Age: 15-17	0	0
FN_THER_DSD	Age: 18+	650	650
FN_THER_DSD	Sum of Age disaggregates	650	650
FN_THER_DSD	Aggregated Age: <18	350	350
FN_THER_DSD	Aggregated Age: 18+	300	300
FN_THER_DSD	Sum of Aggregated Age disaggregates	650	650

Implementing Mechanism Details

Mechanism ID: 10817	Mechanism Name: Jhpiego
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 10817			
Mechanism Name: Jhpiego			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10816	Mechanism Name: Boston University
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Boston University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10816
Mechanism Name:	Boston University
Prime Partner Name:	Boston University



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10726	Mechanism Name: The Thrive Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,400,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,087,146	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,400,000

Sub Partner Name(s)

FHI 360	Overseas Strategic Consulting	TechnoServe
---------	-------------------------------	-------------

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	477,299
Food and Nutrition: Policy, Tools, and Service Delivery	105,770
Human Resources for Health	190,056

Key Issues

TB

Budget Code Information

Mechanism ID: 10726			
Mechanism Name: The Thrive Project			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	29	27
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	13	14
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	16	13
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	21	14
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	8	13
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	4,815	8,600
C2.1.D_NGI	By Age/Sex: <15 Female	1,191	1,183
C2.1.D_NGI	By Age/Sex: <15 Male	975	2,150
C2.1.D_NGI	By Age/Sex: 15+ Female	1,458	3,547
C2.1.D_NGI	By Age/Sex: 15+ Male	1,191	1,720



C2.1.D_NGI	Sum of Age/Sex disaggregates	4,815	8,600
C2.1.D_NGI	By Age: <15	2,166	2,150
C2.1.D_NGI	By Age: 15+	2,649	6,450
C2.1.D_NGI	Sum of Age disaggregates	4,815	8,600
C2.1.D_NGI	By Sex: Female	2,649	4,730
C2.1.D_NGI	By Sex: Male	2,166	3,870
C2.1.D_NGI	Sum of Sex disaggregates	4,815	8,600
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	16	24
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	29	27
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	16	14
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	5	10
FN_SITE	Sum of Numerator Support Type disaggregates	21	24
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	21	14
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	8	13



FN_SITE	Sum of Denominator Support Type disaggregates	29	27
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	4,815	8,600
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	5,600	9,500
FN_THER_DSD	Age: <1	144	258
FN_THER_DSD	Age: 1-4	240	430
FN_THER_DSD	Age: 5-14	819	1,462
FN_THER_DSD	Age: 15-17	1,204	2,150
FN_THER_DSD	Age: 18+	2,408	4,300
FN_THER_DSD	Sum of Age disaggregates	4,815	8,600
FN_THER_DSD	Aggregated Age: <18	2,407	4,300
FN_THER_DSD	Aggregated Age: 18+	2,408	4,300
FN_THER_DSD	Sum of Aggregated Age disaggregates	4,815	8,600

Implementing Mechanism Details

Mechanism ID: 10725	Mechanism Name: CRS-ISAP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0



Sub Partner Name(s)

Chikuni Mission Hospital	Children's AIDS Fund	Chreso Lusaka
Chreso-Kabwe	Chreso-Livingstone	Circle of Hope
Futures Group	Katondwe Mission Hospital	Macha Mission Hospital
Malcom Watson Mine Hospital	Mukinge Mission Hospital	Sichili Mission Hospital
University of Maryland School of medicine	Wusakile Mine Hospital	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Implement activities to change harmful gender norms & promote positive gender norms

Increase gender equity in HIV prevention, care, treatment and support

Child Survival Activities

Mobile Population

Safe Motherhood

TB

Budget Code Information

Mechanism ID:	10725		
Mechanism Name:	CRS-ISAP		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10364	Mechanism Name: Read to Succeed (previously ISEP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Creative Associates International Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,364,978	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 439,851	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,364,978

Sub Partner Name(s)

O'BRIEN AND ASSOCIATES INTERNATIONAL	PLAN International	Research Triangle International
University of Pittsburgh		

Cross-Cutting Budget Attribution(s)

Education	1,364,978
Gender: Gender Equality	150,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	10364		
Mechanism Name:	Read to Succeed (previously ISEP)		
Prime Partner Name:	Creative Associates International Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	1,364,978	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	12	12
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	12	12
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000	52,000
PP_PREV_DSD	Age/sex: 10-14 Male	20,000	21,000
PP_PREV_DSD	Age/sex: 15-19 Male	2,191	2,191
PP_PREV_DSD	Age/sex: 20-24 Male	2,809	2,809
PP_PREV_DSD	Age/sex: 25-49 Male	0	0
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	20,000	21,000
PP_PREV_DSD	Age/sex: 15-19 Female	2,191	2,191
PP_PREV_DSD	Age/sex: 20-24 Female	2,809	2,809
PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	50,000	52,000

Implementing Mechanism Details



Mechanism ID: 10354	Mechanism Name: Zambia OVC System Strengthening Program (ZOVSS) / Zambia Rising
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save the Children US	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 600,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,660,095	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	600,000

Sub Partner Name(s)

American International Health Alliance	CHAMP Services Ltd	Training Resources Group
Trustees of Boston University		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
Economic Strengthening	25,000
Gender: Gender Equality	32,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education



Sub Area:	Implementation
-----------	----------------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10354			
Mechanism Name: Zambia OVC System Strengthening Program (ZOVSS) / Zambia Rising			
Prime Partner Name: Save the Children US			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	600,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	10	14
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	10	14
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	70	320
HRH_PRE	By Graduates: Doctors	0	0
HRH_PRE	By Graduates: Nurses	0	0
HRH_PRE	By Graduates: Midwives	0	0
HRH_PRE	By Graduates: Social service workers	0	0
HRH_PRE	By Graduates: Laboratory professionals	0	0

Approved



HRH_PRE	By Graduates: Other	70	320
HRH_PRE	Sum of Graduates disaggreagtes	70	320

Implementing Mechanism Details

Mechanism ID: 10332	Mechanism Name: UNIVERSITY OF NEBRASKA
Funding Agency: HHS/NIH	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nebraska	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	600,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	50,000
-----------	--------

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID: 10332



Mechanism Name:	UNIVERSITY OF NEBRASKA		
Prime Partner Name:	University of Nebraska		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,050	1,295	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,100	1,350	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	0	0	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	0	0	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	0	0	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,050	1,295	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	1,100	1,350	Redacted

PMTCT_STAT_NG I	By: Known positives at entry	0	0	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	0	0	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	0	0	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,050	1,295	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,100	1,350	Redacted
PMTCT_STAT_TA	By: Known positives at entry	0	0	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	0	0	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	0	0	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	10,000	10,000	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	11,000	11,000	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	0	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	10,000	10,000	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,000	10,000	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	700	700	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2	2	Redacted
LAB_CAP_DSD	By clinical laboratories	2	2	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted



LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	2	2	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	2	2	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	6	6	Redacted
HRH_PRE	By Graduates: Doctors	0	0	Redacted
HRH_PRE	By Graduates: Nurses	0	0	Redacted
HRH_PRE	By Graduates: Midwives	0	0	Redacted
HRH_PRE	By Graduates: Social service workers	0	0	Redacted
HRH_PRE	By Graduates: Laboratory professionals	1	1	Redacted
HRH_PRE	By Graduates: Other	5	5	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	6	6	Redacted

Implementing Mechanism Details

Mechanism ID: 10314	Mechanism Name: Communications Support for Health (CSH)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Approved



GHP-State	0
-----------	---

Sub Partner Name(s)

ICF Macro	The Manoff Group	
-----------	------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10314			
Mechanism Name: Communications Support for Health (CSH)			
Prime Partner Name: Chemonics International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	174,803	
PP_PREV_TA	Total number of people in the target population	2,007,391	
PP_PREV_TA	Age/sex: 15-19 Male	31,830	
PP_PREV_TA	Age/sex: 25-49 Male	59,116	
PP_PREV_TA	Age/sex: 15-19 Female	29,350	
PP_PREV_TA	Age/sex: 25-49 Female	54,507	
PP_PREV_TA	Sum of Age/Sex disaggregates	174,803	

Implementing Mechanism Details

Mechanism ID: 10299	Mechanism Name: Zambia Integrated Systems Strengthening Program (ZISSP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

American College of Nurse Midwives	Banyan Global	Broadreach
Johns Hopkins University Bloomberg School of Public Health	Liverpool Associates in Tropical Health	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)
Child Survival Activities
Safe Motherhood
Family Planning

Budget Code Information

Mechanism ID:	10299
Mechanism Name:	Zambia Integrated Systems Strengthening Program (ZISSP)
Prime Partner Name:	Abt Associates



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	100	
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	50	
HRH_PRE	By Graduates: Midwives	50	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	0	
HRH_PRE	Sum of Graduates disaggreagtes	100	
HRH_PRE	By new graduates who are licensed and registered: Nurses	45	
HRH_PRE	By new graduates who are licensed and registered: Midwives	45	

Implementing Mechanism Details

Mechanism ID: 10296	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 10274	Mechanism Name: MARCH Zambia
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 900,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 200,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	900,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	55,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	11,400
Key Populations: FSW	22,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients

Key Issues

Mobile Population
Safe Motherhood
TB
Family Planning



Budget Code Information

Mechanism ID: 10274			
Mechanism Name: MARCH Zambia			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	350,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	14	14	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery	0	0	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	14	14	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	7	7	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC	0	0	Redacted

	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,700	37,400	Redacted
PP_PREV_DSD	Total number of people in the target population	23,427	60,500	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	7,480	14,960	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	11,220	22,440	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	18,700	37,400	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	13,000	Redacted



PP_PREV_TA	Total number of people in the target population	0	60,500	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0	5,200	Redacted
PP_PREV_TA	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	7,800	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0	13,000	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	200	300	Redacted

Implementing Mechanism Details

Mechanism ID: 10260	Mechanism Name: USAID DELIVER PROJECT
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 8,715,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	8,715,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,515,000
----------------------------	-----------

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- Family Planning

Budget Code Information

Mechanism ID: 10260			
Mechanism Name: USAID DELIVER PROJECT			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	4,357,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,357,500	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	2,250	2,950
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	3,218	3,938
SC_STOCK	Commodity: Condoms	653	1,000
SC_STOCK	Commodity: ARV drugs	274	300
SC_STOCK	Commodity: Rapid test kits	1,638	1,638
SC_STOCK	Commodity: OI drugs	653	1,000

Implementing Mechanism Details

Mechanism ID: 10241	Mechanism Name: CRS FBO follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 5,600,671	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 50,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,600,671

Sub Partner Name(s)



Children's AIDS Fund	Futures Group	Institute of Human Virology, University of Maryland School of Medicine (IHV-UMSOM)
Itezhi-Tezhi District Hospital	Kamoto Mission Hospital	Macha Mission Hospital
Malcom Watson Mine Hospital	Mtendere Mission Hospital	Mwandi Mission Hospital
Siavonga District Hospital	Sichili Mission Hospital	St Francis Mission Hospital
Wusakile Mine Hospital		

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	200,000
Gender: Gender Equality	500,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Key Issues



Child Survival Activities
 Mobile Population
 Safe Motherhood
 TB
 Family Planning

Budget Code Information

Mechanism ID: 10241			
Mechanism Name: CRS FBO follow on			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	948,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	451,222	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	353,253	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	6,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,242,196	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	10	6	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	6	4	Redacted
SITE_SUPP	By program area/support type: HTC	4	2	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	6	4	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	4	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	6	4	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	4	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	6	4	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	4	2	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	5	3	Redacted



SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	6	4	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	4	2	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,918	25,334	Redacted
HTC_TST_DSD	By Test Result: Negative	28,411	23,561	Redacted
HTC_TST_DSD	By Test Result: Positive	4,507	1,773	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	32,918	25,334	Redacted
HTC_TST_DSD	Age/sex: <1 Male	447	355	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,118	887	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	447	355	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	224	177	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,099	872	Redacted



HTC_TST_DSD	Age/sex: 20-24 Male	3,298	2,614	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	5,496	5,219	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,099	871	Redacted
HTC_TST_DSD	Age/sex: <1 Female	447	355	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,118	887	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	447	355	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	224	177	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,649	1,307	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,946	3,922	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	9,210	5,656	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,649	1,325	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	32,918	25,334	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,236	1,773	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,992	8,715	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,236	1,773	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,454	13,073	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,472	3,546	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	28,446	21,788	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	32,918	25,334	Redacted
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,482	39,612	Redacted
HTC_TST_NA	By Test Result: Negative	29,799	33,882	Redacted
HTC_TST_NA	By Test Result: Positive	3,683	5,730	Redacted
HTC_TST_NA	Sum of Test Result disaggregates	33,482	39,612	Redacted
HTC_TST_NA	Age/sex: <1 Male	660	701	Redacted
HTC_TST_NA	Age/sex: 1-4 Male	1,535	1,578	Redacted
HTC_TST_NA	Age/sex: 5-9 Male	787	906	Redacted



HTC_TST_NA	Age/sex: 10-14 Male	2,358	2,512	Redacted
HTC_TST_NA	Age/sex: 15-19 Male	4,720	3,706	Redacted
HTC_TST_NA	Age/sex: 20-24 Male	3,931	6,150	Redacted
HTC_TST_NA	Age/sex: 25-49 Male	1,912	3,068	Redacted
HTC_TST_NA	Age/sex: 50+ Male	11	271	Redacted
HTC_TST_NA	Age/sex: <1 Female	690	735	Redacted
HTC_TST_NA	Age/sex: 1-4 Female	825	872	Redacted
HTC_TST_NA	Age/sex: 5-9 Female	448	593	Redacted
HTC_TST_NA	Age/sex: 10-14 Female	1,752	1,912	Redacted
HTC_TST_NA	Age/sex: 15-19 Female	2,397	2,874	Redacted
HTC_TST_NA	Age/sex: 20-24 Female	6,291	8,242	Redacted
HTC_TST_NA	Age/sex: 25-49 Female	3,931	4,369	Redacted
HTC_TST_NA	Age/sex: 50+ Female	1,234	1,123	Redacted
HTC_TST_NA	Sum of Age/Sex disaggregates	33,482	39,612	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Male	5,340	5,697	Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Male	10,574	14,808	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Female	3,715	4,112	Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Female	13,853	14,995	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex <15	9,055	9,809	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	24,427	29,803	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	33,482	39,612	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	73,496	67,914	Redacted
HTC_TST_NGI	By Test Result: Negative	63,259	57,443	Redacted
HTC_TST_NGI	By Test Result: Positive	10,237	10,471	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	73,496	67,914	Redacted
HTC_TST_NGI	Age/sex: <1 Male	1,148	1,097	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	2,696	2,569	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,353	1,302	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,736	2,710	Redacted



HTC_TST_NGI	Age/sex: 15-19 Male	6,289	4,680	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	8,094	9,071	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	8,563	8,798	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,372	1,245	Redacted
HTC_TST_NGI	Age/sex: <1 Female	1,182	1,131	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,990	1,863	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,040	989	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,136	2,110	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	4,523	4,334	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	12,317	12,623	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	14,321	10,791	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	3,736	2,601	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	73,496	67,914	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	7,933	7,678	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	23,352	24,544	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	6,349	6,093	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	35,862	29,599	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	14,282	13,771	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	59,214	54,143	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	73,496	67,914	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,094	2,969	Redacted
HTC_TST_TA	By Test Result: Negative	4,841	297	Redacted
HTC_TST_TA	By Test Result: Positive	2,253	2,672	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	7,094	2,969	Redacted
HTC_TST_TA	Age/sex: <1 Male	41	42	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	43	104	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	119	42	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	154	21	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	470	102	Redacted

HTC_TST_TA	Age/sex: 20-24 Male	865	306	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	1,155	510	Redacted
HTC_TST_TA	Age/sex: 50+ Male	260	102	Redacted
HTC_TST_TA	Age/sex: <1 Female	45	42	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	47	104	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	145	42	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	160	21	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	477	153	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	1,080	459	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	1,180	766	Redacted
HTC_TST_TA	Age/sex: 50+ Female	853	153	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	7,094	2,969	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	357	208	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,750	1,022	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	397	208	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,590	1,531	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	754	416	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	6,340	2,553	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	7,094	2,969	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	25,319		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,649		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,603		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	13,643		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	8,424		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	25,319		Redacted
C2.1.D_DSD	By Age: <15	3,252		Redacted



C2.1.D_DSD	By Age: 15+	22,067		Redacted
C2.1.D_DSD	Sum of Age disaggregates	25,319		Redacted
C2.1.D_DSD	By Sex: Female	15,292		Redacted
C2.1.D_DSD	By Sex: Male	10,027		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	25,319		Redacted
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	24,049		Redacted
C2.1.D_NA	By Age/Sex: <15 Female	1,170		Redacted
C2.1.D_NA	By Age/Sex: <15 Male	1,207		Redacted
C2.1.D_NA	By Age/Sex: 15+ Female	13,501		Redacted
C2.1.D_NA	By Age/Sex: 15+ Male	8,171		Redacted
C2.1.D_NA	Sum of Age/Sex disaggregates	24,049		Redacted
C2.1.D_NA	By Age: <15	2,377		Redacted
C2.1.D_NA	By Age: 15+	21,672		Redacted
C2.1.D_NA	Sum of Age disaggregates	24,049		Redacted
C2.1.D_NA	By Sex: Female	14,671		Redacted
C2.1.D_NA	By Sex: Male	9,378		Redacted
C2.1.D_NA	Sum of Sex disaggregates	24,049		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	63,525		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	3,583		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	5,341		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	32,672		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	21,929		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	63,525		Redacted
C2.1.D_NGI	By Age: <15	8,924		Redacted
C2.1.D_NGI	By Age: 15+	54,601		Redacted
C2.1.D_NGI	Sum of Age disaggregates	63,525		Redacted
C2.1.D_NGI	By Sex: Female	36,255		Redacted
C2.1.D_NGI	By Sex: Male	27,270		Redacted



C2.1.D_NGI	Sum of Sex disaggregates	63,525		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	14,157		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	764		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	2,531		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	5,528		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	5,334		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	14,157		Redacted
C2.1.D_TA	By Age: <15	3,295		Redacted
C2.1.D_TA	By Age: 15+	10,862		Redacted
C2.1.D_TA	Sum of Age disaggregates	14,157		Redacted
C2.1.D_TA	By Sex: Female	6,292		Redacted
C2.1.D_TA	By Sex: Male	7,865		Redacted
C2.1.D_TA	Sum of Sex disaggregates	14,157		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	25,319		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	25,319		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	39,578	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	9	6	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	9	6	Redacted



TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	5	3	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	4	3	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	9	6	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	5	3	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	4	3	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	9	6	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,934	14,241	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	189	242	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	473	605	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	284	363	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,817	4,728	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	189	242	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	473	605	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	284	363	Redacted

TX_CURR_DSD	Age/Sex: 15+ Female	10,225	7,093	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,892	2,420	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	189	242	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	189	242	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	946	1,210	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,817	4,728	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	946	1,210	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,225	7,093	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,892	2,420	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	17,042	11,821	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,934	14,241	Redacted
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	22,600	35,521	Redacted
TX_CURR_NA	Age/Sex: <1 Male	702	778	Redacted
TX_CURR_NA	Age/Sex: 1-4 Male	102	148	Redacted
TX_CURR_NA	Age/Sex: 5-14 Male	196	524	Redacted
TX_CURR_NA	Age/Sex: 15+ Male	7,269	11,931	Redacted
TX_CURR_NA	Age/Sex: <1 Female	702	736	Redacted
TX_CURR_NA	Age/Sex: 1-4 Female	106	204	Redacted
TX_CURR_NA	Age/Sex: 5-14 Female	194	418	Redacted
TX_CURR_NA	Age/Sex: 15+ Female	13,329	20,782	Redacted
TX_CURR_NA	Sum of Age/Sex disaggregates	22,600	35,521	Redacted
TX_CURR_NA	Aggregated Age/Sex: <1 Male	702	778	Redacted
TX_CURR_NA	Aggregated Age/Sex: <1 Female	702	736	Redacted
TX_CURR_NA	Aggregated Age/Sex: <15 Male	1,000	1,450	Redacted

TX_CURR_NA	Aggregated Age/Sex: 15+ Male	7,269	11,931	Redacted
TX_CURR_NA	Aggregated Age/Sex: <15 Female	1,002	1,358	Redacted
TX_CURR_NA	Aggregated Age/Sex: 15+ Female	13,329	20,782	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex <15	2,002	2,808	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	20,598	32,713	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	22,600	35,521	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	54,455	56,571	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	967	1,136	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	621	1,043	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	808	1,061	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	18,748	18,919	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	925	1,094	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	677	1,099	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	702	955	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	31,007	31,264	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	54,455	56,571	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	967	1,136	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	925	1,049	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2,396	3,240	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	18,748	18,919	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2,304	3,148	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	31,007	31,264	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	54,455	56,571	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	4,700	6,388	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	49,755	50,183	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,921	6,807	Redacted
TX_CURR_TA	Age/Sex: <1 Male	76	116	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	46	289	Redacted



TX_CURR_TA	Age/Sex: 5-14 Male	328	174	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	4,662	2,260	Redacted
TX_CURR_TA	Age/Sex: <1 Female	34	116	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	98	289	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	224	174	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	7,453	3,389	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	806	1,158	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	76	116	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	34	116	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	450	579	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,662	2,260	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	356	579	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	7,453	3,389	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	806	1,158	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,115	5,649	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,921	6,807	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,765	7,091	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	19	158	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	44	475	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	19	178	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	9	316	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	64	613	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	190	699	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	316	726	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	64	123	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	19	166	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	44	298	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	19	172	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	9	325	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	95	414	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	285	998	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	474	1,263	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	95	167	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,765	7,091	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	19	158	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	91	1,127	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	634	2,161	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	19	166	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	91	961	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	949	2,842	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,765	7,091	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,288	4,476	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,389	5,475	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	67	58	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28	25	Redacted

TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	944	808	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66	72	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29	31	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	846	918	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months	0	0	Redacted



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	8	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	0	6	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	6	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of	0	2	Redacted



	PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation			
TX_SITE	Sum of Numerator Site Support Type disaggregates	0	8	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	4	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	2	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	0	6	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	9	5	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	5	3	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	4	2	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	9	5	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	9	4	Redacted
LAB_CAP_DSD	By clinical laboratories	5	3	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	5	3	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5	2	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	4	2	Redacted



LAB_CAP_DSD	Sum of Site Support Type disaggregates	9	4	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	6	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	10	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	4	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	2	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	0	6	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	4	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of	0	6	Redacted



	PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC			
QI_SITE	Sum of Denominator Site Support Type disaggregates	0	10	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	7,501	Redacted
TB_SCREEN_DSD	Age: <1	0		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	0		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	725	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0	7,501	Redacted
TB_SCREEN_DSD	Sex: Male	0	3,017	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	0	7,501	Redacted

Implementing Mechanism Details

Mechanism ID: 10238	Mechanism Name: ZNBTS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Zambia National Blood Transfusion Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,521,350	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,521,350

Sub Partner Name(s)

Custom

Approved



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- Workplace Programs

Budget Code Information

Mechanism ID:	10238		
Mechanism Name:	ZNBTS		
Prime Partner Name:	Zambia National Blood Transfusion Service		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	1,221,350	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	50,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	1		Redacted
BS_COLL	Number of whole blood collections each year by the NBTS network	111,904	130,000	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	111,904	130,000	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	3,735	39,000	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	97,320		Redacted
HTC_TST_DSD	By Test Result: Negative	87,588		Redacted
HTC_TST_DSD	By Test Result: Positive	9,732		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	97,320		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	23,881		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	23,878		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	18,245		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,150		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted



HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	10,079		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	10,073		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	9,358		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	656		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	97,320		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	67,154		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	30,166		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	97,320		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	97,320		Redacted

Implementing Mechanism Details

Mechanism ID: 10236	Mechanism Name: University Teaching Hospital (UTH) UTH-HAP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Teaching Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,280,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 530,000	
FY 2013 Burn Rate: Redacted	

Approved



Funding Source	Funding Amount
GHP-State	4,280,000

Sub Partner Name(s)

Livingstone General Hospital	Zambian Children New Life Centre	
------------------------------	----------------------------------	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	20,000

Key Issues

Child Survival Activities

TB

Workplace Programs

Budget Code Information

Mechanism ID: 10236



Mechanism Name: University Teaching Hospital (UTH) UTH-HAP			
Prime Partner Name: University Teaching Hospital			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	565,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	315,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	900,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1	1	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	1	1	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	4,693	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	4,925	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	0	4,693	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	175	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	4,518	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without	0		Redacted



	tail)			
PMTCT_ARV_NGI	Sum of Regimen disaggregates	0	4,693	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	0	4,693	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,000	9,500	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	19,000	9,500	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	9,500	4,750	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	350	175	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	9,850	4,925	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,000	9,500	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	19,000	9,500	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	9,500	4,750	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	350	175	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	9,850	4,925	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,536	1,268	Redacted
OVC_SERV_DSD	Sex: Male	828	414	Redacted
OVC_SERV_DSD	Sex: Female	1,708	854	Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	2,536	1,268	Redacted
OVC_SERV_DSD	Age: <1	100	50	Redacted



OVC_SERV_DSD	Age: 1-4	226	113	Redacted
OVC_SERV_DSD	Age: 5-9	194	97	Redacted
OVC_SERV_DSD	Age: 10-14	516	258	Redacted
OVC_SERV_DSD	Age: 15-17	266	133	Redacted
OVC_SERV_DSD	Age: 18+	1,234	617	Redacted
OVC_SERV_DSD	Sum of Age disaggregates	2,536	1,268	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,693	2,347	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	9,386	4,693	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,223	2,112	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	470	235	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,693	2,347	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	263	286	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,500	3,500	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	60	60	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	448	448	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,034	1,034	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	208	208	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	60	60	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	448	448	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,034	1,034	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	208	208	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,084	3,084	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	60	60	Redacted



TX_CURR_DSD	Aggregated Age/Sex: <1 Female	60	60	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,542	1,542	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	208	208	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,542	1,542	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	208	208	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,084	3,084	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	416	416	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,500	3,500	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,626	3,626	Redacted

Implementing Mechanism Details

Mechanism ID: 10235	Mechanism Name: UNZA SOM Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------



Motor Vehicles: Purchased	100,400
---------------------------	---------

Key Issues

Workplace Programs

Budget Code Information

Mechanism ID:	10235		
Mechanism Name:	UNZA SOM Follow-on		
Prime Partner Name:	University of Zambia School of Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	40		Redacted



HRH_PRE	By Graduates: Other	40		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	40		Redacted

Implementing Mechanism Details

Mechanism ID: 10227	Mechanism Name: WPHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Health Office - Western Province	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,995,872	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,422,449	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,995,872

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,150,200
Food and Nutrition: Commodities	16,000
Renovation	69,470
Motor Vehicles: Purchased	240,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Mobile Population



Safe Motherhood
 TB
 Workplace Programs
 Family Planning

Budget Code Information

Mechanism ID: 10227			
Mechanism Name: WPHO			
Prime Partner Name: Provincial Health Office - Western Province			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,245,872	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	194	211	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	191	208	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	15	15	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	12	16	Redacted



SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	194	211	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	12	12	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	91	99	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	6	6	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	188	185	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	18	24	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	194	211	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical	1	1	Redacted

	Assistance-only (TA)			
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	8	8	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	186	279	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	219	465	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	186	279	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	171	104	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15	175	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS	Maternal AZT (prophylaxis component)	33	93	Redacted

D	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	219	372	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	186	279	Redacted
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0	Redacted
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0	Redacted
PMTCT_ARV_NA	Life-long ART (including Option B+)	0	0	Redacted
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NA	Sum of Regimen disaggregates	0	0	Redacted
PMTCT_ARV_NA	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant	1,508	3,207	Redacted



	women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,508	3,207	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	1,508	3,207	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,184	1,202	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	324	2,005	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	227	641	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,735	3,848	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	1,508	3,207	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,289	2,194	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,289	2,194	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,289	2,194	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	1,012	823	Redacted

	pregnancy			
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	277	1,371	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	194	548	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,483	2,742	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,289	2,194	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	60	103	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	60	103	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	9	15	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	51	88	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	60	103	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing	9	15	Redacted



	PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	51	88	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	60	103	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,038	3,876	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	2,145	4,080	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	47	116	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	171	349	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	218	465	Redacted
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0	Redacted
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0	Redacted
PMTCT_STAT_NA	By: Known positives at entry	0	0	Redacted
PMTCT_STAT_NA	By: Number of new positives identified	0	0	Redacted
PMTCT_STAT_NA	Sum of Positives Status disaggregates	0	0	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,056	26,728	Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	14,795	28,135	Redacted

I				
PMTCT_STAT_NG I	By: Known positives at entry	326	802	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,182	2,406	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,508	3,208	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,018	22,853	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	12,650	24,055	Redacted
PMTCT_STAT_TA	By: Known positives at entry	279	686	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,011	2,057	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,290	2,743	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	0	0	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	0	0	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	240	120	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0	Redacted

VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	8,000	4,000	Redacted

VMMC_CIRC_DS D	By Age: <1	65	200	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	400	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,074	400	Redacted
VMMC_CIRC_DS D	By Age: 15-19	1,806	800	Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,206	1,000	Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,750	1,000	Redacted
VMMC_CIRC_DS D	By Age: 50+	99	200	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	8,000	4,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,000	4,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	8,000	4,000	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	7,878	3,920	Redacted
VMMC_CIRC_DS	By follow-up status: Number of	122	80	Redacted

D	surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0	Redacted
VMMC_CIRC_NA	By Age: <1	0	0	Redacted
VMMC_CIRC_NA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NA	By Age: 10-14	0	0	Redacted
VMMC_CIRC_NA	By Age: 15-19	0	0	Redacted
VMMC_CIRC_NA	By Age: 20-24	0	0	Redacted
VMMC_CIRC_NA	By Age: 25-49	0	0	Redacted
VMMC_CIRC_NA	By Age: 50+	0	0	Redacted
VMMC_CIRC_NA	Sum of Age disaggregates	0	0	Redacted
VMMC_CIRC_NA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0	Redacted
VMMC_CIRC_NA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_NA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_NA	By circumcision technique: Surgical VMMC	0	0	Redacted
VMMC_CIRC_NA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NA	By follow-up status: Number of	0	0	Redacted



	surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	8,000	4,000	Redacted
VMMC_CIRC_NGI	By Age: <1	65	200	Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	400	Redacted
VMMC_CIRC_NGI	By Age: 10-14	1,074	400	Redacted
VMMC_CIRC_NGI	By Age: 15-19	1,806	800	Redacted
VMMC_CIRC_NGI	By Age: 20-24	2,206	1,000	Redacted
VMMC_CIRC_NGI	By Age: 25-49	2,750	1,000	Redacted
VMMC_CIRC_NGI	By Age: 50+	99	200	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	8,000	4,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,000	4,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	8,000	4,000	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	7,878	3,920	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of	122	80	Redacted

	surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0	Redacted
VMMC_CIRC_TA	By Age: <1	0	0	Redacted
VMMC_CIRC_TA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_TA	By Age: 10-14	0	0	Redacted
VMMC_CIRC_TA	By Age: 15-19	0	0	Redacted
VMMC_CIRC_TA	By Age: 20-24	0	0	Redacted
VMMC_CIRC_TA	By Age: 25-49	0	0	Redacted
VMMC_CIRC_TA	By Age: 50+	0	0	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of	0	0	Redacted



	surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery			
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	80,000	97,000	Redacted
PP_PREV_TA	Total number of people in the target population	952,654	975,282	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	1,936	2,328	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	5,770	6,984	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	11,219	13,968	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	15,331	18,624	Redacted
PP_PREV_TA	Age/sex: 50+ Male	3,845	4,656	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	2,095	2,522	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	6,227	7,566	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	12,512	15,132	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	16,605	20,176	Redacted
PP_PREV_TA	Age/sex: 50+ Female	4,460	5,044	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	80,000	97,000	Redacted
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0	Redacted
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Males who	0	0	Redacted



	inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,050	10,800	Redacted
HTC_TST_DSD	By Test Result: Negative	9,987	9,720	Redacted
HTC_TST_DSD	By Test Result: Positive	1,063	1,080	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	11,050	10,800	Redacted



HTC_TST_DSD	Age/sex: <1 Male	3	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	416	302	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	620	648	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	645	648	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	665	605	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	950	907	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,118	1,058	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	197	151	Redacted
HTC_TST_DSD	Age/sex: <1 Female	5	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	429	454	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	927	972	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	944	972	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	932	907	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,324	1,361	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,637	1,588	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	239	227	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	11,051	10,800	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,678	1,598	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,919	2,722	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,295	2,398	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,159	4,082	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,973	3,996	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,078	6,804	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	11,051	10,800	Redacted
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0	Redacted
HTC_TST_NA	By Test Result: Negative	0	0	Redacted



HTC_TST_NA	By Test Result: Positive	0	0	Redacted
HTC_TST_NA	Sum of Test Result disaggregates	0	0	Redacted
HTC_TST_NA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 15-19 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 20-24 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 25-49 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_NA	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NA	Sum of Age/Sex disaggregates	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Male	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Male	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Female	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Female	0	0	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	0	0	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	130,000	135,000	Redacted
HTC_TST_NGI	By Test Result: Negative	117,498	121,500	Redacted
HTC_TST_NGI	By Test Result: Positive	12,502	13,500	Redacted



HTC_TST_NGI	Sum of Test Result disaggregates	130,000	135,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	30	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,897	3,780	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	7,294	8,100	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	7,590	8,100	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	7,820	7,560	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	11,178	11,340	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	13,150	13,230	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	2,319	1,890	Redacted
HTC_TST_NGI	Age/sex: <1 Female	55	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	5,042	5,670	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	10,905	12,150	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	11,104	12,150	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	10,967	11,340	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	15,582	17,010	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	19,258	19,845	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	2,809	2,835	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	130,000	135,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	19,737	19,980	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	34,341	34,020	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	26,995	29,970	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	48,927	51,030	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	46,732	49,950	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	83,268	85,050	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	130,000	135,000	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	118,950	124,200	Redacted
HTC_TST_TA	By Test Result: Negative	107,511	111,780	Redacted
HTC_TST_TA	By Test Result: Positive	11,439	12,420	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	118,950	124,200	Redacted



HTC_TST_TA	Age/sex: <1 Male	27	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	4,481	3,478	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	6,674	7,452	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	6,945	7,452	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	7,155	6,955	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	10,228	10,433	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	12,032	12,172	Redacted
HTC_TST_TA	Age/sex: 50+ Male	2,122	1,739	Redacted
HTC_TST_TA	Age/sex: <1 Female	50	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	4,613	5,216	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	9,978	11,178	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	10,160	11,178	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	10,035	10,433	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	14,258	15,649	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	17,621	18,257	Redacted
HTC_TST_TA	Age/sex: 50+ Female	2,570	2,608	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	118,949	124,200	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18,059	18,382	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,422	31,298	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24,700	27,572	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	44,768	46,948	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	42,759	45,954	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	76,190	78,246	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	118,949	124,200	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0	Redacted
GEND_NORM_DS	By Age: 0-9	0	0	Redacted

D				
GEND_NORM_DS D	By Age: 10-14	0	0	Redacted
GEND_NORM_DS D	By Age: 15-19	0	0	Redacted
GEND_NORM_DS D	By Age: 20-24	0	0	Redacted
GEND_NORM_DS D	By Age: 25+	0	0	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	0	0	Redacted
GEND_NORM_DS D	By Sex: Male	0	0	Redacted
GEND_NORM_DS D	By Sex: Female	0	0	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	0	0	Redacted
GEND_NORM_DS D	By type of activity: Individual	0	0	Redacted
GEND_NORM_DS D	By type of activity: Small Group	0	0	Redacted
GEND_NORM_DS D	By type of activity: Community-level	0	0	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,360	3,600	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	304	432	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	283	1,296	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	1,615	468	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	1,158	1,404	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	3,360	3,600	Redacted
C2.1.D_DSD	By Age: <15	765	900	Redacted
C2.1.D_DSD	By Age: 15+	2,595	2,700	Redacted
C2.1.D_DSD	Sum of Age disaggregates	3,360	3,600	Redacted



C2.1.D_DSD	By Sex: Female	1,359	900	Redacted
C2.1.D_DSD	By Sex: Male	2,001	2,700	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	3,360	3,600	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	14,000	15,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,267	1,800	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,179	5,400	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	6,731	1,950	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	4,823	5,850	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	14,000	15,000	Redacted
C2.1.D_NGI	By Age: <15	3,188	3,750	Redacted
C2.1.D_NGI	By Age: 15+	10,812	11,250	Redacted
C2.1.D_NGI	Sum of Age disaggregates	14,000	15,000	Redacted
C2.1.D_NGI	By Sex: Female	5,662	3,750	Redacted
C2.1.D_NGI	By Sex: Male	8,338	11,250	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	14,000	15,000	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	10,640	11,400	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	963	1,368	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	896	4,104	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	5,116	1,482	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	3,665	4,446	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	10,640	11,400	Redacted
C2.1.D_TA	By Age: <15	2,423	2,850	Redacted
C2.1.D_TA	By Age: 15+	8,217	8,550	Redacted
C2.1.D_TA	Sum of Age disaggregates	10,640	11,400	Redacted
C2.1.D_TA	By Sex: Female	4,303	2,850	Redacted
C2.1.D_TA	By Sex: Male	6,337	8,550	Redacted
C2.1.D_TA	Sum of Sex disaggregates	10,640	11,400	Redacted
C2.4.D_DSD	Number of HIV-positive patients who	3,360	3,600	Redacted



	were screened for TB in HIV care or treatment setting			
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,360	3,600	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	15,000	15,640	Redacted
CARE_CURR_TA	Age/sex: <1 Male	360	331	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	360	331	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	360	331	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	720	662	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	1,440	2,245	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	1,800	2,576	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	1,800	1,656	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	360	331	Redacted
CARE_CURR_TA	Age/sex: <1 Female	390	359	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	390	359	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	390	359	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	780	718	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	1,560	1,435	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	1,950	1,794	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,950	1,794	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	390	359	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	15,000	15,640	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,800	2,576	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,400	4,968	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,950	2,714	Redacted



CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,850	5,382	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	15,000	15,640	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	15,500	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	0	378	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	0	810	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	0	810	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	0	756	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	0	2,134	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	0	2,323	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	0	189	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	0	567	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	0	1,215	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	0	1,215	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	0	1,134	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	0	1,701	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	0	1,984	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	0	284	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	15,500	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	1,998	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	4,402	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	3,997	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	5,103	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	15,500	Redacted



CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	154	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	211	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	12	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	142	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	0	154	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	17	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of	0	194	Redacted



	PEPFAR supported sites providing clinical care services			
CARE_SITE	Sum of Denominator Site Support Type disaggregates	0	211	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	0	0	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and	0	0	Redacted



	support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	0	0	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	1,200	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	12,027	Redacted
FN_THER_DSD	Age: <1	0	250	Redacted
FN_THER_DSD	Age: 1-4	0	200	Redacted
FN_THER_DSD	Age: 5-14	0	250	Redacted
FN_THER_DSD	Age: 15-17	0	500	Redacted
FN_THER_DSD	Age: 18+	0	0	Redacted
FN_THER_DSD	Sum of Age disaggregates	0	1,200	Redacted
FN_THER_DSD	Aggregated Age: <18	0	1,200	Redacted
FN_THER_DSD	Aggregated Age: 18+	0	0	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	1,200	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0	Redacted
TB_ART_DSD	Age: 0-4	0	0	Redacted
TB_ART_DSD	Age: 5-14	0	0	Redacted
TB_ART_DSD	Age: 15+	0	0	Redacted
TB_ART_DSD	Male	0	0	Redacted
TB_ART_DSD	Female	0	0	Redacted
TB_ART_DSD	Sum of Sex disaggregates	0	0	Redacted

TB_ART_DSD	Newly tested	0	0	Redacted
TB_ART_DSD	Known HIV-positive	0	0	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	0	0	Redacted
TB_ART_DSD	Aggregated Age: <15	0	0	Redacted
TB_ART_DSD	Aggregated Age: 15+	0	0	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	0	0	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	27	31	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	27	31	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	27	31	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	27	31	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	27	31	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of	0	0	Redacted



	PEPFAR-supported TB basic management units			
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	27	31	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	932	2,438	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,508	3,207	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	272	2,194	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	660	244	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	932	2,438	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	34	122	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,088	1,204	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	3	1	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	10	5	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	68	57	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	401	500	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	4	2	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	8	6	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	51	58	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	544	575	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	144	129	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0	Redacted
TX_CURR_DSD	Percent women and girls with	1	0	Redacted



	advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]			
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	3	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4	2	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	81	63	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	401	500	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	63	66	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	544	575	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	144	129	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	945	1,075	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,089	1,204	Redacted
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0	Redacted
TX_CURR_NA	Age/Sex: <1 Male	0	0	Redacted
TX_CURR_NA	Age/Sex: 1-4 Male	0	0	Redacted
TX_CURR_NA	Age/Sex: 5-14 Male	0	0	Redacted
TX_CURR_NA	Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_NA	Age/Sex: <1 Female	0	0	Redacted
TX_CURR_NA	Age/Sex: 1-4 Female	0	0	Redacted
TX_CURR_NA	Age/Sex: 5-14 Female	0	0	Redacted
TX_CURR_NA	Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_NA	Sum of Age/Sex disaggregates	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <1 Female	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <15 Male	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <15 Female	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex <15	0	0	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	0	0	Redacted



TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	0	0	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	10,881	12,026	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	28	13	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	102	46	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	676	566	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	4,008	4,997	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	35	18	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	80	61	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	512	576	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	5,440	5,749	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	10,881	12,026	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	28	13	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	35	18	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	806	625	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	4,008	4,997	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	627	655	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	5,440	5,749	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	10,881	12,026	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,433	1,280	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	9,448	10,746	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,793	10,824	Redacted
TX_CURR_TA	Age/Sex: <1 Male	25	12	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	92	42	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	608	510	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	3,607	4,497	Redacted
TX_CURR_TA	Age/Sex: <1 Female	32	16	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	72	55	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	461	518	Redacted



TX_CURR_TA	Age/Sex: 15+ Female	4,896	5,174	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	1,290	1,153	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	25	12	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	32	16	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	725	564	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	3,607	4,497	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	565	589	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,896	5,174	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,290	1,153	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	8,503	9,671	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,793	10,824	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	7	16	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	7	16	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,500	3,553	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	1	7	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	27	34	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	41	34	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	69	95	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	166	256	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	304	449	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	353	513	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	50	64	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	1	7	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	141	370	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	156	370	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	81	104	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	251	385	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	258	1	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	536	769	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	65	95	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,500	3,553	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1	7	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	138	170	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	873	1,282	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1	7	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	379	851	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,110	1,250	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,500	3,553	Redacted
TX_NEW_DSD	Pregnancy status	82	192	Redacted
TX_NEW_DSD	Breastfeeding status	20	0	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,274	3,307	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,500	3,556	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive	0	0	Redacted



	and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator:	0	0	Redacted

	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2,274	3,307	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	2,500	3,556	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2,274	3,307	Redacted



TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	2,274	3,307	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	2,500	3,556	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	2,500	3,556	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1	1	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1	1	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	10	10	Redacted
LAB_CAP_DSD	By clinical laboratories	10	10	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	10	10	Redacted
LAB_CAP_DSD	By site support type: Technical	10	10	Redacted



	Assistance-only (TA)			
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20	20	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful	0	0	Redacted



	passing criteria in this PT program			
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0	Redacted
HRH_PRE	By Graduates: Doctors	0	0	Redacted
HRH_PRE	By Graduates: Nurses	0	0	Redacted
HRH_PRE	By Graduates: Midwives	0	0	Redacted
HRH_PRE	By Graduates: Social service workers	0	0	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	0	0	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	0	Redacted



HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	0	Redacted
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0	Redacted
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0	Redacted
SC_TRAIN	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to conduct supply chain activities	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to develop distribution plans	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform supportive supervision	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform quantification	0	0	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services	0	0	Redacted



	that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	0	0	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	0	0	Redacted
FPINT_SITE_DSD	Service delivery type: Community	0	0	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	0	0	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	0	0	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement	0	0	Redacted



	activity completed that addresses clinical HIV programs and has documented process results in the last 6 months			
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	0	0	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	0	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted



QI_SITE	Sum of Denominator Site Support Type disaggregates	0	0	Redacted
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0	Redacted
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0	Redacted
SC_STOCK	System Level: Central Medical Stores	0	0	Redacted
SC_STOCK	System Level: Regional Medical Stores	0	0	Redacted
SC_STOCK	System Level: District	0	0	Redacted
SC_STOCK	System Level: Health facility	0	0	Redacted
SC_STOCK	Commodity: Condoms	0	0	Redacted
SC_STOCK	Commodity: ARV drugs	0	0	Redacted
SC_STOCK	Commodity: Rapid test kits	0	0	Redacted
SC_STOCK	Commodity: OI drugs	0	0	Redacted
SC_STOCK	Commodity: Other	0	0	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	1,000	Redacted
TB_SCREEN_DSD	Age: <1	0	0	Redacted
TB_SCREEN_DSD	Age: 1-4	0	0	Redacted
TB_SCREEN_DSD	Age: 5-9	0	0	Redacted
TB_SCREEN_DSD	Age: 10-14	0	0	Redacted
TB_SCREEN_DSD	Age: 15-19	0	0	Redacted
TB_SCREEN_DSD	Age: 20-24	0	0	Redacted
TB_SCREEN_DSD	Age: 25-49	0	0	Redacted



TB_SCREEN_DSD	Age: 50+	0	0	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	0	0	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	0	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	0	0	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0	0	Redacted
TB_SCREEN_DSD	Sex: Male	0	0	Redacted
TB_SCREEN_DSD	Sex: Female	0	0	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	0	0	Redacted

Implementing Mechanism Details

Mechanism ID: 10225	Mechanism Name: EPHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Health Office - Eastern Province	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,198,292	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,207,860	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,198,292

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,156,859
Motor Vehicles: Purchased	520,000



Food and Nutrition: Policy, Tools, and Service Delivery	100,000
---	---------

Key Issues

- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	10225		
Mechanism Name:	EPHO		
Prime Partner Name:	Provincial Health Office - Eastern Province		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	165,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,283,292	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	208	212	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	23	23	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	185	189	Redacted



SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	63	63	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	27	27	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	63	63	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	27	27	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	10	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	10	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	15	15	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	36	73	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	162	166	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	70	70	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	50	50	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical	93	93	Redacted



	Assistance-only (TA)			
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	23	23	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	185	189	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	3	5	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	24	27	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	258	339	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	286	376	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	258	376	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	142	169	Redacted
PMTCT_ARV_DS	Sub-Disag of Life-long ART: Already on	116	207	Redacted

D	treatment at the beginning of the current pregnancy			
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	258	376	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	258	376	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	888	1,992	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	987	2,213	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	888	2,213	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	488	996	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	400	1,217	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	888	2,213	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	888	2,213	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	630	1,653	Redacted



	during pregnancy and delivery			
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	701	1,837	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	630	1,837	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	346	827	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	284	1,010	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	630	1,837	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	630	1,837	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	51	88	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	51	88	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	15	15	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving	36	73	Redacted



	90% ARV or ART coverage for HIV+ pregnant women			
PMTCT_SITE	Sum of Numerator Support Type disaggregates	51	88	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	15	0	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	36	73	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	51	73	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,089	5,390	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,544	5,989	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	164	216	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	123	162	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	287	378	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,101	31,620	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	15,668	35,133	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	564	1,265	Redacted

I				
PMTCT_STAT_NG I	By: Number of new positives identified	423	949	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	987	2,214	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,012	26,230	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	11,124	29,144	Redacted
PMTCT_STAT_TA	By: Known positives at entry	400	1,049	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	300	787	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	700	1,836	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	50	75	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	10	10	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	9	9	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1	1	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	40	40	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category:	38	38	Redacted



	Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2	2	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	1	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	1	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	10,000	15,000	Redacted
VMMC_CIRC_DS D	By Age: <1	100	150	Redacted
VMMC_CIRC_DS D	By Age: 1-9	300	450	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,000	1,500	Redacted
VMMC_CIRC_DS D	By Age: 15-19	2,500	3,750	Redacted
VMMC_CIRC_DS	By Age: 20-24	3,000	4,500	Redacted



D				
VMMC_CIRC_DS D	By Age: 25-49	3,000	4,500	Redacted
VMMC_CIRC_DS D	By Age: 50+	100	150	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	10,000	15,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	600	900	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,000	13,500	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	400	600	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	10,000	15,000	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	10,000	15,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	9,500	14,250	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	500	750	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	10,000	15,000	Redacted
VMMC_CIRC_NGI	By Age: <1	100	150	Redacted
VMMC_CIRC_NGI	By Age: 1-9	300	450	Redacted

VMMC_CIRC_NGI	By Age: 10-14	1,000	1,500	Redacted
VMMC_CIRC_NGI	By Age: 15-19	2,500	3,750	Redacted
VMMC_CIRC_NGI	By Age: 20-24	3,000	4,500	Redacted
VMMC_CIRC_NGI	By Age: 25-49	3,000	4,500	Redacted
VMMC_CIRC_NGI	By Age: 50+	100	150	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	10,000	15,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	600	900	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,000	13,500	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	400	600	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	10,000	15,000	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	10,000	15,000	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	9,500	14,250	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	500	750	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000	60,000	Redacted
PP_PREV_TA	Total number of people in the target population	155,200	164,900	Redacted



PP_PREV_TA	Age/sex: 10-14 Male	8,000	9,500	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	9,000	11,000	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	8,000	9,500	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	8,000	9,500	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	9,000	11,000	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	8,000	9,500	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	50,000	60,000	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,050	32,405	Redacted
HTC_TST_DSD	By Test Result: Negative	26,145	29,161	Redacted
HTC_TST_DSD	By Test Result: Positive	2,905	3,244	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	29,050	32,405	Redacted
HTC_TST_DSD	Age/sex: <1 Male	89	100	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	89	100	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	22	25	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	670	748	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,117	1,246	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,352	3,739	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	2,682	2,991	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,324	2,592	Redacted
HTC_TST_DSD	Age/sex: <1 Female	67	75	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	67	75	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	22	25	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	670	748	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,743	1,944	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	6,973	7,777	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,716	9,721	Redacted



HTC_TST_DSD	Age/sex: 50+ Female	447	499	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	29,050	32,405	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	870	973	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,475	10,568	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	826	923	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,879	19,941	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,696	1,896	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	27,354	30,509	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	29,050	32,405	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	267,800	294,580	Redacted
HTC_TST_NGI	By Test Result: Negative	249,054	268,212	Redacted
HTC_TST_NGI	By Test Result: Positive	18,746	20,188	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	267,800	288,400	Redacted
HTC_TST_NGI	Age/sex: <1 Male	824	906	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	824	906	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	206	227	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	6,180	6,798	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	10,300	11,330	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	30,900	33,990	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	24,720	27,192	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	21,424	23,566	Redacted
HTC_TST_NGI	Age/sex: <1 Female	618	680	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	618	680	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	206	227	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	6,180	6,798	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	16,068	17,675	Redacted



HTC_TST_NGI	Age/sex: 20-24 Female	64,272	70,699	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	80,340	88,374	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	4,120	4,532	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	267,800	294,580	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	8,034	13,596	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	87,344	111,034	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	7,622	11,330	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	164,800	158,620	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	15,656	24,926	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	252,144	269,654	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	267,800	294,580	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	238,750	262,177	Redacted
HTC_TST_TA	By Test Result: Negative	214,875	235,959	Redacted
HTC_TST_TA	By Test Result: Positive	23,875	26,218	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	238,750	262,177	Redacted
HTC_TST_TA	Age/sex: <1 Male	735	807	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	735	807	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	184	202	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	5,510	6,050	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	9,183	10,084	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	27,548	30,251	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	22,038	24,201	Redacted
HTC_TST_TA	Age/sex: 50+ Male	19,100	20,974	Redacted
HTC_TST_TA	Age/sex: <1 Female	551	605	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	551	605	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	184	202	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	5,510	6,050	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	14,325	15,731	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	57,299	62,922	Redacted



HTC_TST_TA	Age/sex: 25-49 Female	71,624	78,653	Redacted
HTC_TST_TA	Age/sex: 50+ Female	3,673	4,033	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	238,750	262,177	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,164	7,866	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	77,869	85,510	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,796	7,462	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	146,921	161,339	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	13,960	15,328	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	224,790	246,849	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	238,750	262,177	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	20,055	23,064	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	760	874	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	760	874	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	10,194	11,724	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	8,341	9,592	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	20,055	23,064	Redacted
C2.1.D_DSD	By Age: <15	1,520	1,749	Redacted
C2.1.D_DSD	By Age: 15+	18,535	21,316	Redacted
C2.1.D_DSD	Sum of Age disaggregates	20,055	23,065	Redacted
C2.1.D_DSD	By Sex: Female	10,955	12,598	Redacted
C2.1.D_DSD	By Sex: Male	9,100	10,466	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	20,055	23,064	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	71,628	82,373	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	2,715	3,123	Redacted



C2.1.D_NGI	By Age/Sex: <15 Male	2,715	3,123	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	36,409	41,870	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	29,789	34,257	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	71,628	82,373	Redacted
C2.1.D_NGI	By Age: <15	5,430	6,245	Redacted
C2.1.D_NGI	By Age: 15+	66,198	76,128	Redacted
C2.1.D_NGI	Sum of Age disaggregates	71,628	82,373	Redacted
C2.1.D_NGI	By Sex: Female	39,124	44,993	Redacted
C2.1.D_NGI	By Sex: Male	32,504	37,380	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	71,628	82,373	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	51,572	59,308	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	1,955	2,248	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	1,955	2,248	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	26,214	30,147	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	21,448	24,665	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	51,572	59,308	Redacted
C2.1.D_TA	By Age: <15	3,910	4,496	Redacted
C2.1.D_TA	By Age: 15+	47,663	54,812	Redacted
C2.1.D_TA	Sum of Age disaggregates	51,573	59,308	Redacted
C2.1.D_TA	By Sex: Female	28,169	32,395	Redacted
C2.1.D_TA	By Sex: Male	23,403	26,914	Redacted
C2.1.D_TA	Sum of Sex disaggregates	51,572	59,309	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	22,205	25,536	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	20,055	23,064	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting	22,205	25,536	Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	85	98	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	171	196	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	256	295	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	598	688	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,623	1,866	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	2,050	2,357	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	5,039	5,795	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	171	196	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	85	98	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	171	196	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	256	295	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	769	884	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,793	2,063	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	2,904	3,339	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	5,978	6,875	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	256	295	Redacted



CARE_CURR_DS D	Sun of Age/Sex disaggregates	22,205	25,536	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,110	1,277	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,882	10,214	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,110	1,277	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,103	12,768	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	22,205	25,536	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	57,101	65,664	Redacted
CARE_CURR_TA	Age/sex: <1 Male	220	253	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	439	505	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	659	758	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	1,537	1,768	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	4,173	4,799	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	5,271	6,061	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	12,957	14,901	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	439	505	Redacted
CARE_CURR_TA	Age/sex: <1 Female	220	253	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	439	505	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	659	758	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	1,977	2,273	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	4,612	5,304	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	7,467	8,587	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	15,373	17,679	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	659	758	Redacted



CARE_CURR_TA	Sum of Age/Sex disaggregates	57,101	65,667	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,855	3,283	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,840	26,266	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,295	3,283	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,111	32,832	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	57,101	65,664	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	21,195	23,519	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	82	90	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	163	181	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	245	271	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	571	633	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1,549	1,719	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	1,956	2,171	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	4,809	5,337	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	163	181	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	82	90	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	163	181	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	245	271	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	734	814	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,712	1,900	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	2,771	3,076	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	5,705	6,333	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	245	271	Redacted



CARE_NEW_DSD	Sum of Age/sex disaggregates	21,195	23,519	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,065	1,176	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	8,475	9,408	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,060	1,176	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,595	11,760	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	21,195	23,520	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	27	32	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	90	90	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	89	5	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	27	27	Redacted



CARE_SITE	Sum of Numerator Site Support Type disaggregates	116	32	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	89	90	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	90	50	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	179	140	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	6	8	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	10	10	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	10	10	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	6	8	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	16	18	Redacted
FN_SITE	By site support type: Direct Service	10	10	Redacted

	Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	10	10	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	20	20	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	600	900	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,989	2,387	Redacted
FN_THER_DSD	Age: <1	30	36	Redacted
FN_THER_DSD	Age: 1-4	570	684	Redacted
FN_THER_DSD	Sum of Age disaggregates	600	720	Redacted
FN_THER_DSD	Aggregated Age: <18	600	720	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	600	720	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,642	1,932	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,642	1,932	Redacted
TB_ART_DSD	Age: 0-4	42	32	Redacted
TB_ART_DSD	Age: 5-14	600	900	Redacted



TB_ART_DSD	Age: 15+	1,000	1,000	Redacted
TB_ART_DSD	Male	657	773	Redacted
TB_ART_DSD	Female	985	1,159	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,642	1,932	Redacted
TB_ART_DSD	Newly tested	492	580	Redacted
TB_ART_DSD	Known HIV-positive	1,150	1,352	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,642	1,932	Redacted
TB_ART_DSD	Aggregated Age: <15	164	193	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,478	1,739	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,642	1,932	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	40	48	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	53	53	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	13	13	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	40	48	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	53	61	Redacted
TB_ARTSITE	By site support type: Direct Service	13	13	Redacted



	Delivery (DSD): The number of PEPFAR-supported TB basic management units			
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	53	53	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	66	66	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	691	1,771	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	987	2,213	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	691	1,771	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	64	80	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	755	1,851	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	35	89	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,404	18,707	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	54	62	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	351	400	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	415	473	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,562	7,483	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	54	62	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	351	400	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	415	473	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	8,202	9,354	Redacted



TX_CURR_DSD	Sum of age/sex disaggregates	1,640	1,870	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	54	18,707	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	54	62	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	820	935	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,562	7,483	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	820	935	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,202	9,354	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,640	1,870	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,764	16,837	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	16,404	18,707	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	58,588	66,811	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	194	221	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	1,254	1,430	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,482	1,690	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	23,435	26,724	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	193	220	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	1,254	1,430	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,482	1,690	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	29,295	33,406	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	58,589	66,811	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	58,588	221	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	194	220	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2,930	3,341	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	23,435	26,724	Redacted



TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2,929	3,340	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	29,295	33,406	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	58,589	66,811	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	5,859	6,681	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	52,730	60,130	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	42,184	48,104	Redacted
TX_CURR_TA	Age/Sex: <1 Male	140	159	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	903	1,030	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	1,067	1,217	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	16,873	19,241	Redacted
TX_CURR_TA	Age/Sex: <1 Female	139	158	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	903	1,030	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	1,067	1,217	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	21,092	24,052	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	4,219	4,811	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	140	159	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	903	159	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,110	2,406	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	16,873	19,241	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,109	2,405	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	21,092	24,052	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	4,219	4,811	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	37,965	43,293	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	42,184	48,104	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	9	9	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	9	9	Redacted



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,100	11,200	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	52	64	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	104	128	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	143	176	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	156	192	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	325	400	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	455	560	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,210	2,720	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	650	800	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	52	64	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	104	128	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	143	176	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	156	192	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	455	560	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	715	880	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,730	3,360	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	650	800	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,100	11,200	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	104	128	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	455	560	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,640	4,480	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	104	128	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	455	560	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,550	5,600	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,100	11,200	Redacted
TX_NEW_DSD	Pregnancy status	2,379	2,928	Redacted



TX_NEW_DSD	Breastfeeding status	2,379	2,928	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,885	8,190	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,650	9,100	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40	40	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100	100	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,260	1,260	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50	50	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	100	100	Redacted

TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,350	1,350	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190	190	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,710	1,710	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200	200	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800	1,800	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,768	1,819	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults	1,780	1,830	Redacted



	and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	90	90	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	90	90	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	63	76	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	27	14	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	90	90	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	63	76	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	27	14	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	90	90	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation	1	2	Redacted



	or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	1	2	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1	2	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	27	32	Redacted
LAB_CAP_DSD	By clinical laboratories	27	32	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	27	32	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	27	27	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	54	59	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	1	1	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	206	212	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	206	212	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	206	212	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	27	10	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	27	32	Redacted

LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	27	32	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	53	57	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	53	57	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	57	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	208	212	Redacted



FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	208	212	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	89	89	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	208	212	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	297	301	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	89	89	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	208	212	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	297	301	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	208	212	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	208	212	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last	150	23	Redacted



	6 months			
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	208	212	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	89	23	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	61	175	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	150	198	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	23	23	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	23	189	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	46	212	Redacted



SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	10,949	12,886	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	22,205	25,536	Redacted
TB_SCREEN_DSD	Age: <1	84	100	Redacted
TB_SCREEN_DSD	Age: 1-4	168	198	Redacted
TB_SCREEN_DSD	Age: 5-9	253	297	Redacted
TB_SCREEN_DSD	Age: 10-14	674	793	Redacted
TB_SCREEN_DSD	Age: 15-19	1,684	1,982	Redacted
TB_SCREEN_DSD	Age: 20-24	2,442	2,875	Redacted
TB_SCREEN_DSD	Age: 25-49	5,432	6,393	Redacted
TB_SCREEN_DSD	Age: 50+	212	248	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	2,863	3,370	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,179	1,388	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	9,770	11,498	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	10,949	12,886	Redacted
TB_SCREEN_DSD	Sex: Male	6,021	7,088	Redacted
TB_SCREEN_DSD	Sex: Female	4,928	5,798	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	10,949	12,886	Redacted



Implementing Mechanism Details

Mechanism ID: 10224	Mechanism Name: National HIV/AIDS/STI/TB Council
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 130,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Malaria (PMI)
- Safe Motherhood
- Workplace Programs

Budget Code Information

Mechanism ID:	10224
----------------------	--------------



Mechanism Name:	National HIV/AIDS/STI/TB Council		
Prime Partner Name:	National HIV/AIDS/STI/TB Council - Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	125,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10220	Mechanism Name: Intrahealth International
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,370,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 172,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,370,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Key Populations: FSW	25,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	25,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Motor Vehicles: Purchased	44,752

Key Issues

- Mobile Population
- Safe Motherhood
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	10220		
Mechanism Name:	Intrahealth International		
Prime Partner Name:	IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,220,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	102	102	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	102	102	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	102	102	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only	0	0	Redacted



	(TA)			
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	49	49	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	11	11	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	102	102	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration	0	0	Redacted

	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	0	0	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	0	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to	0	0	Redacted



	reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0	Redacted
PMTCT_ARV_NA	Life-long ART (including Option B+)	0	0	Redacted
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NA	Sum of Regimen disaggregates	0	0	Redacted
PMTCT_ARV_NA	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	0	0	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted

PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	0	0	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	0	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without	0	0	Redacted



	tail)			
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	0	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	0	0	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	0	0	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network	0	0	Redacted

	laboratory			
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	0	0	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0	Redacted



VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0	Redacted
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	0	0	Redacted
VMMC_CIRC_DS D	By Age: 15-19	0	0	Redacted
VMMC_CIRC_DS D	By Age: 20-24	0	0	Redacted
VMMC_CIRC_DS D	By Age: 25-49	0	0	Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	0	0	Redacted
VMMC_CIRC_DS	By HIV status: Number of HIV-positive	0	0	Redacted



D	clients (tested HIV positive at VMMC site)			
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	0	0	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0	Redacted
VMMC_CIRC_NA	By Age: <1	0	0	Redacted
VMMC_CIRC_NA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NA	By Age: 10-14	0	0	Redacted
VMMC_CIRC_NA	By Age: 15-19	0	0	Redacted
VMMC_CIRC_NA	By Age: 20-24	0	0	Redacted
VMMC_CIRC_NA	By Age: 25-49	0	0	Redacted
VMMC_CIRC_NA	By Age: 50+	0	0	Redacted
VMMC_CIRC_NA	Sum of Age disaggregates	0	0	Redacted
VMMC_CIRC_NA	By HIV status: Number of HIV-positive	0	0	Redacted



	clients (tested HIV positive at VMMC site)			
VMMC_CIRC_NA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_NA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_NA	By circumcision technique: Surgical VMMC	0	0	Redacted
VMMC_CIRC_NA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0	Redacted
VMMC_CIRC_NGI	By Age: <1	0	0	Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	0	0	Redacted
VMMC_CIRC_NGI	By Age: 15-19	0	0	Redacted
VMMC_CIRC_NGI	By Age: 20-24	0	0	Redacted
VMMC_CIRC_NGI	By Age: 25-49	0	0	Redacted
VMMC_CIRC_NGI	By Age: 50+	0	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	0	0	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive	0	0	Redacted



	clients (tested HIV positive at VMMC site)			
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	0	0	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0	Redacted
VMMC_CIRC_TA	By Age: <1	0	0	Redacted
VMMC_CIRC_TA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_TA	By Age: 10-14	0	0	Redacted
VMMC_CIRC_TA	By Age: 15-19	0	0	Redacted
VMMC_CIRC_TA	By Age: 20-24	0	0	Redacted
VMMC_CIRC_TA	By Age: 25-49	0	0	Redacted
VMMC_CIRC_TA	By Age: 50+	0	0	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive	0	0	Redacted

	clients (tested HIV positive at VMMC site)			
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	33,000	36,300	Redacted
PP_PREV_DSD	Total number of people in the target population	532,564	532,564	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	3,053	3,358	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	4,223	4,645	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	7,700	8,470	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	40	44	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,547	3,902	Redacted



PP_PREV_DSD	Age/sex: 20-24 Female	6,329	6,962	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	8,062	8,868	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	46	51	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	33,000	36,300	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0	Redacted
PP_PREV_TA	Total number of people in the target population	0	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0	0	Redacted
PP_PREV_TA	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	0	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0	0	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	300	330	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	300	330	Redacted

KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	330	Redacted
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0	Redacted



KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	0	0	Redacted



	evidence and/or meet the minimum standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	88,000	96,800	Redacted
HTC_TST_DSD	By Test Result: Negative	82,290	91,744	Redacted
HTC_TST_DSD	By Test Result: Positive	5,710	5,056	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	88,000	96,800	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,205	1,326	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	10,849	11,934	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	12,055	13,261	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	14,465	15,912	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	604	663	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,206	1,327	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	13,260	14,586	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	16,876	18,564	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	16,876	18,564	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	604	663	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	88,000	96,800	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,525	1,326	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	36,539	41,770	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,734	1,327	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	42,202	52,377	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,259	2,653	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	78,741	94,147	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	88,000	96,800	Redacted
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0	Redacted
HTC_TST_NA	By Test Result: Negative	0	0	Redacted
HTC_TST_NA	By Test Result: Positive	0	0	Redacted
HTC_TST_NA	Sum of Test Result disaggregates	0	0	Redacted
HTC_TST_NA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 15-19 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 20-24 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 25-49 Male	0	0	Redacted
HTC_TST_NA	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_NA	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NA	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NA	Sum of Age/Sex disaggregates	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Male	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Male	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: <15 Female	0	0	Redacted
HTC_TST_NA	Aggregated Age/sex: 15+ Female	0	0	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex <15	0	0	Redacted

HTC_TST_NA	Sum of Aggregated Age/Sex 15+	0	0	Redacted
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	88,000	96,800	Redacted
HTC_TST_NGI	By Test Result: Negative	82,290	91,744	Redacted
HTC_TST_NGI	By Test Result: Positive	5,710	5,056	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	88,000	96,800	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,205	1,326	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	10,849	11,934	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	12,055	13,261	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	14,465	15,912	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	604	663	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,206	1,327	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	13,260	14,586	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	16,876	18,564	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	16,876	18,564	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	604	663	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	88,000	96,800	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	4,525	1,326	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	36,539	41,770	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	4,734	1,327	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	42,202	52,377	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	9,259	2,653	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	78,741	94,147	Redacted



HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	88,000	96,800	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0	Redacted
HTC_TST_TA	By Test Result: Negative	0	0	Redacted
HTC_TST_TA	By Test Result: Positive	0	0	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	0	0	Redacted
HTC_TST_TA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_TA	Age/sex: <1 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	0	0	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted



HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	0	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0	Redacted
GEND_GBV_DSD	Age: 0-9	0	0	Redacted
GEND_GBV_DSD	Age: 10-14	0	0	Redacted
GEND_GBV_DSD	Age: 15-17	0	0	Redacted
GEND_GBV_DSD	Age: 18-24	0	0	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	0	0	Redacted
GEND_GBV_DSD	Sex: Male	0	0	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	0	0	Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	0	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	0	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0	0	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	1,216	0	Redacted
GEND_NORM_DS D	By Age: 0-9	0	0	Redacted
GEND_NORM_DS D	By Age: 10-14	0	0	Redacted
GEND_NORM_DS D	By Age: 15-19	0	0	Redacted
GEND_NORM_DS D	By Age: 20-24	0	0	Redacted
GEND_NORM_DS D	By Age: 25+	1,216	0	Redacted
GEND_NORM_DS	Sum of Age disaggregates	1,216	0	Redacted



D				
GEND_NORM_DS D	By Sex: Male	608	0	Redacted
GEND_NORM_DS D	By Sex: Female	608	0	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	1,216	0	Redacted
GEND_NORM_DS D	By type of activity: Individual	0	0	Redacted
GEND_NORM_DS D	By type of activity: Small Group	0	0	Redacted
GEND_NORM_DS D	By type of activity: Community-level	0	0	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0	Redacted
OVC_SERV_DSD	Sex: Male	0	0	Redacted
OVC_SERV_DSD	Sex: Female	0	0	Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	0	0	Redacted
OVC_SERV_DSD	Age: <1	0	0	Redacted
OVC_SERV_DSD	Age: 1-4	0	0	Redacted
OVC_SERV_DSD	Age: 5-9	0	0	Redacted
OVC_SERV_DSD	Age: 10-14	0	0	Redacted
OVC_SERV_DSD	Age: 15-17	0	0	Redacted
OVC_SERV_DSD	Age: 18+	0	0	Redacted
OVC_SERV_DSD	Sum of Age disaggregates	0	0	Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0	Redacted
OVC_SERV_TA	Sex: Male	0	0	Redacted
OVC_SERV_TA	Sex: Female	0	0	Redacted
OVC_SERV_TA	Sum of Sex disaggregates	0	0	Redacted
OVC_SERV_TA	Age: <1	0	0	Redacted



OVC_SERV_TA	Age: 1-4	0	0	Redacted
OVC_SERV_TA	Age: 5-9	0	0	Redacted
OVC_SERV_TA	Age: 10-14	0	0	Redacted
OVC_SERV_TA	Age: 15-17	0	0	Redacted
OVC_SERV_TA	Age: 18+	0	0	Redacted
OVC_SERV_TA	Sum of Age disaggregates	0	0	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	0	0	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	0	0	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	0	0	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	0	0	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	0	0	Redacted
C2.1.D_DSD	By Age: <15	0	0	Redacted
C2.1.D_DSD	By Age: 15+	0	0	Redacted
C2.1.D_DSD	Sum of Age disaggregates	0	0	Redacted
C2.1.D_DSD	By Sex: Female	0	0	Redacted
C2.1.D_DSD	By Sex: Male	0	0	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	0	0	Redacted
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0	Redacted
C2.1.D_NA	By Age/Sex: <15 Female	0	0	Redacted
C2.1.D_NA	By Age/Sex: <15 Male	0	0	Redacted
C2.1.D_NA	By Age/Sex: 15+ Female	0	0	Redacted
C2.1.D_NA	By Age/Sex: 15+ Male	0	0	Redacted
C2.1.D_NA	Sum of Age/Sex disaggregates	0	0	Redacted
C2.1.D_NA	By Age: <15	0	0	Redacted
C2.1.D_NA	By Age: 15+	0	0	Redacted
C2.1.D_NA	Sum of Age disaggregates	0	0	Redacted
C2.1.D_NA	By Sex: Female	0	0	Redacted



C2.1.D_NA	By Sex: Male	0	0	Redacted
C2.1.D_NA	Sum of Sex disaggregates	0	0	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	0	0	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	0	0	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	0	0	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	0	0	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	0	0	Redacted
C2.1.D_NGI	By Age: <15	0	0	Redacted
C2.1.D_NGI	By Age: 15+	0	0	Redacted
C2.1.D_NGI	Sum of Age disaggregates	0	0	Redacted
C2.1.D_NGI	By Sex: Female	0	0	Redacted
C2.1.D_NGI	By Sex: Male	0	0	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	0	0	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	0	0	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	0	0	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	0	0	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	0	0	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	0	0	Redacted
C2.1.D_TA	By Age: <15	0	0	Redacted
C2.1.D_TA	By Age: 15+	0	0	Redacted
C2.1.D_TA	Sum of Age disaggregates	0	0	Redacted
C2.1.D_TA	By Sex: Female	0	0	Redacted
C2.1.D_TA	By Sex: Male	0	0	Redacted
C2.1.D_TA	Sum of Sex disaggregates	0	0	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting	0	0	Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	0	0	Redacted



CARE_CURR_DS D	Sun of Age/Sex disaggregates	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0	Redacted
CARE_CURR_TA	Age/sex: <1 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	0	0	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	0	0	Redacted
CARE_CURR_TA	Age/sex: <1 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	0	0	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	0	0	Redacted



CARE_CURR_TA	Sum of Age/Sex disaggregates	0	0	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	0	0	Redacted



CARE_NEW_DSD	Sum of Age/sex disaggregates	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	0	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	0	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted



CARE_SITE	Sum of Numerator Site Support Type disaggregates	0	0	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	0	0	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	0	0	Redacted
FN_SITE	By site support type: Direct Service	0	0	Redacted



	Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	0	0	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0	Redacted
FN_THER_DSD	Age: <1	0	0	Redacted
FN_THER_DSD	Age: 1-4	0	0	Redacted
FN_THER_DSD	Age: 5-14	0	0	Redacted
FN_THER_DSD	Age: 15-17	0	0	Redacted
FN_THER_DSD	Age: 18+	0	0	Redacted
FN_THER_DSD	Sum of Age disaggregates	0	0	Redacted
FN_THER_DSD	Aggregated Age: <18	0	0	Redacted
FN_THER_DSD	Aggregated Age: 18+	0	0	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	0	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0	Redacted



TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	0	0	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	0	0	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	0	Redacted



PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0	0	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0	0	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	0	0	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	0	0	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	0	0	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	0	0	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	0	0	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	0	0	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	0	0	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0	0	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	0	0	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0	Redacted
TX_CURR_NA	Age/Sex: <1 Male	0	0	Redacted
TX_CURR_NA	Age/Sex: 1-4 Male	0	0	Redacted
TX_CURR_NA	Age/Sex: 5-14 Male	0	0	Redacted
TX_CURR_NA	Age/Sex: 15+ Male	0	0	Redacted



TX_CURR_NA	Age/Sex: <1 Female	0	0	Redacted
TX_CURR_NA	Age/Sex: 1-4 Female	0	0	Redacted
TX_CURR_NA	Age/Sex: 5-14 Female	0	0	Redacted
TX_CURR_NA	Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_NA	Sum of Age/Sex disaggregates	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <1 Female	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <15 Male	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: <15 Female	0	0	Redacted
TX_CURR_NA	Aggregated Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex <15	0	0	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	0	0	Redacted
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	0	0	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	0	0	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	0	0	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	0	0	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	0	0	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	0	0	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	0	0	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	0	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	0	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	0	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	0	0	Redacted



TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	0	0	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	0	0	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0	Redacted
TX_CURR_TA	Age/Sex: <1 Male	0	0	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	0	0	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	0	0	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_TA	Age/Sex: <1 Female	0	0	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	0	0	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	0	0	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0	Redacted



TX_NEW_DSD	By Age/Sex: <1 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	0	0	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0	0	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	0	0	Redacted
TX_NEW_DSD	Pregnancy status	0	0	Redacted
TX_NEW_DSD	Breastfeeding status	0	0	Redacted
TX_RET_DSD	Number of adults and children who are	0	0	Redacted



	still alive and on treatment at 12 months after initiating ART			
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART	0	0	Redacted



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	0	0	Redacted



	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	0	0	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	0	0	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0	0	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	0	0	Redacted



	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By clinical laboratories	0	0	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable	0	0	Redacted



	successful passing criteria in this PT program			
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0	0	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	0	0	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0	Redacted
HRH_PRE	By Graduates: Doctors	0	0	Redacted
HRH_PRE	By Graduates: Nurses	0	0	Redacted
HRH_PRE	By Graduates: Midwives	0	0	Redacted
HRH_PRE	By Graduates: Social service workers	0	0	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	0	0	Redacted
HRH_PRE	Sum of Graduates disaggregates	0	0	Redacted



HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	0	Redacted
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0	Redacted
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0	Redacted
SC_TRAIN	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to conduct supply chain activities	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to develop distribution plans	0	0	Redacted



SC_TRAIN	By: Individuals who passed a competency-based training to perform supportive supervision	0	0	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform quantification	0	0	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	0	0	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV	0	0	Redacted



	Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	0	0	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0	Redacted
TB_SCREEN_DSD	Age: <1	0	0	Redacted
TB_SCREEN_DSD	Age: 1-4	0	0	Redacted
TB_SCREEN_DSD	Age: 5-9	0	0	Redacted
TB_SCREEN_DSD	Age: 10-14	0	0	Redacted
TB_SCREEN_DSD	Age: 15-19	0	0	Redacted
TB_SCREEN_DSD	Age: 20-24	0	0	Redacted
TB_SCREEN_DSD	Age: 25-49	0	0	Redacted
TB_SCREEN_DSD	Age: 50+	0	0	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	0	0	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	0	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	0	0	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0	0	Redacted
TB_SCREEN_DSD	Sex: Male	0	0	Redacted

Approved



TB_SCREEN_DSD	Sex: Female	0	0	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	0	0	Redacted

Implementing Mechanism Details

Mechanism ID: 10219	Mechanism Name: EGPAF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,341,223	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 295,599	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,341,223

Sub Partner Name(s)

Barefeet	New Partner	Our Lady's Hospice
----------	-------------	--------------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood

Budget Code Information

Mechanism ID: 10219



Mechanism Name: EGPAF			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	65,006	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,326,217	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	2	2	Redacted



SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted



SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	40	40	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	40	40	Redacted
PMTCT_ARV_DS	Life-long ART (including Option B+)	40	40	Redacted



D				
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	20	20	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	20	20	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	40	40	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	40	40	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	40	40	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	40	40	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	40	40	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	20	20	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	20	20	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis	0	0	Redacted



	(provided with the intention to stop at the end of the breastfeeding period)			
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	40	40	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	40	40	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	1	1	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing	0	0	Redacted

	PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	Sum of Denominator Support Type disaggregates	1	1	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40	40	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	40	40	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	0	0	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	0	0	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40	40	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	40	40	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	0	0	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	0	0	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	0	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	4,500	Redacted
HTC_TST_DSD	By Test Result: Negative	3,879	3,879	Redacted
HTC_TST_DSD	By Test Result: Positive	621	621	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	4,500	4,500	Redacted
HTC_TST_DSD	Age/sex: <1 Male	156	156	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	206	206	Redacted



HTC_TST_DSD	Age/sex: 5-9 Male	299	299	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	272	272	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	270	270	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	196	196	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	622	622	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	173	173	Redacted
HTC_TST_DSD	Age/sex: <1 Female	158	158	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	202	202	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	301	301	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	277	277	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	286	286	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	243	243	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	644	644	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	195	195	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,500	4,500	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	932	932	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,262	1,262	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	938	938	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,368	1,368	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,870	1,870	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,630	2,630	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,500	4,500	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	4,500	Redacted
HTC_TST_NGI	By Test Result: Negative	3,879	3,879	Redacted
HTC_TST_NGI	By Test Result: Positive	621	621	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	4,500	4,500	Redacted



HTC_TST_NGI	Age/sex: <1 Male	156	156	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	206	206	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	299	299	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	272	272	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	270	270	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	196	196	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	622	622	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	173	173	Redacted
HTC_TST_NGI	Age/sex: <1 Female	158	158	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	202	202	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	301	301	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	277	277	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	286	286	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	243	243	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	644	644	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	195	195	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	4,500	4,500	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	932	932	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,262	1,262	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	938	938	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,368	1,368	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	1,870	1,870	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	2,630	2,630	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,500	4,500	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	7,490	7,490	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	302	302	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	260	260	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	4,490	4,490	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	2,438	2,438	Redacted

C2.1.D_DSD	Sum of Age/Sex disaggregates	7,490	7,490	Redacted
C2.1.D_DSD	By Age: <15	562	562	Redacted
C2.1.D_DSD	By Age: 15+	6,928	6,928	Redacted
C2.1.D_DSD	Sum of Age disaggregates	7,490	7,490	Redacted
C2.1.D_DSD	By Sex: Female	4,792	4,792	Redacted
C2.1.D_DSD	By Sex: Male	2,698	2,698	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	7,490	7,490	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	7,490	7,490	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	302	302	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	260	260	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	4,490	4,490	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	2,438	2,438	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	7,490	7,490	Redacted
C2.1.D_NGI	By Age: <15	562	562	Redacted
C2.1.D_NGI	By Age: 15+	6,928	6,928	Redacted
C2.1.D_NGI	Sum of Age disaggregates	7,490	7,490	Redacted
C2.1.D_NGI	By Sex: Female	4,792	4,792	Redacted
C2.1.D_NGI	By Sex: Male	2,698	2,698	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	7,490	7,490	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	7,490	7,490	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	7,490	7,490	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,980	5,980	Redacted
CARE_CURR_DS	Age/sex: <1 Male	3	3	Redacted



D				
CARE_CURR_DS D	Age/sex: 1-4 Male	28	28	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	60	60	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	102	102	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	120	120	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	43	43	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,420	1,420	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	424	424	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	5	5	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	60	60	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	80	80	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	120	120	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	120	120	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	165	165	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	2,740	2,740	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	490	490	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	5,980	5,980	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	193	193	Redacted



D	PERMISSION ONLY: <15 Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,007	2,007	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	265	265	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,515	3,515	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	5,980	5,980	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	620	620	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	6	6	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	12	12	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	12	12	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	11	11	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	56	56	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	41	41	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	128	128	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	35	35	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	5	5	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	9	9	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	12	12	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	12	12	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	59	59	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	50	50	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	133	133	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	39	39	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	620	620	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	21	21	Redacted

CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	315	315	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	21	21	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	263	263	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	620	620	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted



CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	30	30	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	30	30	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	15	15	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	15	15	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	30	30	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	0	0	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,255	6,109	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	6	5	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	15	10	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	82	125	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,092	2,066	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	6	5	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	22	28	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	85	120	Redacted

TX_CURR_DSD	Age/Sex: 15+ Female	1,947	3,750	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	216	293	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	5	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	6	5	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	6	5	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	113	140	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	103	2,066	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,947	153	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,092	3,750	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,060	293	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,195	5,816	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,255	6,109	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,255	6,109	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	6	5	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	15	10	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	82	125	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	1,092	2,066	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	6	5	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	22	28	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	85	120	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	1,947	3,750	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	3,255	6,109	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	6	5	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	6	5	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	113	140	Redacted



TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	103	2,066	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,947	153	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	1,092	3,750	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	3,255	6,109	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,060	293	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,195	5,816	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	475	475	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	6	6	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	10	10	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	11	11	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	10	10	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	41	41	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	30	30	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	94	94	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	26	26	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	5	5	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	8	8	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	12	12	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	17	17	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	43	43	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	37	37	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	96	96	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	29	29	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	475	475	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	6	6	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	37	37	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	191	191	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1	5	5	Redacted

	Female			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	42	42	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	205	205	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	475	475	Redacted
TX_NEW_DSD	Pregnancy status	40	40	Redacted
TX_NEW_DSD	Breastfeeding status	0	0	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	487	487	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	620	620	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	0	0	Redacted



	stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	0	0	Redacted

	those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	0	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	2	0	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	0	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	2	0	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	2	0	Redacted



TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	2	0	Redacted

Implementing Mechanism Details

Mechanism ID: 10212	Mechanism Name: CSO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Central Statistics Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 50,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	50,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 10212			
Mechanism Name: CSO			
Prime Partner Name: Central Statistics Office			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10207		Mechanism Name: Twinning Centre	
Funding Agency: HHS/HRSA		Procurement Type: Grant	
Prime Partner Name: American International Health Alliance Twinning Center			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: No			
G2G: No		Managing Agency:	

Total All Funding Sources: 500,000		Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 300,000			
FY 2013 Burn Rate: Redacted			
Funding Source		Funding Amount	
GHP-State		500,000	

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	50,000
Motor Vehicles: Leased	35,400

Key Issues

Military Population
 Mobile Population

Budget Code Information

Mechanism ID: 10207			
Mechanism Name: Twinning Centre			
Prime Partner Name: American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10203	Mechanism Name: The Zambia Prevention, Care and Treatment Partnership II (ZPCT II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Cardno Emerging Markets	Care International	Churches Health Association of Zambia
Kara Counseling and Training Trust	Management Sciences for Health	Salvation Army
Social Impact	University Teaching Hospital	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10203		
Mechanism Name:	The Zambia Prevention, Care and Treatment Partnership II (ZPCT II)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	431	280
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	361	250
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	70	30
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	153	80
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	24	9
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	393	250
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	38	30
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	391	250
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	26	30
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	393	250
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	38	30
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	54	40
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	4	5
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	140	89
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	27	9



PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,589	8,046
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	15,856	11,045
PMTCT_ARV_DSD	Life-long ART (including Option B+)	12,589	8,046
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,379	4,107
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,212	2,212
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	12,589	8,046
PMTCT_ARV_DSD	Sum of New and Current disaggregates	5,591	6,319
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,789	8,426
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	16,206	11,545
PMTCT_ARV_NGI	Life-long ART (including Option B+)	12,789	8,426
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,390	4,207
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,311	2,392
PMTCT_ARV_NGI	Sum of Regimen disaggregates	12,789	8,426
PMTCT_ARV_NGI	Sum of New and Current disaggregates	5,701	6,599
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	200	380



PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	350	500
PMTCT_ARV_TA	Life-long ART (including Option B+)	200	380
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	20	100
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	180	280
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	200	380
PMTCT_ARV_TA	Sum of New and Current disaggregates	200	380
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	322	200
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	417	250
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	308	180
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	14	20
PMTCT_SITE	Sum of Numerator Support Type disaggregates	322	200
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	391	200
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	26	50



PMTCT_SITE	Sum of Denominator Support Type disaggregates	417	250
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	176,366	116,997
PMTCT_STAT_DSD	Number of new ANC and L&D clients	193,856	128,476
PMTCT_STAT_DSD	By: Known positives at entry	5,519	3,636
PMTCT_STAT_DSD	By: Number of new positives identified	11,177	7,409
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	16,696	11,045
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	176,947	117,797
PMTCT_STAT_NGI	Number of new ANC and L&D clients	194,613	129,476
PMTCT_STAT_NGI	By: Known positives at entry	5,551	3,696
PMTCT_STAT_NGI	By: Number of new positives identified	11,244	7,489
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	16,795	11,185
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	581	800
PMTCT_STAT_TA	Number of new ANC and L&D clients	757	1,000
PMTCT_STAT_TA	By: Known positives at entry	32	60
PMTCT_STAT_TA	By: Number of new positives identified	67	80
PMTCT_STAT_TA	Sum of Positives Status disaggregates	99	140
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	70	90
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0



VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6	10
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	64	80
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	64	80
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	30,758	20,495
VMMC_CIRC_DSD	By Age: <1	57	38
VMMC_CIRC_DSD	By Age: 1-9	4,286	2,857
VMMC_CIRC_DSD	By Age: 10-14	6,635	4,425



VMMC_CIRC_DSD	By Age: 15-19	7,605	5,065
VMMC_CIRC_DSD	By Age: 20-24	5,725	3,815
VMMC_CIRC_DSD	By Age: 25-49	6,292	4,191
VMMC_CIRC_DSD	By Age: 50+	158	104
VMMC_CIRC_DSD	Sum of age disaggregates	30,758	20,495
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	4	2,050
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	16,500	12,000
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	5,827	6,445
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	5,827	6,445
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	21,833	14,550
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	2,829	1,886
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	30,768	20,517
VMMC_CIRC_NGI	By Age: <1	62	48
VMMC_CIRC_NGI	By Age: 1-9	4,286	2,857
VMMC_CIRC_NGI	By Age: 10-14	6,635	4,425
VMMC_CIRC_NGI	By Age: 15-19	7,605	5,065
VMMC_CIRC_NGI	By Age: 20-24	5,727	3,820
VMMC_CIRC_NGI	By Age: 25-49	6,295	4,196
VMMC_CIRC_NGI	By Age: 50+	158	106



VMMC_CIRC_NGI	Sum of Age disaggregates	30,768	20,517
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	4	2,052
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	16,510	12,020
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	5,827	6,445
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	5,827	6,445
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	21,843	14,572
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	2,829	1,886
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	10	22
VMMC_CIRC_TA	By Age: <1	5	10
VMMC_CIRC_TA	By Age: 1-9	0	0
VMMC_CIRC_TA	By Age: 10-14	0	0
VMMC_CIRC_TA	By Age: 15-19	0	0
VMMC_CIRC_TA	By Age: 20-24	2	5
VMMC_CIRC_TA	By Age: 25-49	3	5
VMMC_CIRC_TA	By Age: 50+	0	2
VMMC_CIRC_TA	Sum of Age disaggregations	10	22
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	2
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients	10	20



	(tested HIV negative at VMMC program		
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	10	22
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	597,063	393,524
HTC_TST_DSD	By Test Result: Negative	525,415	346,301
HTC_TST_DSD	By Test Result: Positive	71,648	47,223
HTC_TST_DSD	Sum of Test Result disaggregates	597,063	393,524
HTC_TST_DSD	Age/sex: <1 Male	3,499	2,300
HTC_TST_DSD	Age/sex: 1-4 Male	14,056	9,225
HTC_TST_DSD	Age/sex: 5-9 Male	8,102	5,351
HTC_TST_DSD	Age/sex: 10-14 Male	9,384	6,221
HTC_TST_DSD	Age/sex: 15-19 Male	20,394	13,433
HTC_TST_DSD	Age/sex: 20-24 Male	39,860	26,317
HTC_TST_DSD	Age/sex: 25-49 Male	96,558	63,179
HTC_TST_DSD	Age/sex: 50+ Male	9,629	6,349
HTC_TST_DSD	Age/sex: <1 Female	2,858	1,887
HTC_TST_DSD	Age/sex: 1-4 Female	13,787	9,066
HTC_TST_DSD	Age/sex: 5-9 Female	7,271	4,807
HTC_TST_DSD	Age/sex: 10-14 Female	8,537	5,648



HTC_TST_DSD	Age/sex: 15-19 Female	61,078	40,446
HTC_TST_DSD	Age/sex: 20-24 Female	103,079	68,158
HTC_TST_DSD	Age/sex: 25-49 Female	189,252	124,715
HTC_TST_DSD	Age/sex: 50+ Female	9,719	6,422
HTC_TST_DSD	Sum of Age/Sex disaggregates	597,063	393,524
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	35,041	23,097
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	166,441	109,278
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32,453	21,408
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	363,128	239,741
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	67,494	44,505
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	529,569	349,019
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	597,063	393,524
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	600,953	398,222
HTC_TST_NGI	By Test Result: Negative	528,838	350,435
HTC_TST_NGI	By Test Result: Positive	72,115	47,787
HTC_TST_NGI	Sum of Test Result disaggregates	600,953	398,222
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,890	4,698
HTC_TST_TA	By Test Result: Negative	3,423	4,134
HTC_TST_TA	By Test Result: Positive	467	564
HTC_TST_TA	Sum of Test Result disaggregates	3,890	4,698
HTC_TST_TA	Age/sex: <1 Male	21	35
HTC_TST_TA	Age/sex: 1-4 Male	141	155
HTC_TST_TA	Age/sex: 5-9 Male	32	42
HTC_TST_TA	Age/sex: 10-14 Male	30	40
HTC_TST_TA	Age/sex: 15-19 Male	156	169

HTC_TST_TA	Age/sex: 20-24 Male	259	260
HTC_TST_TA	Age/sex: 25-49 Male	1,194	1,205
HTC_TST_TA	Age/sex: 50+ Male	67	78
HTC_TST_TA	Age/sex: <1 Female	8	19
HTC_TST_TA	Age/sex: 1-4 Female	114	125
HTC_TST_TA	Age/sex: 5-9 Female	32	43
HTC_TST_TA	Age/sex: 10-14 Female	36	46
HTC_TST_TA	Age/sex: 15-19 Female	271	290
HTC_TST_TA	Age/sex: 20-24 Female	557	580
HTC_TST_TA	Age/sex: 25-49 Female	1,446	1,550
HTC_TST_TA	Age/sex: 50+ Female	51	61
HTC_TST_TA	Sum of Age/Sex disaggregates	4,415	4,698
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	224	272
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,676	1,712
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	190	233
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,325	2,481
HTC_TST_TA	Sum of Aggregated Age/Sex <15	414	505
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	4,001	4,193
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	4,415	4,698
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	319,632	295,188
C2.1.D_DSD	By Age/Sex: <15 Female	10,970	10,011
C2.1.D_DSD	By Age/Sex: <15 Male	10,743	9,960
C2.1.D_DSD	By Age/Sex: 15+ Female	185,584	171,704
C2.1.D_DSD	By Age/Sex: 15+ Male	112,335	103,513
C2.1.D_DSD	Sum of Age/Sex disaggregates	319,632	295,188
C2.1.D_DSD	By Age: <15	21,713	19,971
C2.1.D_DSD	By Age: 15+	297,919	275,217



C2.1.D_DSD	Sum of Age disaggregates	319,632	295,188
C2.1.D_DSD	By Sex: Female	196,554	181,715
C2.1.D_DSD	By Sex: Male	123,078	113,473
C2.1.D_DSD	Sum of Sex disaggregates	319,632	295,188
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	323,024	300,846
C2.1.D_NGI	By Age/Sex: <15 Female	11,047	10,188
C2.1.D_NGI	By Age/Sex: <15 Male	10,824	10,141
C2.1.D_NGI	By Age/Sex: 15+ Female	187,344	174,504
C2.1.D_NGI	By Age/Sex: 15+ Male	113,809	106,013
C2.1.D_NGI	Sum of Age/Sex disaggregates	323,024	300,846
C2.1.D_NGI	By Age: <15	21,871	20,329
C2.1.D_NGI	By Age: 15+	301,153	280,517
C2.1.D_NGI	Sum of Age disaggregates	323,024	300,846
C2.1.D_NGI	By Sex: Female	198,391	184,692
C2.1.D_NGI	By Sex: Male	124,633	116,154
C2.1.D_NGI	Sum of Sex disaggregates	323,024	300,846
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	3,392	5,658
C2.1.D_TA	By Age/Sex: <15 Female	77	177
C2.1.D_TA	By Age/Sex: <15 Male	81	181
C2.1.D_TA	By Age/Sex: 15+ Female	1,760	2,800
C2.1.D_TA	By Age/Sex: 15+ Male	1,474	2,500
C2.1.D_TA	Sum of Age/Sex disaggregates	3,392	5,658
C2.1.D_TA	By Age: <15	158	358
C2.1.D_TA	By Age: 15+	3,234	5,300
C2.1.D_TA	Sum of Age disaggregates	3,392	5,658
C2.1.D_TA	By Sex: Female	1,837	2,977
C2.1.D_TA	By Sex: Male	1,555	2,681
C2.1.D_TA	Sum of Sex disaggregates	3,392	5,658
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment	26,822	160,000



	setting		
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	319,632	295,188
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	393	230
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	431	250
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	361	230
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	70	18
CARE_SITE	Sum of Numerator Site Support Type disaggregates	431	248
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	361	230
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of	70	20



	PEPFAR supported sites providing clinical care services		
CARE_SITE	Sum of Denominator Site Support Type disaggregates	431	250
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,297	2,856
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,000	3,000
TB_ART_DSD	Age: 0-4	148	97
TB_ART_DSD	Age: 5-14	1,695	806
TB_ART_DSD	Age: 15+	3,157	2,097
TB_ART_DSD	Male	1,602	1,031
TB_ART_DSD	Female	3,398	1,969
TB_ART_DSD	Sum of Sex disaggregates	5,000	3,000
TB_ART_DSD	Aggregated Age: <15	1,843	903
TB_ART_DSD	Aggregated Age: 15+	3,157	2,097
TB_ART_DSD	Sum of Aggregated Age disaggregates	5,000	3,000
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	431	250
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	431	250
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	393	230
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of	38	20



	PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	431	250
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	393	230
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	38	20
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	431	250
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	9,861	6,559
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	16,696	11,045
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,141	2,752
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	5,720	3,807
PMTCT_EID_DSD	Sum of Infant Age disaggregates	9,861	6,559
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	176	114
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	211,492	192,952
TX_CURR_DSD	Age/Sex: <1 Male	449	423
TX_CURR_DSD	Age/Sex: 1-4 Male	1,217	1,136
TX_CURR_DSD	Age/Sex: 5-14 Male	5,569	5,104



TX_CURR_DSD	Age/Sex: 15+ Male	76,176	69,213
TX_CURR_DSD	Age/Sex: <1 Female	503	472
TX_CURR_DSD	Age/Sex: 1-4 Female	1,241	1,158
TX_CURR_DSD	Age/Sex: 5-14 Female	5,549	5,097
TX_CURR_DSD	Age/Sex: 15+ Female	120,788	110,349
TX_CURR_DSD	Sum of age/sex disaggregates	14,528	13,390
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	449	423
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	503	472
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,793	6,240
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	76,176	69,213
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,796	6,255
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	120,788	110,249
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	13,589	12,495
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	196,964	179,462
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	210,553	191,957
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	211,492	192,952
TX_CURR_NGI	Age/Sex: <1 Male	449	423
TX_CURR_NGI	Age/Sex: 1-4 Male	1,217	1,136
TX_CURR_NGI	Age/Sex: 5-14 Male	5,569	5,104
TX_CURR_NGI	Age/Sex: 15+ Male	76,176	69,213
TX_CURR_NGI	Age/Sex: <1 Female	503	472
TX_CURR_NGI	Age/Sex: 1-4 Female	1,241	1,158
TX_CURR_NGI	Age/Sex: 5-14 Female	5,549	5,097
TX_CURR_NGI	Age/Sex: 15+ Female	120,788	110,349
TX_CURR_NGI	Sum of Age/Sex disaggregates	211,492	192,952
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0	0
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	449	423
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	503	472
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	6,793	6,240
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	76,176	69,213



TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	83,921	76,348
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	7,242	6,663
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	76,679	69,685
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	23,047	15,169
TX_NEW_DSD	By Age/Sex: <1 Male	64	37
TX_NEW_DSD	By Age/Sex: 1-4 Male	335	215
TX_NEW_DSD	By Age/Sex: 5-9 Male	220	137
TX_NEW_DSD	By Age/Sex: 10-14 Male	187	117
TX_NEW_DSD	By Age/Sex: 15-19 Male	294	193
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,007	669
TX_NEW_DSD	By Age/Sex: 25-49 Male	6,217	4,101
TX_NEW_DSD	By Age/Sex: 50+ Male	800	526
TX_NEW_DSD	By Age/Sex: <1 Female	82	49
TX_NEW_DSD	By Age/Sex: 1-4 Female	253	160
TX_NEW_DSD	By Age/Sex: 5-9 Female	226	144
TX_NEW_DSD	By Age/Sex: 10-14 Female	247	154
TX_NEW_DSD	By Age/Sex: 15-19 Female	644	419
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,362	1,564
TX_NEW_DSD	By Age/Sex: 25-49 Female	9,310	6,156
TX_NEW_DSD	By Age/Sex: 50+ Female	799	528
TX_NEW_DSD	Sum of Age/Sex disaggregates	23,047	15,169
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	64	37
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	806	506
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	8,318	5,489
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	82	49
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	808	507
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	13,115	8,667
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	23,047	15,169
TX_RET_DSD	Number of adults and children who are still	19,351	12,903



	alive and on treatment at 12 months after initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	23,047	15,169
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	564	359
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	799	492
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,988	12,052
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	734	461
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	880	552
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,433	14,156
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of	1,363	851



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,988	12,052
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,614	1,013
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,433	14,156
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	177	89
TX_SITE	Total number of PEPFAR-supported ART sites	177	89
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	153	80
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	24	9
TX_SITE	Sum of Numerator Site Support Type disaggregates	177	89
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported	153	80



	ART sites		
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	24	9
TX_SITE	Sum of Denominator Site Support Type disaggregates	177	89
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	167	84
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	140	75
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	27	9
LAB_ACC_DSD	Sum of Support Type disaggregates	167	84
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	167	84
LAB_CAP_DSD	By clinical laboratories	167	84
LAB_CAP_DSD	By Point-of-care testing sites	0	0
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	140	75
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	27	9
LAB_CAP_DSD	Sum of Site Support Type disaggregates	167	84
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	393	393
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	431	431
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	393	393



LAB_PT_DSD	CD4: Number of laboratories that perform this testing	140	140
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	140	140
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	140	140
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	0
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	350	350
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	350	350
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	350	350
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process	177	89



	results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	177	89
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	153	80
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	24	9
QI_SITE	Sum of Numerator Site Support Type disaggregates	177	89
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	153	
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	24	
QI_SITE	Sum of Denominator Site Support Type disaggregates	177	

Implementing Mechanism Details

Mechanism ID: 7428	Mechanism Name: Corridors of Hope III
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,945,024	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,945,024

Sub Partner Name(s)

Afya Mzuri	Development Alternatives, Inc	Howard University
Zambia Health Education and Communication Trust	Zambia Interfaith Networking Group on HIV and AIDS	

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation

Key Issues

Malaria (PMI)
 Mobile Population
 TB



Workplace Programs
Family Planning

Budget Code Information

Mechanism ID: 7428			
Mechanism Name: Corridors of Hope III			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,495,024	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	10	10
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service	10	10



	Delivery (DSD)		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	138,000	3,000
PP_PREV_DSD	Total number of people in the target population	1,806,360	30,000
PP_PREV_DSD	Age/sex: 10-14 Male	1,380	0
PP_PREV_DSD	Age/sex: 15-19 Male	8,970	360
PP_PREV_DSD	Age/sex: 20-24 Male	58,650	1,350
PP_PREV_DSD	Age/sex: 25-49 Male	0	1,200
PP_PREV_DSD	Age/sex: 50+ Male	0	90
PP_PREV_DSD	Age/sex: 10-14 Female	1,380	0
PP_PREV_DSD	Age/sex: 15-19 Female	8,970	0
PP_PREV_DSD	Age/sex: 20-24 Female	58,650	0
PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	138,000	3,000
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,200	3,597
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,200	3,597
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,863	5,450
HTC_TST_DSD	By Test Result: Negative	35,020	4,397
HTC_TST_DSD	By Test Result: Positive	1,843	1,053



HTC_TST_DSD	Sum of Test Result disaggregates	36,863	5,450
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	0	0
HTC_TST_DSD	Age/sex: 5-9 Male	0	0
HTC_TST_DSD	Age/sex: 10-14 Male	177	0
HTC_TST_DSD	Age/sex: 15-19 Male	2,152	218
HTC_TST_DSD	Age/sex: 20-24 Male	8,077	817
HTC_TST_DSD	Age/sex: 25-49 Male	7,185	727
HTC_TST_DSD	Age/sex: 50+ Male	361	55
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	0	0
HTC_TST_DSD	Age/sex: 5-9 Female	0	0
HTC_TST_DSD	Age/sex: 10-14 Female	191	36
HTC_TST_DSD	Age/sex: 15-19 Female	2,271	436
HTC_TST_DSD	Age/sex: 20-24 Female	8,511	1,635
HTC_TST_DSD	Age/sex: 25-49 Female	7,563	1,453
HTC_TST_DSD	Age/sex: 50+ Female	375	73
HTC_TST_DSD	Sum of Age/Sex disaggregates	36,863	5,450
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	177	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,775	1,817
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	191	36
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,720	3,597
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	368	36
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	36,495	5,414
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	36,863	5,450
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,863	5,450
HTC_TST_NGI	By Test Result: Negative	35,020	4,397



HTC_TST_NGI	By Test Result: Positive	1,843	1,053
HTC_TST_NGI	Sum of Test Result disaggregates	36,863	5,450
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	0	0
HTC_TST_NGI	Age/sex: 5-9 Male	0	0
HTC_TST_NGI	Age/sex: 10-14 Male	177	0
HTC_TST_NGI	Age/sex: 15-19 Male	2,152	218
HTC_TST_NGI	Age/sex: 20-24 Male	8,077	817
HTC_TST_NGI	Age/sex: 25-49 Male	7,185	727
HTC_TST_NGI	Age/sex: 50+ Male	361	55
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	0	0
HTC_TST_NGI	Age/sex: 5-9 Female	0	0
HTC_TST_NGI	Age/sex: 10-14 Female	191	36
HTC_TST_NGI	Age/sex: 15-19 Female	2,271	436
HTC_TST_NGI	Age/sex: 20-24 Female	8,511	1,635
HTC_TST_NGI	Age/sex: 25-49 Female	7,563	1,453
HTC_TST_NGI	Age/sex: 50+ Female	375	73
HTC_TST_NGI	Sum of Age/Sex disaggregates	36,863	5,450
HTC_TST_NGI	Aggregated Age/sex: <15 Male	177	0
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	17,775	1,817
HTC_TST_NGI	Aggregated Age/sex: <15 Female	191	36
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	18,720	3,597
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	368	36
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	36,495	5,414
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	36,863	5,450

Implementing Mechanism Details

Mechanism ID: 7427	Mechanism Name: Partnership for Integrated Social Marketing (PRISM)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Booz Allen Hamilton	Care International	Development Aid from People to People Humana Zambia
IntraHealth International, Inc	JHPIEGO	Luapula Foundation
Mwami Adventist Hospital	Overseas Strategic Consulting	Population Council
Solwezi Youth Alive Zambia	Zambia Health Education and Communication Trust	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Increase gender equity in HIV prevention, care, treatment and support
- Malaria (PMI)
- Child Survival Activities
- Military Population
- Mobile Population
- Workplace Programs
- Family Planning



Budget Code Information

Mechanism ID: 7427			
Mechanism Name: Partnership for Integrated Social Marketing (PRISM)			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	77	



SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	77	
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	77	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	77	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	7	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	6	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	1	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the	70,000	



	voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		
VMMC_CIRC_DSD	By Age: 10-14	21,002	
VMMC_CIRC_DSD	By Age: 15-19	24,504	
VMMC_CIRC_DSD	By Age: 20-24	12,605	
VMMC_CIRC_DSD	By Age: 25-49	11,203	
VMMC_CIRC_DSD	By Age: 50+	686	
VMMC_CIRC_DSD	Sum of age disaggregates	70,000	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	250,000	
PP_PREV_DSD	Total number of people in the target population	754,693	
PP_PREV_DSD	Age/sex: 10-14 Male	11,363	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	2,543	
PP_PREV_DSD	Age/sex: 25-49 Male	104,374	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	12,594	
PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	119,126	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	250,000	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	381	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key	381	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	280,000	
HTC_TST_DSD	By Test Result: Negative	260,401	
HTC_TST_DSD	By Test Result: Positive	19,599	
HTC_TST_DSD	Sum of Test Result disaggregates	280,000	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Age/sex: 5-9 Male	0	
HTC_TST_DSD	Age/sex: 10-14 Male	0	
HTC_TST_DSD	Age/sex: 15-19 Male	27,114	
HTC_TST_DSD	Age/sex: 20-24 Male	30,378	
HTC_TST_DSD	Age/sex: 25-49 Male	78,669	
HTC_TST_DSD	Age/sex: 50+ Male	5,418	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	0	
HTC_TST_DSD	Age/sex: 10-14 Female	0	
HTC_TST_DSD	Age/sex: 15-19 Female	16,897	
HTC_TST_DSD	Age/sex: 20-24 Female	37,345	
HTC_TST_DSD	Age/sex: 25-49 Female	75,834	
HTC_TST_DSD	Age/sex: 50+ Female	8,345	
HTC_TST_DSD	Sum of Age/Sex disaggregates	280,000	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	141,579	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	138,421	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	280,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	280,000	



QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	77	
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	77	
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	77	
QI_SITE	Sum of Numerator Site Support Type disaggregates	77	
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	77	
QI_SITE	Sum of Denominator Site Support Type disaggregates	77	

Implementing Mechanism Details

Mechanism ID: 7423	Mechanism Name: Supply Chain Management System Project (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 66,899,554	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	66,899,554

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	175,000
Motor Vehicles: Purchased	112,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- Family Planning

Budget Code Information

Mechanism ID: 7423			
Mechanism Name: Supply Chain Management System Project (SCMS)			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	8,000,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	4,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	49,844,554	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	140	170
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	281	281



SC_STOCK	Commodity: Other	140	170
----------	------------------	-----	-----

Implementing Mechanism Details

Mechanism ID: 7422	Mechanism Name: Central Contraceptive Procurement (CCP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Central Contraceptive Procurement	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,000,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	300,000
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Condom procurement	1,200,000
Condom programming	500,000

Key Issues

Mobile Population

Approved



Budget Code Information

Mechanism ID: 7422			
Mechanism Name: Central Contraceptive Procurement (CCP)			
Prime Partner Name: Central Contraceptive Procurement			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		2,500,000		Redacted	2,500,000	0
Staff Program Travel		878,960		Redacted	878,960	0
USG Staff Salaries and Benefits		2,249,356		Redacted	2,249,356	0
Total	0	5,628,316	0	0	5,628,316	0

U.S. Agency for International Development Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS		GHP-State		Redacted	2,500,000	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		60,000		Redacted	60,000	33,600
Indirect Costs		40,000		Redacted	40,000	16,308
Management Meetings/Profes		72,000		Redacted	72,000	21,000



sional Development						
Non-ICASS Motor Vehicles		9,500		Redacted	9,500	8,400
Staff Program Travel		58,500		Redacted	58,500	63,000
USG Staff Salaries and Benefits		360,000		Redacted	360,000	225,500
Total	0	600,000	0	0	600,000	367,808

U.S. Department of Defense Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS		GHP-State		Redacted	60,000	33,600
Indirect Costs		GHP-State	General running costs - telephone, fuel, office supplies, clearing charges	Redacted	40,000	16,308
Management Meetings/Professional Development		GHP-State		Redacted	72,000	21,000
Non-ICASS Motor Vehicles		GHP-State		Redacted	9,500	8,400

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost	GAP	GHP-State	GHP-USAID	Planned	Cost of	Applied
-------------	-----	-----------	-----------	---------	---------	---------



of Doing Business				Amount As Of Last Q1	Doing Business Category Total	Pipeline
Capital Security Cost Sharing		150,000		Redacted	150,000	0
Computers/IT Services		436,995		Redacted	436,995	0
ICASS		2,157,767		Redacted	2,157,767	0
Institutional Contractors		1,430,000		Redacted	1,430,000	0
Non-ICASS Administrative Costs		1,409,110		Redacted	1,409,110	0
Non-ICASS Motor Vehicles		388,160		Redacted	388,160	0
Staff Program Travel		1,080,000		Redacted	1,080,000	0
USG Renovation		500,000		Redacted	500,000	0
USG Staff Salaries and Benefits	2,412,531	1,691,715		Redacted	4,104,246	0
Total	2,412,531	9,243,747	0	0	11,656,278	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing	OBO Tax	GHP-State		Redacted	150,000	0
Computers/IT Services	ITSO	GHP-State		Redacted	436,995	0



ICASS	ICASS	GHP-State		Redacted	2,157,767	0
Non-ICASS Administrative Costs	Telephone, Office Utilities, Other Office Costs-Printing, computers for HVSI	GHP-State		Redacted	1,409,110	0
Non-ICASS Motor Vehicles	Fuel, Insurance & Maintenance	GHP-State	CDC has purchased 14 USG vehicles with prior year COP funds (04-12). 7 have since been sold. No vehicles are requested with COP 13 funds.	Redacted	388,160	0
USG Renovation	Diplomatic Security	GHP-State	CDC will be undergoing diplomatic security upgrades	Redacted	500,000	0

U.S. Department of Health and Human Services/Office of the Secretary

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
USG Staff Salaries and Benefits		200,000		Redacted	200,000	200,000



Total	0	200,000	0	0	200,000	200,000
--------------	----------	----------------	----------	----------	----------------	----------------

U.S. Department of Health and Human Services/Office of the Secretary Other Costs Details

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		343,936		Redacted	343,936	0
Non-ICASS Administrative Costs		0		Redacted	0	50,000
Staff Program Travel				Redacted	0	46,064
USG Staff Salaries and Benefits		210,000		Redacted	210,000	700,000
Total	0	553,936	0	0	553,936	796,064

U.S. Department of State Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS		GHP-State		Redacted	343,936	0
Non-ICASS Administrative Costs		GHP-State	50,000: public diplomacy activities on behalf of PEPFAR interagency team (printing of PEPFAR	Redacted	0	50,000



			calendars, fact sheets, outreach events, World AIDS Day)			
--	--	--	--	--	--	--

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		7,800		Redacted	7,800	0
Institutional Contractors				Redacted	0	0
Management Meetings/Professional Development		3,600		Redacted	3,600	0
Non-ICASS Administrative Costs		397,368		Redacted	397,368	0
Non-ICASS Motor Vehicles		103,841		Redacted	103,841	0
Peace Corps Volunteer Costs		2,697,945		Redacted	2,697,945	0
Staff Program Travel		121,987		Redacted	121,987	0
USG Staff Salaries and Benefits		869,775		Redacted	869,775	0
Total	0	4,202,316	0	0	4,202,316	0



U.S. Peace Corps Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	7,800	0
Management Meetings/Professional Development		GHP-State		Redacted	3,600	0
Non-ICASS Administrative Costs		GHP-State		Redacted	397,368	0
Non-ICASS Motor Vehicles	Three all-terrain vehicles (ATVs)	GHP-State	3 vehicles will be needed to replace 3 vehicles which will have exceeded their K100,000 recommended maximum. These vehicles will be required for Peace Corps staff to support Peace Corps volunteers in rural areas within 7 Provinces in Zambia for programmatic,	Redacted	103,841	0

Approved



			medical and administrative support throughout their 2 year service.			
--	--	--	---	--	--	--